<!DOCTYPE html PUBLIC "-">
<html>
<body class="spl" id="spl">
    <div class="DocumentTitle"><p class="DocumentTitle"><strong>CYMBALTA- duloxetine hydrochloride capsule, delayed release </strong><br><span class="product-label-link" conceptid="36918942" conceptname="depression">Depression HOI test link</span><br></p></div>
    <div id="Highlights" class="Highlights">
        <table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed">
            <tr>
                <td align="left" valign="top">
                    <div>
                        <h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
                        <div class="HighlightsDisclaimer">
                            These highlights do not include all the information needed to use CYMBALTA safely and effectively. See full prescribing information for CYMBALTA. CYMBALTA (Duloxetine Delayed-Release Capsules) for Oral Use. Initial U.S. Approval: 2004
                            <br><br>
                        </div>
                        <div class="Warning">
                            <div>
                                <h1 class="Warning"><span class="Bold">WARNING: SUICIDALTHOUGHTS AND BEHAVIORS</span></h1>
                                <h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
                                <ul class="Disc">
                                    <li>
                                        <span class="Bold">
                                            Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants ( )
                                            <a href="#s36">5.1</a>
                                        </span>
                                    </li>
                                    <li>
                                        <span class="Bold">
                                            Monitor for worsening and emergence of suicidal thoughts and behaviors ( )
                                            <a href="#s36">5.1</a>
                                        </span>
                                    </li>
                                    <li>
                                        <span class="Bold">
                                            Cymbalta is not approved for use in pediatric patients ( )
                                            <a href="#s115">8.4</a>
                                        </span>
                                    </li>
                                </ul>
                            </div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
                            <div>
                                <p class="Highlighta">Contraindications: </p>
                                <p class="Highlighta">        Removed: Uncontrolled Narrow-Angle <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">Glaucoma</span> (4.2)        07/2014 </p>
                                <p class="Highlighta">Warnings and Precautions: </p>
                                <p class="Highlighta">
                                    Angle-Closure <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">Glaucoma</span> ( )        07/2014
                                    <a href="#e44">5.9</a>
                                </p>
                            </div>
                        </div>
                        <div></div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
                            <div>
                                <p class="Highlighta">
                                    Cymbalta is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for:
                                    <span class="Sup">®</span>
                                </p>
                                <ul class="Disc">
                                    <li>
                                        Major <span class="conditions" mdrptid="36918942" mdrpt="depression">Depressive Disorder</span> (MDD) ( )
                                        <a href="#s4">1.1</a>
                                    </li>
                                    <li>
                                        <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">Generalized Anxiety Disorder</span> (<span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span>) ( )
                                        <a href="#s5">1.2</a>
                                    </li>
                                    <li>
                                        <span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span> (DPNP) ( )
                                        <a href="#s6">1.3</a>
                                    </li>
                                    <li>
                                        <span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">Fibromyalgia</span> (FM) ( )
                                        <a href="#s7">1.4</a>
                                    </li>
                                    <li>
                                        Chronic <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">Musculoskeletal Pain</span> ( )
                                        <a href="#s8">1.5</a>
                                    </li>
                                </ul>
                            </div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
                            <div>
                                <ul class="Disc">
                                    <li>
                                        Cymbalta should generally be administered once daily without regard to meals. Cymbalta should be swallowed whole and should not be chewed or crushed, nor should the capsule be opened and its contents be sprinkled on food or mixed with liquids ( )
                                        <a href="#s9">2</a>
                                    </li>
                                </ul>
                                <table width="100%">
                                    <col align="left" width="31.850%">
                                    <col align="left" width="19.125%">
                                    <col align="left" width="26.900%">
                                    <col align="left" width="22.125%">
                                    <tbody class="Headless">
                                        <tr class="First">
                                            <td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Indication</span></td>
                                            <td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Starting Dose</span></td>
                                            <td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Target Dose</span></td>
                                            <td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Maximum Dose</span></td>
                                        </tr>
                                        <tr>
                                            <td class="Botrule Lrule Rrule" align="left" valign="top">
                                                MDD ( , )
                                                <a href="#s10">2.1</a><a href="#s16">2.2</a>
                                            </td>
                                            <td class="Botrule Rrule" align="left" valign="top">40 mg/day to 60 mg/day</td>
                                            <td class="Botrule Rrule" align="left" valign="top">Acute Treatment: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance Treatment: 60 mg/day</td>
                                            <td class="Botrule Rrule" align="left" valign="top">120 mg/day</td>
                                        </tr>
                                        <tr>
                                            <td class="Botrule Lrule Rrule" align="left" valign="top">
                                                <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span> ( )
                                                <a href="#s10">2.1</a>
                                            </td>
                                            <td class="Botrule Rrule" align="left" valign="top">60 mg/day</td>
                                            <td class="Botrule Rrule" align="left" valign="top">60 mg/day (once daily)</td>
                                            <td class="Botrule Rrule" align="left" valign="top">120 mg/day</td>
                                        </tr>
                                        <tr>
                                            <td class="Botrule Lrule Rrule" align="left" valign="top">
                                                DPNP ( )
                                                <a href="#s10">2.1</a>
                                            </td>
                                            <td class="Botrule Rrule" align="left" valign="top">60 mg/day</td>
                                            <td class="Botrule Rrule" align="left" valign="top">60 mg/day (once daily)</td>
                                            <td class="Botrule Rrule" align="left" valign="top">60 mg/day</td>
                                        </tr>
                                        <tr>
                                            <td class="Botrule Lrule Rrule" align="left" valign="top">
                                                FM ( )
                                                <a href="#s10">2.1</a>
                                            </td>
                                            <td class="Botrule Rrule" align="left" valign="top">30 mg/day</td>
                                            <td class="Botrule Rrule" align="left" valign="top">60 mg/day (once daily)</td>
                                            <td class="Botrule Rrule" align="left" valign="top">60 mg/day</td>
                                        </tr>
                                        <tr class="Last">
                                            <td class="Botrule Lrule Rrule" align="left" valign="top">
                                                Chronic <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">Musculoskeletal Pain</span> ( )
                                                <a href="#s10">2.1</a>
                                            </td>
                                            <td class="Botrule Rrule" align="left" valign="top">30 mg/day</td>
                                            <td class="Botrule Rrule" align="left" valign="top">60 mg/day (once daily)</td>
                                            <td class="Botrule Rrule" align="left" valign="top">60 mg/day</td>
                                        </tr>
                                    </tbody>
                                </table>
                                <ul class="Disc">
                                    <li>
                                        Some patients may benefit from starting at 30 mg once daily ( )
                                        <a href="#s10">2.1</a>
                                    </li>
                                    <li>
                                        There is no evidence that doses greater than 60 mg/day confers additional benefit, while some adverse reactions were observed to be dose-dependent ( )
                                        <a href="#s10">2.1</a>
                                    </li>
                                    <li>
                                        Discontinuing Cymbalta: A gradual dose reduction is recommended to avoid discontinuation symptoms ( , )
                                        <a href="#s29">2.4</a><a href="#s43">5.7</a>
                                    </li>
                                </ul>
                            </div>
                            <div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                            </div>
                            <div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                            </div>
                            <div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                            </div>
                            <div></div>
                            <div></div>
                            <div></div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
                            <div>
                                <p class="Highlighta">
                                    20 mg, 30 mg, and 60 mg capsules ( )
                                    <a href="#s31">3</a>
                                </p>
                            </div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
                            <div>
                                <ul class="Disc">
                                    <li>
                                        <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">Serotonin Syndrome</span> and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with Cymbalta or within 5 days of stopping treatment with Cymbalta. Do not use Cymbalta within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start Cymbalta in a patient who is being treated with linezolid or intravenous methylene blue ( )
                                        <a href="#s33">4.1</a>
                                    </li>
                                </ul>
                            </div>
                            <div></div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
                            <div>
                                <ul class="Disc">
                                    <li>
                                        Suicidality: Monitor for clinical worsening and <span class="conditions" mdrptid="36919230" mdrpt="completed suicide">suicide</span> risk ( )
                                        <a href="#s36">5.1</a>
                                    </li>
                                    <li>
                                        <span class="conditions" mdrptid="35909625" mdrpt="hepatotoxicity">Hepatotoxicity</span>: <span class="conditions" mdrptid="35909518" mdrpt="hepatic failure">Hepatic failure</span>, sometimes fatal, has been reported in patients treated with Cymbalta. Cymbalta should be discontinued in patients who develop <span class="conditions" mdrptid="35104306" mdrpt="jaundice">jaundice</span> or other evidence of clinically significant liver dysfunction and should not be resumed unless another cause can be established. Cymbalta should not be prescribed to patients with substantial <span class="conditions" mdrptid="37420495" mdrpt="alcohol use">alcohol use</span> or evidence of <span class="conditions" mdrptid="35909501" mdrpt="liver disorder">chronic liver disease</span> ( )
                                        <a href="#s38">5.2</a>
                                    </li>
                                    <li>
                                        <span class="conditions" mdrptid="37622451" mdrpt="orthostatic hypotension">Orthostatic Hypotension</span> and <span class="conditions" mdrptid="35205037" mdrpt="syncope">Syncope</span>: Cases have been reported with duloxetine therapy ( )
                                        <a href="#s39">5.3</a>
                                    </li>
                                    <li>
                                        <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">Serotonin Syndrome</span>: <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">Serotonin syndrome</span> has been reported with SSRIs and SNRIs, including with Cymbalta, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone and St. John's Wort). If such symptoms occur, discontinue Cymbalta and initiate supportive treatment. If concomitant use of Cymbalta with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span>, particularly during treatment initiation and dose increases ( )
                                        <a href="#s40">5.4</a>
                                    </li>
                                    <li>
                                        Abnormal <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">Bleeding</span>: Cymbalta may increase the risk of <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">bleeding</span> events. Patients should be cautioned about the risk of <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">bleeding</span> associated with the concomitant use of duloxetine and NSAIDs, aspirin, or other drugs that affect coagulation ( , )
                                        <a href="#s41">5.5</a><a href="#s94">7.4</a>
                                    </li>
                                    <li>
                                        Severe Skin Reactions: Severe skin reactions, including <span class="conditions" mdrptid="36009707" mdrpt="erythema multiforme">erythema multiforme</span> and <span class="conditions" mdrptid="36009724" mdrpt="stevens-johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), can occur with Cymbalta. Cymbalta should be discontinued at the first appearance of <span class="conditions" mdrptid="36211383" mdrpt="blister">blisters</span>, <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">peeling</span> <span class="conditions" mdrptid="37320212" mdrpt="rash">rash</span>, mucosal erosions, or any other sign of <span class="conditions" mdrptid="36009711" mdrpt="hypersensitivity">hypersensitivity</span> if no other etiology can be identified. ( )
                                        <a href="#s42">5.6</a>
                                    </li>
                                    <li>
                                        Discontinuation: May result in symptoms, including <span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span>, <span class="conditions" mdrptid="36718132" mdrpt="headache">headache</span>, <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span>, <span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">diarrhea</span>, <span class="conditions" mdrptid="36718379" mdrpt="paraesthesia">paresthesia</span>, <span class="conditions" mdrptid="35809139" mdrpt="irritability">irritability</span>, <span class="conditions" mdrptid="35708208" mdrpt="vomiting">vomiting</span>, <span class="conditions" mdrptid="36718555" mdrpt="insomnia">insomnia</span>, <span class="conditions" mdrptid="36918858" mdrpt="anxiety">anxiety</span>, <span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">hyperhidrosis</span>, and <span class="conditions" mdrptid="35809076" mdrpt="fatigue">fatigue</span> ( )
                                        <a href="#s43">5.7</a>
                                    </li>
                                    <li>
                                        Activation of <span class="conditions" mdrptid="36919036" mdrpt="mania">mania</span> or <span class="conditions" mdrptid="36919035" mdrpt="hypomania">hypomania</span> has occurred ( )
                                        <a href="#s44">5.8</a>
                                    </li>
                                    <li>
                                        Angle-Closure <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">Glaucoma</span>: Angle-closure <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">glaucoma</span> has occurred in patients with untreated anatomically narrow angles treated with antidepressants. ( )
                                        <a href="#e44">5.9</a>
                                    </li>
                                    <li>
                                        <span class="conditions" mdrptid="36718526" mdrpt="convulsion">Seizures</span>: Prescribe with care in patients with a history of <span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizure</span> disorder ( )
                                        <a href="#s45">5.10</a>
                                    </li>
                                    <li>
                                        <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">Blood Pressure</span>: Monitor <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span> prior to initiating treatment and periodically throughout treatment ( )
                                        <a href="#s46">5.11</a>
                                    </li>
                                    <li>
                                        Inhibitors of CYP1A2 or Thioridazine: Should not administer with Cymbalta ( )
                                        <a href="#s47">5.12</a>
                                    </li>
                                    <li>
                                        <span class="conditions" mdrptid="36416600" mdrpt="hyponatraemia">Hyponatremia</span>: Cases of <span class="conditions" mdrptid="36416600" mdrpt="hyponatraemia">hyponatremia</span> have been reported ( )
                                        <a href="#s56">5.13</a>
                                    </li>
                                    <li>
                                        <span class="conditions" mdrptid="35909518" mdrpt="hepatic failure">Hepatic Insufficiency</span> and Severe <span class="conditions" mdrptid="37019321" mdrpt="renal impairment">Renal Impairment</span>: Should ordinarily not be administered to these patients ( )
                                        <a href="#s57">5.14</a>
                                    </li>
                                    <li>
                                        <span class="conditions" mdrptid="36314155" mdrpt="blood glucose">Glucose</span> Control in <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">Diabetes</span>: In <span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">diabetic peripheral neuropathic pain</span> patients, small increases in <span class="conditions" mdrptid="36314155" mdrpt="blood glucose">fasting blood glucose</span>, and HbA have been observed ( )
                                        <span class="Sub">1c</span><a href="#s57">5.14</a>
                                    </li>
                                    <li>
                                        Conditions that Slow Gastric Emptying: Use cautiously in these patients ( )
                                        <a href="#s57">5.14</a>
                                    </li>
                                    <li>
                                        <span class="conditions" mdrptid="37019409" mdrpt="urinary hesitation">Urinary Hesitation</span> and Retention ( )
                                        <a href="#s62">5.15</a>
                                    </li>
                                </ul>
                            </div>
                            <div><div></div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div>
                                <div>
                                    <div></div>
                                    <div></div>
                                </div>
                                <div>
                                    <div></div>
                                    <div></div>
                                    <div></div>
                                    <div></div>
                                </div>
                            </div>
                            <div></div>
                            <div>
                                <div></div>
                                <div></div>
                                <div></div>
                            </div>
                            <div></div>
                            <div></div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
                            <div>
                                <ul class="Disc">
                                    <li>
                                        Most common adverse reactions (≥5% and at least twice the incidence of placebo patients): <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span>, <span class="conditions" mdrptid="35708690" mdrpt="dry mouth">dry mouth</span>, <span class="conditions" mdrptid="36718321" mdrpt="somnolence">somnolence</span>, <span class="conditions" mdrptid="35708100" mdrpt="constipation">constipation</span>, <span class="conditions" mdrptid="36416514" mdrpt="decreased appetite">decreased appetite</span>, and <span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">hyperhidrosis</span> ( ).
                                        <a href="#s73">6.3</a>
                                    </li>
                                </ul>
                                <p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
                            </div>
                            <div></div>
                            <div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                            </div>
                            <div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                                <div></div>
                            </div>
                            <div></div>
                            <div>
                                <div></div>
                                <div></div>
                            </div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
                            <div>
                                <ul class="Disc">
                                    <li>
                                        Potent inhibitors of CYP1A2 should be avoided ( ).
                                        <a href="#s91">7.1</a>
                                    </li>
                                    <li>
                                        Potent inhibitors of CYP2D6 may increase duloxetine concentrations ( ).
                                        <a href="#s92">7.2</a>
                                    </li>
                                    <li>
                                        Duloxetine is a moderate inhibitor of CYP2D6 ( ).
                                        <a href="#s99">7.9</a>
                                    </li>
                                </ul>
                            </div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                        </div>
                        <div class="HighlightSection">
                            <h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
                            <div>
                                <ul class="Disc">
                                    <li>
                                        <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span> and Nursing Mothers: Use only if the potential benefit justifies the potential risk to the fetus or child ( , , ).
                                        <a href="#s22">2.3</a><a href="#s110">8.1</a><a href="#s114">8.3</a>
                                    </li>
                                </ul>
                            </div>
                            <div>
                                <div></div>
                                <div></div>
                            </div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                        </div>
                        <div>
                            <div></div>
                            <div></div>
                        </div>
                        <div>
                            <div></div>
                            <div></div>
                        </div>
                        <div></div>
                        <div>
                            <div></div>
                            <div></div>
                            <div>
                                <div></div>
                                <div></div>
                            </div>
                        </div>
                        <div>
                            <div>
                                <div></div>
                                <div></div>
                                <div></div>
                            </div>
                        </div>
                        <div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div>
                                <div></div>
                                <div>
                                    <div></div>
                                    <div></div>
                                </div>
                            </div>
                        </div>
                        <div>
                            <div></div>
                            <div></div>
                        </div>
                        <div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                            <div></div>
                        </div>
                        <div></div>
                        <div></div>
                        <div></div>
                        <p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
                        <p class="HighlightsRevision">Revised: 8/2014</p>
                    </div>
                </td>
            </tr>
        </table>
    </div>
    <div id="Index" class="Index">
        <table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed">
            <tr>
                <td align="left" valign="top">
                    <div>
                        <h1 class="Colspan">
                            FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
                        </h1>
                        <h1><a href="#section-1" class="toc">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</a></h1>
                        <h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
                        <h2><a href="#section-1.1" class="toc">1.1 Major <span class="conditions" mdrptid="36918942" mdrpt="depression">Depressive Disorder</span></a></h2>
                        <h2><a href="#section-1.2" class="toc">1.2 <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">Generalized Anxiety Disorder</span></a></h2>
                        <h2><a href="#section-1.3" class="toc">1.3 <span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></a></h2>
                        <h2><a href="#section-1.4" class="toc">1.4 <span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">Fibromyalgia</span></a></h2>
                        <h2><a href="#section-1.5" class="toc">1.5 Chronic <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">Musculoskeletal Pain</span></a></h2>
                        <h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
                        <h2><a href="#section-2.1" class="toc">2.1 Initial Treatment</a></h2>
                        <h2><a href="#section-2.2" class="toc">2.2 Maintenance/Continuation/Extended Treatment</a></h2>
                        <h2><a href="#section-2.3" class="toc">2.3 Dosing in Special Populations</a></h2>
                        <h2><a href="#section-2.4" class="toc">2.4 Discontinuing Cymbalta</a></h2>
                        <h2><a href="#section-2.5" class="toc">2.5 Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders</a></h2>
                        <h2><a href="#section-2.6" class="toc">2.6 Use of Cymbalta with Other MAOIs such as Linezolid or Methylene Blue</a></h2>
                        <h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
                        <h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
                        <h2><a href="#section-4.1" class="toc">4.1 Monoamine Oxidase Inhibitors (MAOIs)</a></h2>
                        <h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
                        <h2><a href="#section-5.1" class="toc">5.1 Suicidal Thoughts and Behaviors in Adolescents and Young Adults</a></h2>
                        <h2><a href="#section-5.2" class="toc">5.2 <span class="conditions" mdrptid="35909625" mdrpt="hepatotoxicity">Hepatotoxicity</span></a></h2>
                        <h2><a href="#section-5.3" class="toc">5.3 <span class="conditions" mdrptid="37622451" mdrpt="orthostatic hypotension">Orthostatic Hypotension</span> and <span class="conditions" mdrptid="35205037" mdrpt="syncope">Syncope</span></a></h2>
                        <h2><a href="#section-5.4" class="toc">5.4 <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">Serotonin Syndrome</span></a></h2>
                        <h2><a href="#section-5.5" class="toc">5.5 Abnormal <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">Bleeding</span></a></h2>
                        <h2><a href="#section-5.6" class="toc">5.6 Severe Skin Reactions</a></h2>
                        <h2><a href="#section-5.7" class="toc">5.7 Discontinuation of Treatment with Cymbalta</a></h2>
                        <h2><a href="#section-5.8" class="toc">5.8 Activation of <span class="conditions" mdrptid="36919036" mdrpt="mania">Mania</span>/<span class="conditions" mdrptid="36919035" mdrpt="hypomania">Hypomania</span></a></h2>
                        <h2>
                            <a href="#section-5.9" class="toc">
                                5.9 Angle-Closure <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">Glaucoma</span>
                                <span class="XmChange"></span>
                            </a>
                        </h2>
                        <h2><a href="#section-5.10" class="toc">5.10 <span class="conditions" mdrptid="36718526" mdrpt="convulsion">Seizures</span></a></h2>
                        <h2><a href="#section-5.11" class="toc">5.11 Effect on <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">Blood Pressure</span></a></h2>
                        <h2><a href="#section-5.12" class="toc">5.12 Clinically Important Drug Interactions</a></h2>
                        <h2><a href="#section-5.13" class="toc">5.13 <span class="conditions" mdrptid="36416600" mdrpt="hyponatraemia">Hyponatremia</span></a></h2>
                        <h2><a href="#section-5.14" class="toc">5.14 Use in Patients with Concomitant Illness</a></h2>
                        <h2><a href="#section-5.15" class="toc">5.15 <span class="conditions" mdrptid="37019409" mdrpt="urinary hesitation">Urinary Hesitation</span> and Retention</a></h2>
                        <h2><a href="#section-5.16" class="toc">5.16 Laboratory Tests</a></h2>
                        <h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
                        <h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Data Sources</a></h2>
                        <h2><a href="#section-6.2" class="toc">6.2 Adverse Reactions Reported as Reasons for Discontinuation of Treatment in Placebo-Controlled Trials</a></h2>
                        <h2><a href="#section-6.3" class="toc">6.3 Most Common Adverse Reactions</a></h2>
                        <h2><a href="#section-6.4" class="toc">6.4 Adverse Reactions Occurring at an Incidence of 5% or More Among Duloxetine-Treated Patients in Placebo-Controlled Trials</a></h2>
                        <h2><a href="#section-6.5" class="toc">6.5 Adverse Reactions Occurring at an Incidence of 2% or More Among Duloxetine-Treated Patients in Placebo-Controlled Trials</a></h2>
                        <h2><a href="#section-6.6" class="toc">6.6 Effects on Male and Female Sexual Function</a></h2>
                        <h2><a href="#section-6.7" class="toc">6.7 Vital Sign Changes</a></h2>
                        <h2><a href="#section-6.8" class="toc">6.8 Weight Changes</a></h2>
                        <h2><a href="#section-6.9" class="toc">6.9 Laboratory Changes</a></h2>
                        <h2><a href="#section-6.10" class="toc">6.10 <span class="conditions" mdrptid="36311902" mdrpt="electrocardiogram">Electrocardiogram</span> Changes</a></h2>
                        <h2><a href="#section-6.11" class="toc">6.11 Other Adverse Reactions Observed During the Premarketing and Postmarketing Clinical Trial Evaluation of Duloxetine</a></h2>
                        <h2><a href="#section-6.12" class="toc">6.12 Postmarketing Spontaneous Reports</a></h2>
                        <h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
                        <h2><a href="#section-7.1" class="toc">7.1 Inhibitors of CYP1A2</a></h2>
                        <h2><a href="#section-7.2" class="toc">7.2 Inhibitors of CYP2D6</a></h2>
                        <h2><a href="#section-7.3" class="toc">7.3 Dual Inhibition of CYP1A2 and CYP2D6</a></h2>
                        <h2><a href="#section-7.4" class="toc">7.4 Drugs that Interfere with <span class="conditions" mdrptid="37521165" mdrpt="haemostasis">Hemostasis</span> (e.g., NSAIDs, Aspirin, and Warfarin)</a></h2>
                        <h2><a href="#section-7.5" class="toc">7.5 Lorazepam</a></h2>
                        <h2><a href="#section-7.6" class="toc">7.6 Temazepam</a></h2>
                        <h2><a href="#section-7.7" class="toc">7.7 Drugs that Affect Gastric Acidity</a></h2>
                        <h2><a href="#section-7.8" class="toc">7.8 Drugs Metabolized by CYP1A2</a></h2>
                        <h2><a href="#section-7.9" class="toc">7.9 Drugs Metabolized by CYP2D6</a></h2>
                        <h2><a href="#section-7.10" class="toc">7.10 Drugs Metabolized by CYP2C9</a></h2>
                        <h2><a href="#section-7.11" class="toc">7.11 Drugs Metabolized by CYP3A</a></h2>
                        <h2><a href="#section-7.12" class="toc">7.12 Drugs Metabolized by CYP2C19</a></h2>
                        <h2><a href="#section-7.13" class="toc">7.13 Monoamine Oxidase Inhibitors (MAOIs)</a></h2>
                        <h2><a href="#section-7.14" class="toc">7.14 Serotonergic Drugs</a></h2>
                        <h2><a href="#section-7.15" class="toc">7.15 Alcohol</a></h2>
                        <h2><a href="#section-7.16" class="toc">7.16 CNS Drugs</a></h2>
                        <h2><a href="#section-7.17" class="toc">7.17 Drugs Highly Bound to <span class="conditions" mdrptid="36315537" mdrpt="protein total">Plasma Protein</span></a></h2>
                        <h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
                        <h2><a href="#section-8.1" class="toc">8.1 <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span></a></h2>
                        <h2><a href="#section-8.2" class="toc">8.2 Labor and <span class="conditions" mdrptid="36818826" mdrpt="delivery">Delivery</span></a></h2>
                        <h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
                        <h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
                        <h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
                        <h2><a href="#section-8.6" class="toc">8.6 Gender</a></h2>
                        <h2><a href="#section-8.7" class="toc">8.7 Smoking Status</a></h2>
                        <h2><a href="#section-8.8" class="toc">8.8 Race</a></h2>
                        <h2><a href="#section-8.9" class="toc">8.9 <span class="conditions" mdrptid="35909518" mdrpt="hepatic failure">Hepatic Insufficiency</span></a></h2>
                        <h2><a href="#section-8.10" class="toc">8.10 Severe <span class="conditions" mdrptid="37019321" mdrpt="renal impairment">Renal Impairment</span></a></h2>
                        <h1><a href="#section-9" class="toc">9 <span class="conditions" mdrptid="36919127" mdrpt="drug abuse">DRUG ABUSE</span> AND <span class="conditions" mdrptid="36919126" mdrpt="dependence">DEPENDENCE</span></a></h1>
                        <h2><a href="#section-9.1" class="toc">9.2 <span class="conditions" mdrptid="36919132" mdrpt="substance abuse">Abuse</span></a></h2>
                        <h2><a href="#section-9.2" class="toc">9.3 <span class="conditions" mdrptid="36919126" mdrpt="dependence">Dependence</span></a></h2>
                        <h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
                        <h2><a href="#section-10.1" class="toc">10.1 Signs and Symptoms</a></h2>
                        <h2><a href="#section-10.2" class="toc">10.2 Management of <span class="conditions" mdrptid="36211496" mdrpt="overdose">Overdose</span></a></h2>
                        <h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
                        <h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
                        <h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
                        <h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
                        <h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
                        <h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
                        <h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
                        <h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
                        <h2><a href="#section-14.1" class="toc">14.1 Major <span class="conditions" mdrptid="36918942" mdrpt="depression">Depressive Disorder</span></a></h2>
                        <h2><a href="#section-14.2" class="toc">14.2 <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">Generalized Anxiety Disorder</span></a></h2>
                        <h2><a href="#section-14.3" class="toc">14.3 <span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></a></h2>
                        <h2><a href="#section-14.4" class="toc">14.4 <span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">Fibromyalgia</span></a></h2>
                        <h2><a href="#section-14.5" class="toc">14.5 Chronic <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">Musculoskeletal Pain</span></a></h2>
                        <h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
                        <h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
                        <h2><a href="#section-15.2" class="toc">16.2 Storage and Handling</a></h2>
                        <h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
                        <h2><a href="#section-16.1" class="toc">17.1 Information on Medication Guide</a></h2>
                        <h2><a href="#section-16.2" class="toc">17.2 Suicidal Thoughts and Behaviors</a></h2>
                        <h2><a href="#section-16.3" class="toc">17.3 Medication Administration</a></h2>
                        <h2><a href="#section-16.4" class="toc">17.4 Continuing the Therapy Prescribed</a></h2>
                        <h2><a href="#section-16.5" class="toc">17.5 <span class="conditions" mdrptid="35909625" mdrpt="hepatotoxicity">Hepatotoxicity</span></a></h2>
                        <h2><a href="#section-16.6" class="toc">17.6 Alcohol</a></h2>
                        <h2><a href="#section-16.7" class="toc">17.7 <span class="conditions" mdrptid="37622451" mdrpt="orthostatic hypotension">Orthostatic Hypotension</span> and <span class="conditions" mdrptid="35205037" mdrpt="syncope">Syncope</span></a></h2>
                        <h2><a href="#section-16.8" class="toc">17.8 <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">Serotonin Syndrome</span></a></h2>
                        <h2><a href="#section-16.9" class="toc">17.9 Abnormal <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">Bleeding</span></a></h2>
                        <h2><a href="#section-16.10" class="toc">17.10 Severe Skin Reactions</a></h2>
                        <h2><a href="#section-16.11" class="toc">17.11 Discontinuation of Treatment</a></h2>
                        <h2><a href="#section-16.12" class="toc">17.12 Activation of <span class="conditions" mdrptid="36919036" mdrpt="mania">Mania</span> or <span class="conditions" mdrptid="36919035" mdrpt="hypomania">Hypomania</span></a></h2>
                        <h2><a href="#section-16.13" class="toc">17.13 Angle-Closure <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">Glaucoma</span></a></h2>
                        <h2><a href="#section-16.14" class="toc">17.14 <span class="conditions" mdrptid="36718526" mdrpt="convulsion">Seizures</span></a></h2>
                        <h2><a href="#section-16.15" class="toc">17.15 Effects on <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">Blood Pressure</span></a></h2>
                        <h2><a href="#section-16.16" class="toc">17.16 Concomitant Medications</a></h2>
                        <h2><a href="#section-16.17" class="toc">17.17 <span class="conditions" mdrptid="36416600" mdrpt="hyponatraemia">Hyponatremia</span></a></h2>
                        <h2><a href="#section-16.18" class="toc">17.18 Concomitant Illnesses</a></h2>
                        <h2><a href="#section-16.19" class="toc">17.19 <span class="conditions" mdrptid="37019409" mdrpt="urinary hesitation">Urinary Hesitancy</span> and Retention</a></h2>
                        <h2><a href="#section-16.20" class="toc">17.20 <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span> and <span class="conditions" mdrptid="37420447" mdrpt="breast feeding">Breast Feeding</span></a></h2>
                        <h2><a href="#section-16.21" class="toc">17.21 Interference with Psychomotor Performance</a></h2>
                        <dl class="Footnote">
                            <dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
                            <dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
                        </dl>
                    </div>
                </td>
            </tr>
        </table>
    </div>
    <div class="Contents">
        <h1>FULL PRESCRIBING INFORMATION</h1>
        <div class="Section" data-sectionCode="48780-1">
            <a name="dcl-dpl"></a><a name="section-1"></a><p></p>
        </div>
        <div class="Warning">
            <a name="s2"></a><a name="section-1"></a><p></p>
            <h1>WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</h1>
            <p class="First">
                <span class="Bold">Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older</span><span class="Bold Italics">
                    [see Warnings and Precautions ( )]
                    <a href="#s36">5.1</a>
                </span><span class="Bold">.</span>
            </p>
            <p>
                <span class="Bold">In patients of all ages who are started on <span class="conditions" mdrptid="37521688" mdrpt="antidepressant therapy">antidepressant therapy</span>, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber</span><span class="Bold Italics">
                    [see Warnings and Precautions ( )]
                    <a href="#s36">5.1</a>
                </span><span class="Bold">.</span>
            </p>
            <p>
                <span class="Bold">Cymbalta is not approved for use in pediatric patients</span><span class="Bold Italics">
                    [see Use in Specific Populations ( )]
                    <a href="#s115">8.4</a>
                </span><span class="Bold">.</span>
            </p>
        </div>
        <div class="Section" data-sectionCode="34067-9">
            <a name="s3"></a><a name="section-1"></a><p></p>
            <h1>1 INDICATIONS AND USAGE</h1>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s4"></a><a name="section-1.1"></a><p></p>
                <h2>1.1 Major <span class="conditions" mdrptid="36918942" mdrpt="depression">Depressive Disorder</span></h2>
                <p class="First">
                    Cymbalta is indicated for the treatment of major <span class="conditions" mdrptid="36918942" mdrpt="depression">depressive disorder</span> (MDD). The efficacy of Cymbalta was established in four short-term and one maintenance trial in adults .
                    <span class="Italics">
                        [see Clinical Studies ( )]
                        <a href="#s141">14.1</a>
                    </span>
                </p>
                <p>A major <span class="conditions" mdrptid="36918942" mdrpt="depression">depressive episode</span> (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: <span class="conditions" mdrptid="36918949" mdrpt="depressed mood">depressed mood</span>, <span class="conditions" mdrptid="36918948" mdrpt="decreased interest">loss of interest</span> in usual activities, significant change in weight and/or appetite, <span class="conditions" mdrptid="36718555" mdrpt="insomnia">insomnia</span> or <span class="conditions" mdrptid="36718563" mdrpt="hypersomnia">hypersomnia</span>, <span class="conditions" mdrptid="36718214" mdrpt="psychomotor hyperactivity">psychomotor agitation</span> or retardation, increased <span class="conditions" mdrptid="35809076" mdrpt="fatigue">fatigue</span>, feelings of guilt or worthlessness, <span class="conditions" mdrptid="36718178" mdrpt="bradyphrenia">slowed thinking</span> or impaired concentration, or a <span class="conditions" mdrptid="36919236" mdrpt="suicide attempt">suicide attempt</span> or <span class="conditions" mdrptid="36919235" mdrpt="suicidal ideation">suicidal ideation</span>.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s5"></a><a name="section-1.2"></a><p></p>
                <h2>1.2 <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">Generalized Anxiety Disorder</span></h2>
                <p class="First">
                    Cymbalta is indicated for the treatment of <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">generalized anxiety disorder</span> (<span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span>). The efficacy of Cymbalta was established in three short-term trials and one maintenance trial in adults .
                    <span class="Italics">
                        [see Clinical Studies ( )]
                        <a href="#s142">14.2</a>
                    </span>
                </p>
                <p><span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">Generalized anxiety disorder</span> is defined by the DSM-IV as excessive <span class="conditions" mdrptid="36918858" mdrpt="anxiety">anxiety</span> and <span class="conditions" mdrptid="36918858" mdrpt="anxiety">worry</span>, present more days than not, for at least 6 months. The excessive <span class="conditions" mdrptid="36918858" mdrpt="anxiety">anxiety</span> and <span class="conditions" mdrptid="36918858" mdrpt="anxiety">worry</span> must be difficult to control and must cause significant <span class="conditions" mdrptid="36919046" mdrpt="emotional distress">distress</span> or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms: <span class="conditions" mdrptid="36718368" mdrpt="restlessness">restlessness</span> or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, <span class="conditions" mdrptid="35809139" mdrpt="irritability">irritability</span>, muscle <span class="conditions" mdrptid="36918862" mdrpt="tension">tension</span>, and/or <span class="conditions" mdrptid="36919209" mdrpt="sleep disorder">sleep disturbance</span>.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s6"></a><a name="section-1.3"></a><p></p>
                <h2>1.3 <span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></h2>
                <p class="First">
                    Cymbalta is indicated for the management of <span class="conditions" mdrptid="36718401" mdrpt="neuralgia">neuropathic pain</span> (DPNP) associated with <span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">diabetic peripheral neuropathy</span> .
                    <span class="Italics">
                        [see Clinical Studies ( )]
                        <a href="#s143">14.3</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s7"></a><a name="section-1.4"></a><p></p>
                <h2>1.4 <span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">Fibromyalgia</span></h2>
                <p class="First">
                    Cymbalta is indicated for the management of <span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">fibromyalgia</span> (FM) .
                    <span class="Italics">
                        [see Clinical Studies ( )]
                        <a href="#s144">14.4</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s8"></a><a name="section-1.5"></a><p></p>
                <h2>1.5 Chronic <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">Musculoskeletal Pain</span></h2>
                <p class="First">
                    Cymbalta is indicated for the management of chronic <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">musculoskeletal pain</span>. This has been established in studies in patients with chronic <span class="conditions" mdrptid="36516951" mdrpt="back pain">low back pain</span> (CLBP) and <span class="conditions" mdrptid="35809243" mdrpt="pain">chronic pain</span> due to <span class="conditions" mdrptid="36516824" mdrpt="osteoarthritis">osteoarthritis</span> .
                    <span class="Italics">
                        [see Clinical Studies ( )]
                        <a href="#s145">14.5</a>
                    </span>
                </p>
            </div>
        </div>
        <div class="Section" data-sectionCode="34068-7">
            <a name="s9"></a><a name="section-2"></a><p></p>
            <h1>2 DOSAGE AND ADMINISTRATION</h1>
            <p class="First">Cymbalta should be swallowed whole and should not be chewed or crushed, nor should the capsule be opened and its contents sprinkled on food or mixed with liquids. All of these might affect the enteric coating. Cymbalta can be given without regard to meals.</p>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s10"></a><a name="section-2.1"></a><p></p>
                <h2>2.1 Initial Treatment</h2>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s11"></a><a name="section-2.1.1"></a><p></p>
                    <p class="First">
                        — Cymbalta should be administered at a total dose of 40 mg/day (given as 20 mg twice daily) to 60 mg/day (given either once daily or as 30 mg twice daily). For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily. While a 120 mg/day dose was shown to be effective, there is no evidence that doses greater than 60 mg/day confer any additional benefits. The safety of doses above 120 mg/day has not been adequately evaluated .
                        <span class="Underline">Major <span class="conditions" mdrptid="36918942" mdrpt="depression">Depressive Disorder</span></span><span class="Italics">
                            [see Clinical Studies ( )]
                            <a href="#s141">14.1</a>
                        </span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s12"></a><a name="section-2.1.2"></a><p></p>
                    <p class="First">
                        — For most patients, the recommended starting dose for Cymbalta is 60 mg administered once daily. For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily. While a 120 mg once daily dose was shown to be effective, there is no evidence that doses greater than 60 mg/day confer additional benefit. Nevertheless, if a decision is made to increase the dose beyond 60 mg once daily, dose increases should be in increments of 30 mg once daily. The safety of doses above 120 mg once daily has not been adequately evaluated .
                        <span class="Underline"><span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">Generalized Anxiety Disorder</span></span><span class="Italics">
                            [see Clinical Studies ( )]
                            <a href="#s142">14.2</a>
                        </span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s13"></a><a name="section-2.1.3"></a><p></p>
                    <p class="First">
                        — The recommended dose for Cymbalta is 60 mg administered once daily. There is no evidence that doses higher than 60 mg confer additional significant benefit and the higher dose is clearly less well tolerated . For patients for whom tolerability is a concern, a lower starting dose may be considered.
                        <span class="Underline"><span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></span><span class="Italics">
                            [see Clinical Studies ( )]
                            <a href="#s143">14.3</a>
                        </span>
                    </p>
                    <p>
                        Since <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span> is frequently complicated by <span class="conditions" mdrptid="37019308" mdrpt="renal disorder">renal disease</span>, a lower starting dose and gradual increase in dose should be considered for patients with <span class="conditions" mdrptid="37019321" mdrpt="renal impairment">renal impairment</span> .
                        <span class="Italics">
                            [see Dosage and Administration ( ), Use in Specific Populations ( ), and Clinical Pharmacology ( )]
                            <a href="#s22">2.3</a><a href="#s121">8.10</a><a href="#s132">12.3</a>
                        </span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s14"></a><a name="section-2.1.4"></a><p></p>
                    <p class="First">
                        — The recommended dose for Cymbalta is 60 mg administered once daily. Treatment should begin at 30 mg once daily for 1 week, to allow patients to adjust to the medication before increasing to 60 mg once daily. Some patients may respond to the starting dose. There is no evidence that doses greater than 60 mg/day confer additional benefit, even in patients who do not respond to a 60 mg dose, and higher doses are associated with a higher rate of adverse reactions .
                        <span class="Underline"><span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">Fibromyalgia</span></span><span class="Italics">
                            [see Clinical Studies ( )]
                            <a href="#s144">14.4</a>
                        </span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s15"></a><a name="section-2.1.5"></a><p></p>
                    <p class="First">
                        — The recommended dose for Cymbalta is 60 mg once daily. Dosing may be started at 30 mg for one week, to allow patients to adjust to the medication before increasing to 60 mg once daily. There is no evidence that higher doses confer additional benefit, even in patients who do not respond to a 60 mg dose, and higher doses are associated with a higher rate of adverse reactions .
                        <span class="Underline">Chronic <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">Musculoskeletal Pain</span></span><span class="Italics">
                            [see Clinical Studies ( )]
                            <a href="#s145">14.5</a>
                        </span>
                    </p>
                </div>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s16"></a><a name="section-2.2"></a><p></p>
                <h2>2.2 Maintenance/Continuation/Extended Treatment</h2>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s17"></a><a name="section-2.2.1"></a><p></p>
                    <p class="First">
                        — It is generally agreed that acute episodes of <span class="conditions" mdrptid="36918945" mdrpt="major depression">major depression</span> require several months or longer of sustained pharmacologic therapy. Maintenance of efficacy in MDD was demonstrated with Cymbalta as monotherapy. Cymbalta should be administered at a total dose of 60 mg once daily. Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose for such treatment .
                        <span class="Underline">Major <span class="conditions" mdrptid="36918942" mdrpt="depression">Depressive Disorder</span></span><span class="Italics">
                            [see Clinical Studies ( )]
                            <a href="#s141">14.1</a>
                        </span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s18"></a><a name="section-2.2.2"></a><p></p>
                    <p class="First">
                        — It is generally agreed that episodes of <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">generalized anxiety disorder</span> require several months or longer of sustained pharmacological therapy. Maintenance of efficacy in <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span> was demonstrated with Cymbalta as monotherapy. Cymbalta should be administered in a dose range of 60-120 mg once daily. Patients should be periodically reassessed to determine the continued need for maintenance treatment and the appropriate dose for such treatment .
                        <span class="Underline"><span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">Generalized Anxiety Disorder</span></span><span class="Italics">
                            [see Clinical Studies ( )]
                            <a href="#s142">14.2</a>
                        </span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s19"></a><a name="section-2.2.3"></a><p></p>
                    <p class="First">
                        — As the progression of <span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">diabetic peripheral neuropathy</span> is highly variable and management of <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> is empirical, the effectiveness of Cymbalta must be assessed individually. Efficacy beyond 12 weeks has not been systematically studied in placebo-controlled trials.
                        <span class="Underline"><span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s20"></a><a name="section-2.2.4"></a><p></p>
                    <p class="First">
                        — <span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">Fibromyalgia</span> is recognized as a chronic condition. The efficacy of Cymbalta in the management of <span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">fibromyalgia</span> has been demonstrated in placebo-controlled studies up to 3 months. The efficacy of Cymbalta was not demonstrated in longer studies; however, continued treatment should be based on individual patient response.
                        <span class="Underline"><span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">Fibromyalgia</span></span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s21"></a><a name="section-2.2.5"></a><p></p>
                    <p class="First">
                        — The efficacy of Cymbalta has not been established in placebo-controlled studies beyond 13 weeks.
                        <span class="Underline">Chronic <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">Musculoskeletal Pain</span></span>
                    </p>
                </div>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s22"></a><a name="section-2.3"></a><p></p>
                <h2>2.3 Dosing in Special Populations</h2>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s23"></a><a name="section-2.3.1"></a><p></p>
                    <p class="First">
                        — It is recommended that Cymbalta should ordinarily not be administered to patients with any <span class="conditions" mdrptid="35909518" mdrpt="hepatic failure">hepatic insufficiency</span> .
                        <span class="Underline"><span class="conditions" mdrptid="35909518" mdrpt="hepatic failure">Hepatic Insufficiency</span></span><span class="Italics">
                            [see Warnings and Precautions ( ) and Use in Specific Populations ( )]
                            <a href="#s57">5.14</a><a href="#s120">8.9</a>
                        </span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s24"></a><a name="section-2.3.2"></a><p></p>
                    <p class="First">
                        — Cymbalta is not recommended for patients with end-stage <span class="conditions" mdrptid="37019308" mdrpt="renal disorder">renal disease</span> or severe <span class="conditions" mdrptid="37019321" mdrpt="renal impairment">renal impairment</span> (estimated <span class="conditions" mdrptid="36315593" mdrpt="creatinine renal clearance">creatinine clearance</span> &lt;30 mL/min) .
                        <span class="Underline">Severe <span class="conditions" mdrptid="37019321" mdrpt="renal impairment">Renal Impairment</span></span><span class="Italics">
                            [see Warnings and Precautions ( ) and Use in Specific Populations ( )]
                            <a href="#s57">5.14</a><a href="#s121">8.10</a>
                        </span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s25"></a><a name="section-2.3.3"></a><p></p>
                    <p class="First">
                        — No dose adjustment is recommended for <span class="conditions" mdrptid="37420350" mdrpt="elderly">elderly</span> patients on the basis of age. As with any drug, caution should be exercised in treating the <span class="conditions" mdrptid="37420350" mdrpt="elderly">elderly</span>. When individualizing the dosage in <span class="conditions" mdrptid="37420350" mdrpt="elderly">elderly</span> patients, extra care should be taken when increasing the dose .
                        <span class="Underline"><span class="conditions" mdrptid="37420350" mdrpt="elderly">Elderly</span> Patients</span><span class="Italics">
                            [see Use in Specific Populations ( )]
                            <a href="#s116">8.5</a>
                        </span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s26"></a><a name="section-2.3.4"></a><p></p>
                    <p class="First">
                        — There are no adequate and well-controlled studies in <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> women; therefore, Cymbalta should be used during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> only if the potential benefit justifies the potential risk to the fetus .
                        <span class="Underline"><span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnant</span> Women</span><span class="Italics">
                            [see Use in Specific Populations ( )]
                            <a href="#s110">8.1</a>
                        </span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s27"></a><a name="section-2.3.5"></a><p></p>
                    <p class="First">Lilly maintains a <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> registry to monitor the <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> outcomes of women exposed to Cymbalta while <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span>. Healthcare providers are encouraged to register any patient who is exposed to Cymbalta during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> by calling the Cymbalta <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span> Registry at 1-866-814-6975 or by visiting www.cymbaltapregnancyregistry.com</p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s28"></a><a name="section-2.3.6"></a><p></p>
                    <p class="First">
                        — Because the safety of duloxetine in infants is not known, nursing while on Cymbalta is not recommended .
                        <span class="Underline">Nursing Mothers</span><span class="Italics">
                            [see Use in Specific Populations ( )]
                            <a href="#s114">8.3</a>
                        </span>
                    </p>
                </div>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s29"></a><a name="section-2.4"></a><p></p>
                <h2>2.4 Discontinuing Cymbalta</h2>
                <p class="First">
                    Symptoms associated with discontinuation of Cymbalta and other SSRIs and SNRIs have been reported. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s43">5.7</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s30"></a><a name="section-2.5"></a><p></p>
                <h2>2.5 Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders</h2>
                <p class="First">
                    At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with Cymbalta. Conversely, at least 5 days should be allowed after stopping Cymbalta before starting an MAOI intended to treat psychiatric disorders
                    <span class="Italics">
                        [see Contraindications ( )].
                        <a href="#s33">4.1</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s30a"></a><a name="section-2.6"></a><p></p>
                <h2>2.6 Use of Cymbalta with Other MAOIs such as Linezolid or Methylene Blue</h2>
                <p class="First">
                    Do not start Cymbalta in a patient who is being treated with linezolid or intravenous methylene blue because there is an increased risk of <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span>. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered
                    <span class="Italics">
                        [see Contraindications ( )].
                        <a href="#s33">4.1</a>
                    </span>
                </p>
                <p>
                    In some cases, a patient already receiving Cymbalta therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span> in a particular patient, Cymbalta should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span> for 5 days or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with Cymbalta may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s40">5.4</a>
                    </span>
                </p>
                <p>
                    The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local <span class="conditions" mdrptid="37522193" mdrpt="injection">injection</span>) or in intravenous doses much lower than 1 mg/kg with Cymbalta is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span> with such use .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s40">5.4</a>
                    </span>
                </p>
            </div>
        </div>
        <div class="Section" data-sectionCode="43678-2">
            <a name="s31"></a><a name="section-3"></a><p></p>
            <h1>3 DOSAGE FORMS AND STRENGTHS</h1>
            <p class="First">Cymbalta is available as delayed release capsules:</p>
            <p>20 mg opaque green capsules imprinted with “Lilly 3235 20mg”</p>
            <p>30 mg opaque white and blue capsules imprinted with “Lilly 3240 30mg”</p>
            <p>60 mg opaque green and blue capsules imprinted with “Lilly 3270 60mg”</p>
        </div>
        <div class="Section" data-sectionCode="34070-3">
            <a name="s32"></a><a name="section-4"></a><p></p>
            <h1>4 CONTRAINDICATIONS</h1>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s33"></a><a name="section-4.1"></a><p></p>
                <h2>4.1 Monoamine Oxidase Inhibitors (MAOIs)</h2>
                <p class="First">
                    The use of MAOIs intended to treat psychiatric disorders with Cymbalta or within 5 days of stopping treatment with Cymbalta is contraindicated because of an increased risk of <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span>. The use of Cymbalta within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated
                    <span class="Italics">
                        [see Dosage and Administration ( ) and Warnings and Precautions ( )].
                        <a href="#s30">2.5</a><a href="#s40">5.4</a>
                    </span>
                </p>
                <p>
                    Starting Cymbalta in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span>
                    <span class="Italics">
                        [see Dosage and Administration ( ) and Warnings and Precautions ( )].
                        <a href="#s30a">2.6</a><a href="#s40">5.4</a>
                    </span>
                </p>
            </div>
        </div>
        <div class="Section" data-sectionCode="43685-7">
            <a name="s35"></a><a name="section-5"></a><p></p>
            <h1>5 WARNINGS AND PRECAUTIONS</h1>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s36"></a><a name="section-5.1"></a><p></p>
                <h2>5.1 Suicidal Thoughts and Behaviors in Adolescents and Young Adults</h2>
                <p class="First">Patients with major <span class="conditions" mdrptid="36918942" mdrpt="depression">depressive disorder</span> (MDD), both adult and pediatric, may experience worsening of their <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span> and/or the emergence of <span class="conditions" mdrptid="36919235" mdrpt="suicidal ideation">suicidal ideation</span> and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. <span class="conditions" mdrptid="36919230" mdrpt="completed suicide">Suicide</span> is a known risk of <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span> and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of <span class="conditions" mdrptid="36919230" mdrpt="completed suicide">suicide</span>. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span> and the emergence of suicidality in certain patients during the early phases of treatment.</p>
                <p>Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major <span class="conditions" mdrptid="36918942" mdrpt="depression">depressive disorder</span> (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.</p>
                <p>
                    The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (<span class="conditions" mdrptid="36918902" mdrpt="obsessive-compulsive disorder">OCD</span>), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk of differences (drug vs placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in .
                    <a href="#t1">Table 1</a>
                </p>
                <a name="t1"></a><table width="100%">
                    <caption><span>Table 1</span></caption>
                    <col align="left" width="50.000%">
                    <col align="left" width="50.000%">
                    <tbody class="Headless">
                        <tr class="First">
                            <td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Age Range</span></td>
                            <td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated</span></td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="center" valign="top"></td>
                            <td class="Botrule Rrule" align="center" valign="top">Increases Compared to Placebo</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="center" valign="top">&lt;18</td>
                            <td class="Botrule Rrule" align="center" valign="top">14 additional cases</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="center" valign="top">18-24</td>
                            <td class="Botrule Rrule" align="center" valign="top">5 additional cases</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="center" valign="top"></td>
                            <td class="Botrule Rrule" align="center" valign="top">Decreases Compared to Placebo</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="center" valign="top">25-64</td>
                            <td class="Botrule Rrule" align="center" valign="top">1 fewer case</td>
                        </tr>
                        <tr class="Last">
                            <td class="Botrule Lrule Rrule" align="center" valign="top">≥65</td>
                            <td class="Botrule Rrule" align="center" valign="top">6 fewer cases</td>
                        </tr>
                    </tbody>
                </table>
                <p>No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on <span class="conditions" mdrptid="36919230" mdrpt="completed suicide">suicide</span>.</p>
                <p>It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span> that the use of antidepressants can delay the recurrence of <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span>.</p>
                <p><span class="Bold">All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of <span class="conditions" mdrptid="37522151" mdrpt="drug therapy">drug therapy</span>, or at times of dose changes, either increases or decreases.</span></p>
                <p>The following symptoms, <span class="conditions" mdrptid="36918858" mdrpt="anxiety">anxiety</span>, <span class="conditions" mdrptid="36718347" mdrpt="agitation">agitation</span>, <span class="conditions" mdrptid="36918904" mdrpt="panic attack">panic attacks</span>, <span class="conditions" mdrptid="36718555" mdrpt="insomnia">insomnia</span>, <span class="conditions" mdrptid="35809139" mdrpt="irritability">irritability</span>, <span class="conditions" mdrptid="36919069" mdrpt="hostility">hostility</span>, <span class="conditions" mdrptid="36919059" mdrpt="aggression">aggressiveness</span>, impulsivity, <span class="conditions" mdrptid="36718193" mdrpt="akathisia">akathisia</span> (<span class="conditions" mdrptid="36718368" mdrpt="restlessness">psychomotor restlessness</span>), <span class="conditions" mdrptid="36919035" mdrpt="hypomania">hypomania</span>, and <span class="conditions" mdrptid="36919036" mdrpt="mania">mania</span>, have been reported in adult and pediatric patients being treated with antidepressants for major <span class="conditions" mdrptid="36918942" mdrpt="depression">depressive disorder</span> as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span> and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.</p>
                <p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span> is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span> or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.</p>
                <p>
                    If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that discontinuation can be associated with certain symptoms .
                    <span class="Italics">
                        [see Dosage and Administration ( ) and Warnings and Precautions ( ) for descriptions of the risks of discontinuation of Cymbalta]
                        <a href="#s29">2.4</a><a href="#s43">5.7</a>
                    </span>
                </p>
                <p><span class="Bold">Families and caregivers of patients being treated with antidepressants for major <span class="conditions" mdrptid="36918942" mdrpt="depression">depressive disorder</span> or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of <span class="conditions" mdrptid="36718347" mdrpt="agitation">agitation</span>, <span class="conditions" mdrptid="35809139" mdrpt="irritability">irritability</span>, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for Cymbalta should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of <span class="conditions" mdrptid="36211496" mdrpt="overdose">overdose</span>.</span></p>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s37"></a><a name="section-5.1.1"></a><p></p>
                    <p class="First">
                        — A major <span class="conditions" mdrptid="36918942" mdrpt="depression">depressive episode</span> may be the initial presentation of <span class="conditions" mdrptid="36919033" mdrpt="bipolar disorder">bipolar disorder</span>. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/<span class="conditions" mdrptid="36919036" mdrpt="mania">manic episode</span> in patients at risk for <span class="conditions" mdrptid="36919033" mdrpt="bipolar disorder">bipolar disorder</span>. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for <span class="conditions" mdrptid="36919033" mdrpt="bipolar disorder">bipolar disorder</span>; such screening should include a detailed psychiatric history, including a <span class="conditions" mdrptid="37420426" mdrpt="familial risk factor">family history of suicide</span>, <span class="conditions" mdrptid="36919033" mdrpt="bipolar disorder">bipolar disorder</span>, and <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span>. It should be noted that Cymbalta (duloxetine) is not approved for use in treating <span class="conditions" mdrptid="36919031" mdrpt="bipolar i disorder">bipolar depression</span>.
                        <span class="Bold">Screening Patients for <span class="conditions" mdrptid="36919033" mdrpt="bipolar disorder">Bipolar Disorder</span></span>
                    </p>
                </div>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s38"></a><a name="section-5.2"></a><p></p>
                <h2>5.2 <span class="conditions" mdrptid="35909625" mdrpt="hepatotoxicity">Hepatotoxicity</span></h2>
                <p class="First">There have been reports of <span class="conditions" mdrptid="35909518" mdrpt="hepatic failure">hepatic failure</span>, sometimes fatal, in patients treated with Cymbalta. These cases have presented as <span class="conditions" mdrptid="35909613" mdrpt="hepatitis">hepatitis</span> with <span class="conditions" mdrptid="35708154" mdrpt="abdominal pain">abdominal pain</span>, <span class="conditions" mdrptid="35909594" mdrpt="hepatomegaly">hepatomegaly</span>, and elevation of transaminase levels to more than twenty times the upper limit of normal with or without <span class="conditions" mdrptid="35104306" mdrpt="jaundice">jaundice</span>, reflecting a mixed or hepatocellular pattern of <span class="conditions" mdrptid="35909503" mdrpt="liver injury">liver injury</span>. Cymbalta should be discontinued in patients who develop <span class="conditions" mdrptid="35104306" mdrpt="jaundice">jaundice</span> or other evidence of clinically significant liver dysfunction and should not be resumed unless another cause can be established.</p>
                <p>Cases of <span class="conditions" mdrptid="35909473" mdrpt="jaundice cholestatic">cholestatic jaundice</span> with minimal elevation of transaminase levels have also been reported. Other postmarketing reports indicate that elevated <span class="conditions" mdrptid="36313602" mdrpt="transaminases">transaminases</span>, <span class="conditions" mdrptid="36313547" mdrpt="blood bilirubin">bilirubin</span>, and <span class="conditions" mdrptid="36312565" mdrpt="blood alkaline phosphatase">alkaline phosphatase</span> have occurred in patients with <span class="conditions" mdrptid="35909501" mdrpt="liver disorder">chronic liver disease</span> or cirrhosis.</p>
                <p>Cymbalta increased the risk of elevation of serum transaminase levels in development program clinical trials. Liver transaminase elevations resulted in the discontinuation of 0.3% (92/34,756) of Cymbalta-treated patients. In most patients, the median time to detection of the transaminase elevation was about two months. In placebo-controlled trials in any indication, for patients with normal and abnormal baseline ALT values, elevation of ALT &gt;3 times the upper limit of normal occurred in 1.25% (144/11,496) of Cymbalta-treated patients compared to 0.45% (39/8716) of placebo-treated patients. In placebo-controlled studies using a fixed dose design, there was evidence of a dose response relationship for ALT and <span class="conditions" mdrptid="36313531" mdrpt="aspartate aminotransferase">AST</span> elevation of &gt;3 times the upper limit of normal and &gt;5 times the upper limit of normal, respectively.</p>
                <p>Because it is possible that duloxetine and alcohol may interact to cause <span class="conditions" mdrptid="35909503" mdrpt="liver injury">liver injury</span> or that duloxetine may aggravate pre-existing liver disease, Cymbalta should not be prescribed to patients with substantial <span class="conditions" mdrptid="37420495" mdrpt="alcohol use">alcohol use</span> or evidence of <span class="conditions" mdrptid="35909501" mdrpt="liver disorder">chronic liver disease</span>.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s39"></a><a name="section-5.3"></a><p></p>
                <h2>5.3 <span class="conditions" mdrptid="37622451" mdrpt="orthostatic hypotension">Orthostatic Hypotension</span> and <span class="conditions" mdrptid="35205037" mdrpt="syncope">Syncope</span></h2>
                <p class="First">
                    <span class="conditions" mdrptid="37622451" mdrpt="orthostatic hypotension">Orthostatic hypotension</span> and <span class="conditions" mdrptid="35205037" mdrpt="syncope">syncope</span> have been reported with therapeutic doses of duloxetine. <span class="conditions" mdrptid="35205037" mdrpt="syncope">Syncope</span> and <span class="conditions" mdrptid="37622451" mdrpt="orthostatic hypotension">orthostatic hypotension</span> tend to occur within the first week of therapy but can occur at any time during duloxetine treatment, particularly after dose increases. The risk of <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span> decreases may be greater in patients taking concomitant medications that induce <span class="conditions" mdrptid="37622451" mdrpt="orthostatic hypotension">orthostatic hypotension</span> (such as antihypertensives) or are potent CYP1A2 inhibitors and in patients taking duloxetine at doses above 60 mg daily. Consideration should be given to discontinuing duloxetine in patients who experience symptomatic <span class="conditions" mdrptid="37622451" mdrpt="orthostatic hypotension">orthostatic hypotension</span> and/or <span class="conditions" mdrptid="35205037" mdrpt="syncope">syncope</span> during duloxetine therapy.
                    <span class="Italics">
                        [see Warnings and Precautions ( ) and Drug Interactions ( )]
                        <a href="#s47">5.12</a><a href="#s91">7.1</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s40"></a><a name="section-5.4"></a><p></p>
                <h2>5.4 <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">Serotonin Syndrome</span></h2>
                <p class="First">The development of a potentially life-threatening <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span> has been reported with SNRIs and SSRIs, including Cymbalta, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</p>
                <p><span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="conditions" mdrptid="36919118" mdrpt="mental status changes">mental status changes</span> (e.g., <span class="conditions" mdrptid="36718347" mdrpt="agitation">agitation</span>, <span class="conditions" mdrptid="36918984" mdrpt="hallucination">hallucinations</span>, <span class="conditions" mdrptid="36918937" mdrpt="delirium">delirium</span>, and <span class="conditions" mdrptid="36718288" mdrpt="coma">coma</span>), <span class="conditions" mdrptid="35809073" mdrpt="autonomic nervous system imbalance">autonomic instability</span> (e.g., <span class="conditions" mdrptid="35204948" mdrpt="tachycardia">tachycardia</span>, <span class="conditions" mdrptid="37622440" mdrpt="labile blood pressure">labile blood pressure</span>, <span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span>, <span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">diaphoresis</span>, <span class="conditions" mdrptid="35809130" mdrpt="flushing">flushing</span>, <span class="conditions" mdrptid="35809039" mdrpt="hyperthermia">hyperthermia</span>), neuromuscular symptoms (e.g., <span class="conditions" mdrptid="36718265" mdrpt="tremor">tremor</span>, <span class="conditions" mdrptid="36516867" mdrpt="muscle rigidity">rigidity</span>, <span class="conditions" mdrptid="36718362" mdrpt="myoclonus">myoclonus</span>, <span class="conditions" mdrptid="36718272" mdrpt="hyperreflexia">hyperreflexia</span>, <span class="conditions" mdrptid="36718285" mdrpt="coordination abnormal">incoordination</span>), <span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizures</span>, and/or gastrointestinal symptoms (e.g., <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span>, <span class="conditions" mdrptid="35708208" mdrpt="vomiting">vomiting</span>, <span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">diarrhea</span>). Patients should be monitored for the emergence of <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span>.</p>
                <p>
                    The concomitant use of Cymbalta with MAOIs intended to treat psychiatric disorders is contraindicated. Cymbalta should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue <span class="conditions" mdrptid="37522193" mdrpt="injection">injection</span>) or at lower doses. There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking Cymbalta. Cymbalta should be discontinued before initiating treatment with the MAOI
                    <span class="Italics">
                        [see Dosage and Administration ( , ), and Contraindications ( )].
                        <a href="#s30">2.5</a><a href="#s30a">2.6</a><a href="#s33">4.1</a>
                    </span>
                </p>
                <p>If concomitant use of Cymbalta with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span>, particularly during treatment initiation and dose increases. Treatment with Cymbalta and any concomitant serotonergic agents, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s41"></a><a name="section-5.5"></a><p></p>
                <h2>5.5 Abnormal <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">Bleeding</span></h2>
                <p class="First">SSRIs and SNRIs, including duloxetine, may increase the risk of <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">bleeding</span> events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anti-coagulants may <span class="conditions" mdrptid="36918918" mdrpt="attention deficit/hyperactivity disorder">add</span> to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of <span class="conditions" mdrptid="35707864" mdrpt="gastrointestinal haemorrhage">gastrointestinal bleeding</span>. <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">Bleeding</span> events related to SSRIs and SNRIs use have ranged from <span class="conditions" mdrptid="35104119" mdrpt="ecchymosis">ecchymoses</span>, hematomas, <span class="conditions" mdrptid="37220014" mdrpt="epistaxis">epistaxis</span>, and <span class="conditions" mdrptid="35104125" mdrpt="petechiae">petechiae</span> to life-threatening hemorrhages.</p>
                <p>Patients should be cautioned about the risk of <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">bleeding</span> associated with the concomitant use of duloxetine and NSAIDs, aspirin, or other drugs that affect coagulation.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s42"></a><a name="section-5.6"></a><p></p>
                <h2>5.6 Severe Skin Reactions</h2>
                <p class="First">Severe skin reactions, including <span class="conditions" mdrptid="36009707" mdrpt="erythema multiforme">erythema multiforme</span> and <span class="conditions" mdrptid="36009724" mdrpt="stevens-johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), can occur with Cymbalta. The reporting rate of SJS associated with Cymbalta use exceeds the general population background incidence rate for this serious <span class="conditions" mdrptid="36009723" mdrpt="skin reaction">skin reaction</span> (1 to 2 cases per million person years). The reporting rate is generally accepted to be an underestimate due to underreporting.</p>
                <p>Cymbalta should be discontinued at the first appearance of <span class="conditions" mdrptid="36211383" mdrpt="blister">blisters</span>, <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">peeling</span> <span class="conditions" mdrptid="37320212" mdrpt="rash">rash</span>, mucosal erosions, or any other sign of <span class="conditions" mdrptid="36009711" mdrpt="hypersensitivity">hypersensitivity</span> if no other etiology can be identified.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s43"></a><a name="section-5.7"></a><p></p>
                <h2>5.7 Discontinuation of Treatment with Cymbalta</h2>
                <p class="First">Discontinuation symptoms have been systematically evaluated in patients taking duloxetine. Following abrupt or tapered discontinuation in placebo-controlled clinical trials, the following symptoms occurred at 1% or greater and at a significantly higher rate in duloxetine-treated patients compared to those discontinuing from placebo: <span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span>, <span class="conditions" mdrptid="36718132" mdrpt="headache">headache</span>, <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span>, <span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">diarrhea</span>, <span class="conditions" mdrptid="36718379" mdrpt="paraesthesia">paresthesia</span>, <span class="conditions" mdrptid="35809139" mdrpt="irritability">irritability</span>, <span class="conditions" mdrptid="35708208" mdrpt="vomiting">vomiting</span>, <span class="conditions" mdrptid="36718555" mdrpt="insomnia">insomnia</span>, <span class="conditions" mdrptid="36918858" mdrpt="anxiety">anxiety</span>, <span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">hyperhidrosis</span>, and <span class="conditions" mdrptid="35809076" mdrpt="fatigue">fatigue</span>.</p>
                <p>During marketing of other SSRIs and SNRIs (serotonin and norepinephrine reuptake inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, <span class="conditions" mdrptid="35809139" mdrpt="irritability">irritability</span>, <span class="conditions" mdrptid="36718347" mdrpt="agitation">agitation</span>, <span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span>, sensory disturbances (e.g., paresthesias such as <span class="conditions" mdrptid="36211294" mdrpt="electric shock">electric shock</span> sensations), <span class="conditions" mdrptid="36918858" mdrpt="anxiety">anxiety</span>, <span class="conditions" mdrptid="36718301" mdrpt="confusional state">confusion</span>, <span class="conditions" mdrptid="36718132" mdrpt="headache">headache</span>, <span class="conditions" mdrptid="35809077" mdrpt="lethargy">lethargy</span>, <span class="conditions" mdrptid="36919037" mdrpt="affect lability">emotional lability</span>, <span class="conditions" mdrptid="36718555" mdrpt="insomnia">insomnia</span>, <span class="conditions" mdrptid="36919035" mdrpt="hypomania">hypomania</span>, <span class="conditions" mdrptid="35406391" mdrpt="tinnitus">tinnitus</span>, and <span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizures</span>. Although these events are generally self-limiting, some have been reported to be severe.</p>
                <p>
                    Patients should be monitored for these symptoms when discontinuing treatment with Cymbalta. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate .
                    <span class="Italics">
                        [see Dosage and Administration ( )]
                        <a href="#s29">2.4</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s44"></a><a name="section-5.8"></a><p></p>
                <h2>5.8 Activation of <span class="conditions" mdrptid="36919036" mdrpt="mania">Mania</span>/<span class="conditions" mdrptid="36919035" mdrpt="hypomania">Hypomania</span></h2>
                <p class="First">In placebo-controlled trials in patients with major <span class="conditions" mdrptid="36918942" mdrpt="depression">depressive disorder</span>, activation of <span class="conditions" mdrptid="36919036" mdrpt="mania">mania</span> or <span class="conditions" mdrptid="36919035" mdrpt="hypomania">hypomania</span> was reported in 0.1% (4/3779) of duloxetine-treated patients and 0.04% (1/2536) of placebo-treated patients. No activation of <span class="conditions" mdrptid="36919036" mdrpt="mania">mania</span> or <span class="conditions" mdrptid="36919035" mdrpt="hypomania">hypomania</span> was reported in <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span>, <span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">fibromyalgia</span>, or chronic <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">musculoskeletal pain</span> placebo-controlled trials. Activation of <span class="conditions" mdrptid="36919036" mdrpt="mania">mania</span> or <span class="conditions" mdrptid="36919035" mdrpt="hypomania">hypomania</span> has been reported in a small proportion of patients with mood disorders who were treated with other marketed drugs effective in the treatment of major <span class="conditions" mdrptid="36918942" mdrpt="depression">depressive disorder</span>. As with these other agents, Cymbalta should be used cautiously in patients with a history of <span class="conditions" mdrptid="36919036" mdrpt="mania">mania</span>.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="e44"></a><a name="section-5.9"></a><p></p>
                <h2 style="border-left:1px solid;">
                    5.9 Angle-Closure <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">Glaucoma</span>
                    <span class="XmChange"></span>
                </h2>
                <p class="First" style="border-left:1px solid;">
                    — The pupillary dilation that occurs following use of many antidepressant drugs including Cymbalta may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent <span class="conditions" mdrptid="37520878" mdrpt="iridectomy">iridectomy</span>.
                    <span class="XmChange"></span><span class="Underline">Angle-Closure <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">Glaucoma</span></span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s45"></a><a name="section-5.10"></a><p></p>
                <h2>5.10 <span class="conditions" mdrptid="36718526" mdrpt="convulsion">Seizures</span></h2>
                <p class="First">Duloxetine has not been systematically evaluated in patients with a <span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizure</span> disorder, and such patients were excluded from clinical studies. In placebo-controlled clinical trials, <span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizures</span>/<span class="conditions" mdrptid="36718526" mdrpt="convulsion">convulsions</span> occurred in 0.02% (3/12,722) of patients treated with duloxetine and 0.01% (1/9513) of patients treated with placebo. Cymbalta should be prescribed with care in patients with a history of a <span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizure</span> disorder.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s46"></a><a name="section-5.11"></a><p></p>
                <h2>5.11 Effect on <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">Blood Pressure</span></h2>
                <p class="First">In placebo-controlled clinical trials across indications from baseline to endpoint, duloxetine treatment was associated with mean increases of 0.5 mm Hg in <span class="conditions" mdrptid="36312084" mdrpt="blood pressure systolic">systolic blood pressure</span> and 0.8 mm Hg in diastolic <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span> compared to mean decreases of 0.6 mm Hg systolic and 0.3 mm Hg diastolic in placebo-treated patients. There was no significant difference in the frequency of sustained (3 consecutive visits) elevated <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span>. In a clinical pharmacology study designed to evaluate the effects of duloxetine on various parameters, including <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span> at supratherapeutic doses with an accelerated dose titration, there was evidence of increases in supine <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span> at doses up to 200 mg twice daily. At the highest 200 mg twice daily dose, the increase in mean <span class="conditions" mdrptid="36311980" mdrpt="heart rate">pulse rate</span> was 5.0 to 6.8 beats and increases in mean <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span> were 4.7 to 6.8 mm Hg (systolic) and 4.5 to 7 mm Hg (diastolic) up to 12 hours after dosing.</p>
                <p>
                    <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">Blood pressure</span> should be measured prior to initiating treatment and periodically measured throughout treatment .
                    <span class="Italics">
                        [see Adverse Reactions ( )]
                        <a href="#s84">6.7</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s47"></a><a name="section-5.12"></a><p></p>
                <h2>5.12 Clinically Important Drug Interactions</h2>
                <p class="First">Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism.</p>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s48"></a><a name="section-5.12.1"></a><p></p>
                    <p class="First"><span class="Underline">Potential for Other Drugs to Affect Cymbalta</span></p>
                    <div class="Section" data-sectionCode="42229-5">
                        <a name="s49"></a><a name="section-5.12.1.1"></a><p></p>
                        <p class="First">
                            — Co-administration of Cymbalta with potent CYP1A2 inhibitors should be avoided .
                            <span class="Italics">CYP1A2 Inhibitors</span><span class="Italics">
                                [see Drug Interactions ( )]
                                <a href="#s91">7.1</a>
                            </span>
                        </p>
                    </div>
                    <div class="Section" data-sectionCode="42229-5">
                        <a name="s50"></a><a name="section-5.12.1.2"></a><p></p>
                        <p class="First">
                            — Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 would be expected to, and does, result in higher concentrations (on average of 60%) of duloxetine .
                            <span class="Italics">CYP2D6 Inhibitors</span><span class="Italics">
                                [see Drug Interactions ( )]
                                <a href="#s92">7.2</a>
                            </span>
                        </p>
                    </div>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s51"></a><a name="section-5.12.2"></a><p></p>
                    <p class="First"><span class="Underline">Potential for Cymbalta to Affect Other Drugs</span></p>
                    <div class="Section" data-sectionCode="42229-5">
                        <a name="s52"></a><a name="section-5.12.2.1"></a><p></p>
                        <p class="First">
                            — Co-administration of Cymbalta with drugs that are extensively metabolized by CYP2D6 and that have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution. Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Cymbalta. Because of the risk of serious ventricular arrhythmias and <span class="conditions" mdrptid="35204976" mdrpt="sudden death">sudden death</span> potentially associated with elevated plasma levels of thioridazine, Cymbalta and thioridazine should not be co-administered .
                            <span class="Italics">Drugs Metabolized by CYP2D6</span><span class="Italics">
                                [see Drug Interactions ( )]
                                <a href="#s99">7.9</a>
                            </span>
                        </p>
                    </div>
                    <div class="Section" data-sectionCode="42229-5">
                        <a name="s53"></a><a name="section-5.12.2.2"></a><p></p>
                        <p class="First"><span class="Underline">Other Clinically Important Drug Interactions</span></p>
                    </div>
                    <div class="Section" data-sectionCode="42229-5">
                        <a name="s54"></a><a name="section-5.12.2.3"></a><p></p>
                        <p class="First">
                            — Use of Cymbalta concomitantly with heavy alcohol intake may be associated with severe <span class="conditions" mdrptid="35909503" mdrpt="liver injury">liver injury</span>. For this reason, Cymbalta should not be prescribed for patients with substantial <span class="conditions" mdrptid="37420495" mdrpt="alcohol use">alcohol use</span> .
                            <span class="Italics">Alcohol</span><span class="Italics">
                                [see Warnings and Precautions ( ) and Drug Interactions ( )]
                                <a href="#s38">5.2</a><a href="#s106">7.15</a>
                            </span>
                        </p>
                    </div>
                    <div class="Section" data-sectionCode="42229-5">
                        <a name="s55"></a><a name="section-5.12.2.4"></a><p></p>
                        <p class="First">
                            — Given the primary CNS effects of Cymbalta, it should be used with caution when it is taken in combination with or substituted for other centrally acting drugs, including those with a similar mechanism of action .
                            <span class="Italics">CNS Acting Drugs</span><span class="Italics">
                                [see Warnings and Precautions ( ) and Drug Interactions ( )]
                                <a href="#s47">5.12</a><a href="#s107">7.16</a>
                            </span>
                        </p>
                    </div>
                </div>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s56"></a><a name="section-5.13"></a><p></p>
                <h2>5.13 <span class="conditions" mdrptid="36416600" mdrpt="hyponatraemia">Hyponatremia</span></h2>
                <p class="First">
                    <span class="conditions" mdrptid="36416600" mdrpt="hyponatraemia">Hyponatremia</span> may occur as a result of treatment with SSRIs and SNRIs, including Cymbalta. In many cases, this <span class="conditions" mdrptid="36416600" mdrpt="hyponatraemia">hyponatremia</span> appears to be the result of the syndrome of <span class="conditions" mdrptid="35506690" mdrpt="inappropriate antidiuretic hormone secretion">inappropriate antidiuretic hormone secretion</span> (<span class="conditions" mdrptid="35506690" mdrpt="inappropriate antidiuretic hormone secretion">SIADH</span>). Cases with <span class="conditions" mdrptid="36316389" mdrpt="blood sodium">serum sodium</span> lower than 110 mmol/L have been reported and appeared to be reversible when Cymbalta was discontinued. <span class="conditions" mdrptid="37420350" mdrpt="elderly">Elderly</span> patients may be at greater risk of developing <span class="conditions" mdrptid="36416600" mdrpt="hyponatraemia">hyponatremia</span> with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk . Discontinuation of Cymbalta should be considered in patients with symptomatic <span class="conditions" mdrptid="36416600" mdrpt="hyponatraemia">hyponatremia</span> and appropriate medical intervention should be instituted.
                    <span class="Italics">
                        [see Use in Specific Populations ( )]
                        <a href="#s116">8.5</a>
                    </span>
                </p>
                <p>Signs and symptoms of <span class="conditions" mdrptid="36416600" mdrpt="hyponatraemia">hyponatremia</span> include <span class="conditions" mdrptid="36718132" mdrpt="headache">headache</span>, difficulty concentrating, <span class="conditions" mdrptid="36718175" mdrpt="memory impairment">memory impairment</span>, <span class="conditions" mdrptid="36718301" mdrpt="confusional state">confusion</span>, <span class="conditions" mdrptid="35809072" mdrpt="asthenia">weakness</span>, and <span class="conditions" mdrptid="36718280" mdrpt="balance disorder">unsteadiness</span>, which may lead to falls. More severe and/or acute cases have been associated with <span class="conditions" mdrptid="36918984" mdrpt="hallucination">hallucination</span>, <span class="conditions" mdrptid="35205037" mdrpt="syncope">syncope</span>, <span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizure</span>, <span class="conditions" mdrptid="36718288" mdrpt="coma">coma</span>, <span class="conditions" mdrptid="37219893" mdrpt="respiratory arrest">respiratory arrest</span>, and <span class="conditions" mdrptid="35809059" mdrpt="death">death</span>.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s57"></a><a name="section-5.14"></a><p></p>
                <h2>5.14 Use in Patients with Concomitant Illness</h2>
                <p class="First">Clinical experience with Cymbalta in patients with concomitant systemic illnesses is limited. There is no information on the effect that alterations in gastric motility may have on the stability of Cymbalta's enteric coating. In extremely acidic conditions, Cymbalta, unprotected by the enteric coating, may undergo hydrolysis to form naphthol. Caution is advised in using Cymbalta in patients with conditions that may slow gastric emptying (e.g., some diabetics).</p>
                <p>Cymbalta has not been systematically evaluated in patients with a recent history of <span class="conditions" mdrptid="35205189" mdrpt="myocardial infarction">myocardial infarction</span> or unstable <span class="conditions" mdrptid="35205164" mdrpt="coronary artery disease">coronary artery disease</span>. Patients with these diagnoses were generally excluded from clinical studies during the product's premarketing testing.</p>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s58"></a><a name="section-5.14.1"></a><p></p>
                    <p class="First">
                        — Cymbalta should ordinarily not be used in patients with <span class="conditions" mdrptid="35909518" mdrpt="hepatic failure">hepatic insufficiency</span> .
                        <span class="Underline"><span class="conditions" mdrptid="35909518" mdrpt="hepatic failure">Hepatic Insufficiency</span></span><span class="Italics">
                            [see Dosage and Administration ( ), Warnings and Precautions ( ), and Use in Specific Populations ( )]
                            <a href="#s22">2.3</a><a href="#s38">5.2</a><a href="#s120">8.9</a>
                        </span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s59"></a><a name="section-5.14.2"></a><p></p>
                    <p class="First">
                        — Cymbalta should ordinarily not be used in patients with end-stage <span class="conditions" mdrptid="37019308" mdrpt="renal disorder">renal disease</span> or severe <span class="conditions" mdrptid="37019321" mdrpt="renal impairment">renal impairment</span> (<span class="conditions" mdrptid="36315593" mdrpt="creatinine renal clearance">creatinine clearance</span> &lt;30 mL/min). Increased plasma concentration of duloxetine, and especially of its metabolites, occur in patients with end-stage <span class="conditions" mdrptid="37019308" mdrpt="renal disorder">renal disease</span> (requiring <span class="conditions" mdrptid="37521159" mdrpt="dialysis">dialysis</span>) .
                        <span class="Underline">Severe <span class="conditions" mdrptid="37019321" mdrpt="renal impairment">Renal Impairment</span></span><span class="Italics">
                            [see Dosage and Administration ( ) and Use in Specific Populations ( )]
                            <a href="#s22">2.3</a><a href="#s121">8.10</a>
                        </span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s61"></a><a name="section-5.14.3"></a><p></p>
                    <p class="First">
                        — As observed in DPNP trials, Cymbalta treatment worsens glycemic control in some patients with <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span>. In three clinical trials of Cymbalta for the management of <span class="conditions" mdrptid="36718401" mdrpt="neuralgia">neuropathic pain</span> associated with <span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">diabetic peripheral neuropathy</span>, the mean duration of <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span> was approximately 12 years, the mean baseline <span class="conditions" mdrptid="36314155" mdrpt="blood glucose">fasting blood glucose</span> was 176 mg/dL, and the mean baseline <span class="conditions" mdrptid="36313224" mdrpt="haemoglobin">hemoglobin</span> A (HbA ) was 7.8%. In the 12-week acute treatment phase of these studies, Cymbalta was associated with a small increase in mean <span class="conditions" mdrptid="36314155" mdrpt="blood glucose">fasting blood glucose</span> as compared to placebo. In the extension phase of these studies, which lasted up to 52 weeks, mean <span class="conditions" mdrptid="36314160" mdrpt="blood glucose increased">fasting blood glucose increased</span> by 12 mg/dL in the Cymbalta group and decreased by 11.5 mg/dL in the routine care group. HbA increased by 0.5% in the Cymbalta and by 0.2% in the routine care groups.
                        <span class="Underline">Glycemic Control in Patients with <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">Diabetes</span></span><span class="Sub">1c</span><span class="Sub">1c</span><span class="Sub">1c</span>
                    </p>
                </div>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s62"></a><a name="section-5.15"></a><p></p>
                <h2>5.15 <span class="conditions" mdrptid="37019409" mdrpt="urinary hesitation">Urinary Hesitation</span> and Retention</h2>
                <p class="First">Cymbalta is in a class of drugs known to affect urethral resistance. If symptoms of <span class="conditions" mdrptid="37019409" mdrpt="urinary hesitation">urinary hesitation</span> develop during treatment with Cymbalta, consideration should be given to the possibility that they might be drug-related.</p>
                <p>In post marketing experience, cases of <span class="conditions" mdrptid="37019410" mdrpt="urinary retention">urinary retention</span> have been observed. In some instances of <span class="conditions" mdrptid="37019410" mdrpt="urinary retention">urinary retention</span> associated with duloxetine use, hospitalization and/or catheterization has been needed.</p>
            </div>
            <div class="Section" data-sectionCode="34075-2">
                <a name="s63"></a><a name="section-5.16"></a><p></p>
                <h2>5.16 Laboratory Tests</h2>
                <p class="First">No specific laboratory tests are recommended.</p>
            </div>
        </div>
        <div class="Section" data-sectionCode="34084-4">
            <a name="s64"></a><a name="section-6"></a><p></p>
            <h1>6 ADVERSE REACTIONS</h1>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s65"></a><a name="section-6.1"></a><p></p>
                <h2>6.1 Clinical Trial Data Sources</h2>
                <p class="First">
                    The data described below reflect exposure to duloxetine in placebo-controlled trials for MDD (N=3779), <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span> (N=1018), OA (N=503), CLBP (N=600), DPNP (N=906), and FM (N=1294). The population studied was 17 to 89 years of age; 65.7%, 60.8%, 60.6%, 42.9%, and 94.4% female; and 81.8%, 72.6%, 85.3%, 74.0%, and 85.7% Caucasian for MDD, <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span>, OA and CLBP, DPNP, and FM, respectively. Most patients received doses of a total of 60 to 120 mg per day .
                    <span class="Italics">
                        [see Clinical Studies ( )]
                        <a href="#s140">14</a>
                    </span>
                </p>
                <p>The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent <span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">adverse reaction</span> of the type listed. A reaction was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. Reactions reported during the studies were not necessarily caused by the therapy, and the frequencies do not reflect investigator impression (assessment) of causality.</p>
                <p>Because clinical trials are conducted under widely varying conditions, <span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">adverse reaction</span> rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s66"></a><a name="section-6.2"></a><p></p>
                <h2>6.2 Adverse Reactions Reported as Reasons for Discontinuation of Treatment in Placebo-Controlled Trials</h2>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s67"></a><a name="section-6.2.1"></a><p></p>
                    <p class="First">
                        — Approximately 8.4% (319/3779) of the patients who received duloxetine in placebo-controlled trials for MDD discontinued treatment due to an <span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">adverse reaction</span>, compared with 4.6% (117/2536) of the patients receiving placebo. <span class="conditions" mdrptid="35708202" mdrpt="nausea">Nausea</span> (duloxetine 1.1%, placebo 0.4%) was the only common <span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">adverse reaction</span> reported as a reason for discontinuation and considered to be drug-related (i.e., discontinuation occurring in at least 1% of the duloxetine-treated patients and at a rate of at least twice that of placebo).
                        <span class="Underline">Major <span class="conditions" mdrptid="36918942" mdrpt="depression">Depressive Disorder</span></span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s68"></a><a name="section-6.2.2"></a><p></p>
                    <p class="First">
                        — Approximately 13.7% (139/1018) of the patients who received duloxetine in placebo-controlled trials for <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span> discontinued treatment due to an <span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">adverse reaction</span>, compared with 5.0% (38/767) for placebo. Common adverse reactions reported as a reason for discontinuation and considered to be drug-related (as defined above) included <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span> (duloxetine 3.3%, placebo 0.4%), and <span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span> (duloxetine 1.3%, placebo 0.4%).
                        <span class="Underline"><span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">Generalized Anxiety Disorder</span></span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s69"></a><a name="section-6.2.3"></a><p></p>
                    <p class="First">
                        — Approximately 12.9% (117/906) of the patients who received duloxetine in placebo-controlled trials for DPNP discontinued treatment due to an <span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">adverse reaction</span>, compared with 5.1% (23/448) for placebo. Common adverse reactions reported as a reason for discontinuation and considered to be drug-related (as defined above) included <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span> (duloxetine 3.5%, placebo 0.7%), <span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span> (duloxetine 1.2%, placebo 0.4%), and <span class="conditions" mdrptid="36718321" mdrpt="somnolence">somnolence</span> (duloxetine 1.1%, placebo 0.0%).
                        <span class="Underline"><span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s70"></a><a name="section-6.2.4"></a><p></p>
                    <p class="First">
                        — Approximately 17.5% (227/1294) of the patients who received duloxetine in 3 to 6 month placebo-controlled trials for FM discontinued treatment due to an <span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">adverse reaction</span>, compared with 10.1% (96/955) for placebo. Common adverse reactions reported as a reason for discontinuation and considered to be drug-related (as defined above) included <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span> (duloxetine 2.0%, placebo 0.5%), <span class="conditions" mdrptid="36718132" mdrpt="headache">headache</span> (duloxetine 1.2%, placebo 0.3%), <span class="conditions" mdrptid="36718321" mdrpt="somnolence">somnolence</span> (duloxetine 1.1%, placebo 0.0%), and <span class="conditions" mdrptid="35809076" mdrpt="fatigue">fatigue</span> (duloxetine 1.1%, placebo 0.1%).
                        <span class="Underline"><span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">Fibromyalgia</span></span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s71"></a><a name="section-6.2.5"></a><p></p>
                    <p class="First">
                        — Approximately 15.7% (79/503) of the patients who received duloxetine in 13-week, placebo-controlled trials for <span class="conditions" mdrptid="35809243" mdrpt="pain">chronic pain</span> due to OA discontinued treatment due to an <span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">adverse reaction</span>, compared with 7.3% (37/508) for placebo. Common adverse reactions reported as a reason for discontinuation and considered to be drug-related (as defined above) included <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span> (duloxetine 2.2%, placebo 1.0%).
                        <span class="Underline"><span class="conditions" mdrptid="35809243" mdrpt="pain">Chronic Pain</span> due to <span class="conditions" mdrptid="36516824" mdrpt="osteoarthritis">Osteoarthritis</span></span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s72"></a><a name="section-6.2.6"></a><p></p>
                    <p class="First">
                        — Approximately 16.5% (99/600) of the patients who received duloxetine in 13-week, placebo-controlled trials for CLBP discontinued treatment due to an <span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">adverse reaction</span>, compared with 6.3% (28/441) for placebo. Common adverse reactions reported as a reason for discontinuation and considered to be drug-related (as defined above) included <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span> (duloxetine 3.0%, placebo 0.7%), and <span class="conditions" mdrptid="36718321" mdrpt="somnolence">somnolence</span> (duloxetine 1.0%, placebo 0.0%).
                        <span class="Underline">Chronic <span class="conditions" mdrptid="36516951" mdrpt="back pain">Low Back Pain</span></span>
                    </p>
                </div>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s73"></a><a name="section-6.3"></a><p></p>
                <h2>6.3 Most Common Adverse Reactions</h2>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s74"></a><a name="section-6.3.1"></a><p></p>
                    <p class="First">
                        — The most commonly observed adverse reactions in Cymbalta-treated patients (incidence of at least 5% and at least twice the incidence in placebo patients) were <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span>, <span class="conditions" mdrptid="35708690" mdrpt="dry mouth">dry mouth</span>, <span class="conditions" mdrptid="36718321" mdrpt="somnolence">somnolence</span>, <span class="conditions" mdrptid="35708100" mdrpt="constipation">constipation</span>, <span class="conditions" mdrptid="36416514" mdrpt="decreased appetite">decreased appetite</span>, and <span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">hyperhidrosis</span>.
                        <span class="Underline">Pooled Trials for all Approved Indications</span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s75"></a><a name="section-6.3.2"></a><p></p>
                    <p class="First">
                        — The most commonly observed adverse reactions in Cymbalta-treated patients (as defined above) were <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span>, <span class="conditions" mdrptid="36718321" mdrpt="somnolence">somnolence</span>, <span class="conditions" mdrptid="36416514" mdrpt="decreased appetite">decreased appetite</span>, <span class="conditions" mdrptid="35708100" mdrpt="constipation">constipation</span>, <span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">hyperhidrosis</span>, and <span class="conditions" mdrptid="35708690" mdrpt="dry mouth">dry mouth</span>.
                        <span class="Underline"><span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s76"></a><a name="section-6.3.3"></a><p></p>
                    <p class="First">
                        — The most commonly observed adverse reactions in Cymbalta-treated patients (as defined above) were <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span>, <span class="conditions" mdrptid="35708690" mdrpt="dry mouth">dry mouth</span>, <span class="conditions" mdrptid="35708100" mdrpt="constipation">constipation</span>, <span class="conditions" mdrptid="36718321" mdrpt="somnolence">somnolence</span>, <span class="conditions" mdrptid="36416514" mdrpt="decreased appetite">decreased appetite</span>, <span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">hyperhidrosis</span>, and <span class="conditions" mdrptid="36718347" mdrpt="agitation">agitation</span>.
                        <span class="Underline"><span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">Fibromyalgia</span></span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s77"></a><a name="section-6.3.4"></a><p></p>
                    <p class="First">
                        — The most commonly observed adverse reactions in Cymbalta-treated patients (as defined above) were <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span>, <span class="conditions" mdrptid="35809076" mdrpt="fatigue">fatigue</span>, <span class="conditions" mdrptid="35708100" mdrpt="constipation">constipation</span>, <span class="conditions" mdrptid="35708690" mdrpt="dry mouth">dry mouth</span>, <span class="conditions" mdrptid="36718555" mdrpt="insomnia">insomnia</span>, <span class="conditions" mdrptid="36718321" mdrpt="somnolence">somnolence</span>, and <span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span>.
                        <span class="Underline"><span class="conditions" mdrptid="35809243" mdrpt="pain">Chronic Pain</span> due to <span class="conditions" mdrptid="36516824" mdrpt="osteoarthritis">Osteoarthritis</span></span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s78"></a><a name="section-6.3.5"></a><p></p>
                    <p class="First">
                        — The most commonly observed adverse reactions in Cymbalta-treated patients (as defined above) were <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span>, <span class="conditions" mdrptid="35708690" mdrpt="dry mouth">dry mouth</span>, <span class="conditions" mdrptid="36718555" mdrpt="insomnia">insomnia</span>, <span class="conditions" mdrptid="36718321" mdrpt="somnolence">somnolence</span>, <span class="conditions" mdrptid="35708100" mdrpt="constipation">constipation</span>, <span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span>, and <span class="conditions" mdrptid="35809076" mdrpt="fatigue">fatigue</span>.
                        <span class="Underline">Chronic <span class="conditions" mdrptid="36516951" mdrpt="back pain">Low Back Pain</span></span>
                    </p>
                </div>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s79"></a><a name="section-6.4"></a><p></p>
                <h2>6.4 Adverse Reactions Occurring at an Incidence of 5% or More Among Duloxetine-Treated Patients in Placebo-Controlled Trials</h2>
                <p class="First">
                    gives the incidence of treatment-emergent adverse reactions in placebo-controlled trials for approved indications that occurred in 5% or more of patients treated with duloxetine and with an incidence greater than placebo.
                    <a href="#t2">Table 2</a>
                </p>
                <a name="t2"></a><table width="100%">
                    <caption>
                        <span>
                            Table 2: Treatment-Emergent Adverse Reactions: Incidence of 5% or More and Greater than Placebo in Placebo-Controlled Trials of Approved Indications
                            <span class="Sup">a</span>
                        </span>
                    </caption>
                    <col align="left" width="33.333%">
                    <col align="left" width="33.333%">
                    <col align="left" width="33.333%">
                    <tfoot>
                        <tr class="First">
                            <td align="left" colspan="3" valign="top">
                                <p class="First Footnote">
                                    The inclusion of an event in the table is determined based on the percentages before rounding; however, the percentages displayed in the table are rounded to the nearest integer.
                                    <span class="Sup">a</span>
                                </p>
                            </td>
                        </tr>
                        <tr>
                            <td align="left" colspan="3" valign="top">
                                <p class="First Footnote">
                                    Also includes <span class="conditions" mdrptid="35809072" mdrpt="asthenia">asthenia</span>.
                                    <span class="Sup">b</span>
                                </p>
                            </td>
                        </tr>
                        <tr>
                            <td align="left" colspan="3" valign="top">
                                <p class="First Footnote">
                                    Events for which there was a significant dose-dependent relationship in fixed-dose studies, excluding three MDD studies which did not have a placebo lead-in period or dose titration.
                                    <span class="Sup">c</span>
                                </p>
                            </td>
                        </tr>
                        <tr>
                            <td align="left" colspan="3" valign="top">
                                <p class="First Footnote">
                                    Also includes <span class="conditions" mdrptid="36718554" mdrpt="initial insomnia">initial insomnia</span>, <span class="conditions" mdrptid="36718556" mdrpt="middle insomnia">middle insomnia</span>, and <span class="conditions" mdrptid="36718557" mdrpt="terminal insomnia">early morning awakening</span>.
                                    <span class="Sup">d</span>
                                </p>
                            </td>
                        </tr>
                        <tr>
                            <td align="left" colspan="3" valign="top">
                                <p class="First Footnote">
                                    Also includes <span class="conditions" mdrptid="36718563" mdrpt="hypersomnia">hypersomnia</span> and <span class="conditions" mdrptid="36718320" mdrpt="sedation">sedation</span>.
                                    <span class="Sup">e</span>
                                </p>
                            </td>
                        </tr>
                        <tr class="Last">
                            <td align="left" colspan="3" valign="top">
                                <p class="First Footnote">
                                    Also includes <span class="conditions" mdrptid="35708164" mdrpt="abdominal discomfort">abdominal discomfort</span>, <span class="conditions" mdrptid="35708155" mdrpt="abdominal pain lower">abdominal pain lower</span>, <span class="conditions" mdrptid="35708156" mdrpt="abdominal pain upper">abdominal pain upper</span>, <span class="conditions" mdrptid="35708159" mdrpt="abdominal tenderness">abdominal tenderness</span>, and <span class="conditions" mdrptid="35708160" mdrpt="gastrointestinal pain">gastrointestinal pain</span>.
                                    <span class="Sup">f</span>
                                </p>
                            </td>
                        </tr>
                    </tfoot>
                    <tbody class="Headless">
                        <tr class="First">
                            <td class="Lrule Rrule Toprule" align="left" valign="top"></td>
                            <td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Percentage of Patients Reporting Reaction</span></td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">Adverse Reaction</span></span></td>
                            <td class="Botrule Rrule" align="center" valign="top">
                                <span class="Bold">
                                    Cymbalta (N=8100)
                                    <br>
                                </span>
                            </td>
                            <td class="Botrule Rrule" align="center" valign="top">
                                <span class="Bold">
                                    Placebo (N=5655)
                                    <br>
                                </span>
                            </td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">
                                <span class="conditions" mdrptid="35708202" mdrpt="nausea">Nausea</span>
                                <span class="Sup">c</span>
                            </td>
                            <td class="Botrule Rrule" align="center" valign="top">23</td>
                            <td class="Botrule Rrule" align="center" valign="top">8</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="36718132" mdrpt="headache">Headache</span></td>
                            <td class="Botrule Rrule" align="center" valign="top">14</td>
                            <td class="Botrule Rrule" align="center" valign="top">12</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="35708690" mdrpt="dry mouth">Dry mouth</span></td>
                            <td class="Botrule Rrule" align="center" valign="top">13</td>
                            <td class="Botrule Rrule" align="center" valign="top">5</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">
                                <span class="conditions" mdrptid="36718321" mdrpt="somnolence">Somnolence</span>
                                <span class="Sup">e</span>
                            </td>
                            <td class="Botrule Rrule" align="center" valign="top">10</td>
                            <td class="Botrule Rrule" align="center" valign="top">3</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">
                                <span class="conditions" mdrptid="35809076" mdrpt="fatigue">Fatigue</span>
                                <span class="Sup">b,c</span>
                            </td>
                            <td class="Botrule Rrule" align="center" valign="top">9</td>
                            <td class="Botrule Rrule" align="center" valign="top">5</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">
                                <span class="conditions" mdrptid="36718555" mdrpt="insomnia">Insomnia</span>
                                <span class="Sup">d</span>
                            </td>
                            <td class="Botrule Rrule" align="center" valign="top">9</td>
                            <td class="Botrule Rrule" align="center" valign="top">5</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">
                                <span class="conditions" mdrptid="35708100" mdrpt="constipation">Constipation</span>
                                <span class="Sup">c</span>
                            </td>
                            <td class="Botrule Rrule" align="center" valign="top">9</td>
                            <td class="Botrule Rrule" align="center" valign="top">4</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">
                                <span class="conditions" mdrptid="35205025" mdrpt="dizziness">Dizziness</span>
                                <span class="Sup">c</span>
                            </td>
                            <td class="Botrule Rrule" align="center" valign="top">9</td>
                            <td class="Botrule Rrule" align="center" valign="top">5</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">Diarrhea</span></td>
                            <td class="Botrule Rrule" align="center" valign="top">9</td>
                            <td class="Botrule Rrule" align="center" valign="top">6</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">
                                <span class="conditions" mdrptid="36416514" mdrpt="decreased appetite">Decreased appetite</span>
                                <span class="Sup">c</span>
                            </td>
                            <td class="Botrule Rrule" align="center" valign="top">7</td>
                            <td class="Botrule Rrule" align="center" valign="top">2</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">
                                <span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">Hyperhidrosis</span>
                                <span class="Sup">c</span>
                            </td>
                            <td class="Botrule Rrule" align="center" valign="top">6</td>
                            <td class="Botrule Rrule" align="center" valign="top">1</td>
                        </tr>
                        <tr class="Last">
                            <td class="Botrule Lrule Rrule" align="left" valign="top">
                                <span class="conditions" mdrptid="35708154" mdrpt="abdominal pain">Abdominal pain</span>
                                <span class="Sup">f</span>
                            </td>
                            <td class="Botrule Rrule" align="center" valign="top">5</td>
                            <td class="Botrule Rrule" align="center" valign="top">4</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s80"></a><a name="section-6.5"></a><p></p>
                <h2>6.5 Adverse Reactions Occurring at an Incidence of 2% or More Among Duloxetine-Treated Patients in Placebo-Controlled Trials</h2>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s81"></a><a name="section-6.5.1"></a><p></p>
                    <p class="First">
                        — gives the incidence of treatment-emergent adverse reactions in MDD and <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span> placebo-controlled trials for approved indications that occurred in 2% or more of patients treated with duloxetine and with an incidence greater than placebo.
                        <span class="Underline">Pooled MDD and <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span> Trials</span><a href="#t3">Table 3</a>
                    </p>
                    <a name="t3"></a><table width="100%">
                        <caption>
                            <span>
                                Table 3: Treatment-Emergent Adverse Reactions: Incidence of 2% or More and Greater than Placebo in MDD and <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span> Placebo-Controlled Trials
                                <span class="Sup">a</span>
                            </span>
                        </caption>
                        <col align="left" width="45.467%">
                        <col align="left" width="27.267%">
                        <col align="left" width="27.267%">
                        <tfoot>
                            <tr class="First">
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        The inclusion of an event in the table is determined based on the percentages before rounding; however, the percentages displayed in the table are rounded to the nearest integer.
                                        <span class="Sup">a</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Events for which there was a significant dose-dependent relationship in fixed-dose studies, excluding three MDD studies which did not have a placebo lead-in period or dose titration.
                                        <span class="Sup">b</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="35708156" mdrpt="abdominal pain upper">abdominal pain upper</span>, <span class="conditions" mdrptid="35708155" mdrpt="abdominal pain lower">abdominal pain lower</span>, <span class="conditions" mdrptid="35708159" mdrpt="abdominal tenderness">abdominal tenderness</span>, <span class="conditions" mdrptid="35708164" mdrpt="abdominal discomfort">abdominal discomfort</span>, and <span class="conditions" mdrptid="35708160" mdrpt="gastrointestinal pain">gastrointestinal pain</span>
                                        <span class="Sup">c</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="35809072" mdrpt="asthenia">asthenia</span>
                                        <span class="Sup">d</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="36718563" mdrpt="hypersomnia">hypersomnia</span> and <span class="conditions" mdrptid="36718320" mdrpt="sedation">sedation</span>
                                        <span class="Sup">e</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="36718554" mdrpt="initial insomnia">initial insomnia</span>, <span class="conditions" mdrptid="36718556" mdrpt="middle insomnia">middle insomnia</span>, and <span class="conditions" mdrptid="36718557" mdrpt="terminal insomnia">early morning awakening</span>
                                        <span class="Sup">f</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="35809087" mdrpt="feeling jittery">feeling jittery</span>, <span class="conditions" mdrptid="36918860" mdrpt="nervousness">nervousness</span>, <span class="conditions" mdrptid="36718368" mdrpt="restlessness">restlessness</span>, <span class="conditions" mdrptid="36918862" mdrpt="tension">tension</span> and <span class="conditions" mdrptid="36718214" mdrpt="psychomotor hyperactivity">psychomotor hyperactivity</span>
                                        <span class="Sup">g</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="36919197" mdrpt="loss of libido">loss of libido</span>
                                        <span class="Sup">h</span>
                                    </p>
                                </td>
                            </tr>
                            <tr class="Last">
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="36919165" mdrpt="anorgasmia">anorgasmia</span>
                                        <span class="Sup">i</span>
                                    </p>
                                </td>
                            </tr>
                        </tfoot>
                        <tbody class="Headless">
                            <tr class="First">
                                <td class="Lrule Rrule Toprule" align="left" valign="middle"></td>
                                <td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Percentage of Patients Reporting Reaction</span></td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">System Organ Class / <span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">Adverse Reaction</span></span></td>
                                <td class="Botrule Rrule" align="center" valign="top">
                                    <span class="Bold">
                                        Cymbalta (N=4797)
                                        <br>
                                    </span>
                                </td>
                                <td class="Botrule Rrule" align="center" valign="top">
                                    <span class="Bold">
                                        Placebo (N=3303)
                                        <br>
                                    </span>
                                </td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Cardiac Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="35205034" mdrpt="palpitations">Palpitations</span></td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                                <td class="Botrule Rrule" align="center" valign="top">1</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Eye Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="35607483" mdrpt="vision blurred">Vision blurred</span></td>
                                <td class="Botrule Rrule" align="center" valign="top">3</td>
                                <td class="Botrule Rrule" align="center" valign="top">1</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Gastrointestinal Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="35708202" mdrpt="nausea">Nausea</span>
                                    <span class="Sup">b</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">23</td>
                                <td class="Rrule" align="center" valign="top">8</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="35708690" mdrpt="dry mouth">Dry mouth</span></td>
                                <td class="Rrule" align="center" valign="top">14</td>
                                <td class="Rrule" align="center" valign="top">6</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="35708100" mdrpt="constipation">Constipation</span>
                                    <span class="Sup">b</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">9</td>
                                <td class="Rrule" align="center" valign="top">4</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">Diarrhea</span></td>
                                <td class="Rrule" align="center" valign="top">9</td>
                                <td class="Rrule" align="center" valign="top">6</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="35708154" mdrpt="abdominal pain">Abdominal pain</span>
                                    <span class="Sup">c</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">5</td>
                                <td class="Rrule" align="center" valign="top">4</td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="35708208" mdrpt="vomiting">Vomiting</span></td>
                                <td class="Botrule Rrule" align="center" valign="top">4</td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">General Disorders and Administration Site Conditions</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="35809076" mdrpt="fatigue">Fatigue</span>
                                    <span class="Sup">d</span>
                                </td>
                                <td class="Botrule Rrule" align="center" valign="top">9</td>
                                <td class="Botrule Rrule" align="center" valign="top">5</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Metabolism and Nutrition Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36416514" mdrpt="decreased appetite">Decreased appetite</span>
                                    <span class="Sup">b</span>
                                </td>
                                <td class="Botrule Rrule" align="center" valign="top">6</td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="conditions" mdrptid="36918860" mdrpt="nervousness">Nervous</span> System Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="36718132" mdrpt="headache">Headache</span></td>
                                <td class="Rrule" align="center" valign="top">14</td>
                                <td class="Rrule" align="center" valign="top">14</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="35205025" mdrpt="dizziness">Dizziness</span>
                                    <span class="Sup">b</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">9</td>
                                <td class="Rrule" align="center" valign="top">5</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36718321" mdrpt="somnolence">Somnolence</span>
                                    <span class="Sup">e</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">9</td>
                                <td class="Rrule" align="center" valign="top">3</td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="36718265" mdrpt="tremor">Tremor</span></td>
                                <td class="Botrule Rrule" align="center" valign="top">3</td>
                                <td class="Botrule Rrule" align="center" valign="top">1</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Psychiatric Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36718555" mdrpt="insomnia">Insomnia</span>
                                    <span class="Sup">f</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">9</td>
                                <td class="Rrule" align="center" valign="top">5</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36718347" mdrpt="agitation">Agitation</span>
                                    <span class="Sup">g</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">4</td>
                                <td class="Rrule" align="center" valign="top">2</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36919194" mdrpt="libido decreased">Libido decreased</span>
                                    <span class="Sup">h</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">3</td>
                                <td class="Rrule" align="center" valign="top">1</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="36918858" mdrpt="anxiety">Anxiety</span></td>
                                <td class="Rrule" align="center" valign="top">3</td>
                                <td class="Rrule" align="center" valign="top">2</td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36919168" mdrpt="orgasm abnormal">Orgasm abnormal</span>
                                    <span class="Sup">i</span>
                                </td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                                <td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Reproductive System and Breast Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="36919183" mdrpt="erectile dysfunction">Erectile dysfunction</span></td>
                                <td class="Rrule" align="center" valign="top">4</td>
                                <td class="Rrule" align="center" valign="top">1</td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="37119646" mdrpt="ejaculation delayed">Ejaculation delayed</span>
                                    <span class="Sup">b</span>
                                </td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                                <td class="Botrule Rrule" align="center" valign="top">1</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Respiratory, Thoracic, and Mediastinal Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="37219966" mdrpt="yawning">Yawning</span></td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                                <td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr class="Last">
                                <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">Hyperhidrosis</span></td>
                                <td class="Botrule Rrule" align="center" valign="top">6</td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s82"></a><a name="section-6.5.2"></a><p></p>
                    <p class="First">
                        — gives the incidence of treatment-emergent adverse events that occurred in 2% or more of patients treated with Cymbalta (determined prior to rounding) in the premarketing acute phase of DPNP, FM, OA, and CLBP placebo-controlled trials and with an incidence greater than placebo.
                        <span class="Underline">DPNP, FM, OA, and CLBP</span><a href="#t4">Table 4</a>
                    </p>
                    <a name="t4"></a><table width="100%">
                        <caption>
                            <span>
                                Table 4: Treatment-Emergent Adverse Reactions: Incidence of 2% or More and Greater than Placebo in DPNP, FM, OA, and CLBP Placebo-Controlled Trials
                                <span class="Sup">a</span>
                            </span>
                        </caption>
                        <col align="left" width="45.082%">
                        <col align="left" width="27.876%">
                        <col align="left" width="27.042%">
                        <tfoot>
                            <tr class="First">
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        The inclusion of an event in the table is determined based on the percentages before rounding; however, the percentages displayed in the table are rounded to the nearest integer.
                                        <span class="Sup">a</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Incidence of 120 mg/day is significantly greater than the incidence for 60 mg/day.
                                        <span class="Sup">b</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="35708164" mdrpt="abdominal discomfort">abdominal discomfort</span>, <span class="conditions" mdrptid="35708155" mdrpt="abdominal pain lower">abdominal pain lower</span>, <span class="conditions" mdrptid="35708156" mdrpt="abdominal pain upper">abdominal pain upper</span>, <span class="conditions" mdrptid="35708159" mdrpt="abdominal tenderness">abdominal tenderness</span> and <span class="conditions" mdrptid="35708160" mdrpt="gastrointestinal pain">gastrointestinal pain</span>
                                        <span class="Sup">c</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="35809072" mdrpt="asthenia">asthenia</span>
                                        <span class="Sup">d</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="36516837" mdrpt="myalgia">myalgia</span> and <span class="conditions" mdrptid="36516958" mdrpt="neck pain">neck pain</span>
                                        <span class="Sup">e</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="36718563" mdrpt="hypersomnia">hypersomnia</span> and <span class="conditions" mdrptid="36718320" mdrpt="sedation">sedation</span>
                                        <span class="Sup">f</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="36718395" mdrpt="hypoaesthesia">hypoaesthesia</span>, <span class="conditions" mdrptid="36718395" mdrpt="hypoaesthesia">hypoaesthesia</span> facial, <span class="conditions" mdrptid="36718392" mdrpt="genital hypoaesthesia">genital hypoaesthesia</span> and <span class="conditions" mdrptid="35708608" mdrpt="paraesthesia oral">paraesthesia oral</span>
                                        <span class="Sup">g</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="36718556" mdrpt="middle insomnia">middle insomnia</span>, <span class="conditions" mdrptid="36718557" mdrpt="terminal insomnia">early morning awakening</span> and <span class="conditions" mdrptid="36718554" mdrpt="initial insomnia">initial insomnia</span>
                                        <span class="Sup">h</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="35809087" mdrpt="feeling jittery">feeling jittery</span>, <span class="conditions" mdrptid="36918860" mdrpt="nervousness">nervousness</span>, <span class="conditions" mdrptid="36718368" mdrpt="restlessness">restlessness</span>, <span class="conditions" mdrptid="36918862" mdrpt="tension">tension</span> and <span class="conditions" mdrptid="36718214" mdrpt="psychomotor hyperactivity">psychomotor hyperactivity</span>
                                        <span class="Sup">i</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="37119648" mdrpt="ejaculation failure">ejaculation failure</span>
                                        <span class="Sup">j</span>
                                    </p>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="35809133" mdrpt="hot flush">hot flush</span>
                                        <span class="Sup">k</span>
                                    </p>
                                </td>
                            </tr>
                            <tr class="Last">
                                <td align="left" colspan="3" valign="top">
                                    <p class="First Footnote">
                                        Also includes <span class="conditions" mdrptid="36312074" mdrpt="blood pressure diastolic increased">blood pressure diastolic increased</span>, <span class="conditions" mdrptid="36312087" mdrpt="blood pressure systolic increased">blood pressure systolic increased</span>, <span class="conditions" mdrptid="37622527" mdrpt="diastolic hypertension">diastolic hypertension</span>, <span class="conditions" mdrptid="37622528" mdrpt="essential hypertension">essential hypertension</span>, <span class="conditions" mdrptid="37622529" mdrpt="hypertension">hypertension</span>, <span class="conditions" mdrptid="37622521" mdrpt="hypertensive crisis">hypertensive crisis</span>, <span class="conditions" mdrptid="37622530" mdrpt="labile hypertension">labile hypertension</span>, <span class="conditions" mdrptid="37622531" mdrpt="orthostatic hypertension">orthostatic hypertension</span>, <span class="conditions" mdrptid="37622534" mdrpt="secondary hypertension">secondary hypertension</span>, and <span class="conditions" mdrptid="37622535" mdrpt="systolic hypertension">systolic hypertension</span>
                                        <span class="Sup">l</span>
                                    </p>
                                </td>
                            </tr>
                        </tfoot>
                        <tbody class="Headless">
                            <tr class="First">
                                <td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="middle"><span class="Bold">System Organ Class / <span class="conditions" mdrptid="35809321" mdrpt="adverse reaction">Adverse Reaction</span></span></td>
                                <td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Percentage of Patients Reporting Reaction</span></td>
                            </tr>
                            <tr>
                                <td class="Botrule Rrule" align="center" valign="top">
                                    <span class="Bold">
                                        Cymbalta (N=3303)
                                        <br>
                                    </span>
                                </td>
                                <td class="Botrule Rrule" align="center" valign="top">
                                    <span class="Bold">Placebo</span><br><span class="Bold">(N=2352)</span>
                                </td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Gastrointestinal Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="35708202" mdrpt="nausea">Nausea</span></td>
                                <td class="Rrule" align="center" valign="top">23</td>
                                <td class="Rrule" align="center" valign="top">7</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="35708690" mdrpt="dry mouth">Dry Mouth</span>
                                    <span class="Sup">b</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">11</td>
                                <td class="Rrule" align="center" valign="top">3</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="35708100" mdrpt="constipation">Constipation</span>
                                    <span class="Sup">b</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">10</td>
                                <td class="Rrule" align="center" valign="top">3</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">Diarrhea</span></td>
                                <td class="Rrule" align="center" valign="top">9</td>
                                <td class="Rrule" align="center" valign="top">5</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="35708154" mdrpt="abdominal pain">Abdominal Pain</span>
                                    <span class="Sup">c</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">5</td>
                                <td class="Rrule" align="center" valign="top">4</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="35708208" mdrpt="vomiting">Vomiting</span></td>
                                <td class="Rrule" align="center" valign="top">3</td>
                                <td class="Rrule" align="center" valign="top">2</td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="35708139" mdrpt="dyspepsia">Dyspepsia</span></td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                                <td class="Botrule Rrule" align="center" valign="top">1</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">General Disorders and Administration Site Conditions</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="35809076" mdrpt="fatigue">Fatigue</span>
                                    <span class="Sup">d</span>
                                </td>
                                <td class="Botrule Rrule" align="center" valign="top">11</td>
                                <td class="Botrule Rrule" align="center" valign="top">5</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Infections and Infestations</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="36110697" mdrpt="nasopharyngitis">Nasopharyngitis</span></td>
                                <td class="Rrule" align="center" valign="top">4</td>
                                <td class="Rrule" align="center" valign="top">4</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="36110715" mdrpt="upper respiratory tract infection">Upper Respiratory Tract Infection</span></td>
                                <td class="Rrule" align="center" valign="top">3</td>
                                <td class="Rrule" align="center" valign="top">3</td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="36110933" mdrpt="influenza">Influenza</span></td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Metabolism and Nutrition Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36416514" mdrpt="decreased appetite">Decreased Appetite</span>
                                    <span class="Sup">b</span>
                                </td>
                                <td class="Botrule Rrule" align="center" valign="top">8</td>
                                <td class="Botrule Rrule" align="center" valign="top">1</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">Musculoskeletal Pain</span>
                                    <span class="Bold">Musculoskeletal and Connective Tissue</span><br><span class="Sup">e</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">
                                    3
                                    <br>
                                </td>
                                <td class="Rrule" align="center" valign="top">
                                    3
                                    <br>
                                </td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="36516848" mdrpt="muscle spasms">Muscle Spasms</span></td>
                                <td class="Rrule" align="center" valign="top">2</td>
                                <td class="Rrule" align="center" valign="top">2</td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="36516951" mdrpt="back pain">Back Pain</span></td>
                                <td class="Botrule Rrule" align="center" valign="top">3</td>
                                <td class="Botrule Rrule" align="center" valign="top">3</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="conditions" mdrptid="36918860" mdrpt="nervousness">Nervous</span> System Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="36718132" mdrpt="headache">Headache</span></td>
                                <td class="Rrule" align="center" valign="top">13</td>
                                <td class="Rrule" align="center" valign="top">8</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36718321" mdrpt="somnolence">Somnolence</span>
                                    <span class="Sup">b,f</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">11</td>
                                <td class="Rrule" align="center" valign="top">3</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="35205025" mdrpt="dizziness">Dizziness</span></td>
                                <td class="Rrule" align="center" valign="top">9</td>
                                <td class="Rrule" align="center" valign="top">5</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36718379" mdrpt="paraesthesia">Paraesthesia</span>
                                    <span class="Sup">g</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">2</td>
                                <td class="Rrule" align="center" valign="top">2</td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36718265" mdrpt="tremor">Tremor</span>
                                    <span class="Sup">b</span>
                                </td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                                <td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Psychiatric Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36718555" mdrpt="insomnia">Insomnia</span>
                                    <span class="Sup">b,h</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">10</td>
                                <td class="Rrule" align="center" valign="top">5</td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36718347" mdrpt="agitation">Agitation</span>
                                    <span class="Sup">i</span>
                                </td>
                                <td class="Botrule Rrule" align="center" valign="top">3</td>
                                <td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Reproductive System and Breast Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36919183" mdrpt="erectile dysfunction">Erectile Dysfunction</span>
                                    <span class="Sup">b</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">4</td>
                                <td class="Rrule" align="center" valign="top">&lt;1</td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="37119647" mdrpt="ejaculation disorder">Ejaculation Disorder</span>
                                    <span class="Sup">j</span>
                                </td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                                <td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Respiratory, Thoracic, and Mediastinal Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="37219907" mdrpt="cough">Cough</span></td>
                                <td class="Rrule" align="center" valign="top">2</td>
                                <td class="Rrule" align="center" valign="top">2</td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="35708628" mdrpt="oropharyngeal pain">Oropharyngeal Pain</span>
                                    <span class="Sup">b</span>
                                </td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">Hyperhidrosis</span></td>
                                <td class="Botrule Rrule" align="center" valign="top">6</td>
                                <td class="Botrule Rrule" align="center" valign="top">1</td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Vascular Disorders</span></td>
                                <td class="Rrule" align="center" valign="top"></td>
                                <td class="Rrule" align="center" valign="top"></td>
                            </tr>
                            <tr>
                                <td class="Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="35809130" mdrpt="flushing">Flushing</span>
                                    <span class="Sup">k</span>
                                </td>
                                <td class="Rrule" align="center" valign="top">3</td>
                                <td class="Rrule" align="center" valign="top">&lt;1</td>
                            </tr>
                            <tr class="Last">
                                <td class="Botrule Lrule Rrule" align="left" valign="top">
                                    <span class="conditions" mdrptid="36312077" mdrpt="blood pressure increased">Blood pressure increased</span>
                                    <span class="Sup">l</span>
                                </td>
                                <td class="Botrule Rrule" align="center" valign="top">2</td>
                                <td class="Botrule Rrule" align="center" valign="top">1</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s83"></a><a name="section-6.6"></a><p></p>
                <h2>6.6 Effects on Male and Female Sexual Function</h2>
                <p class="First">
                    Changes in sexual desire, sexual performance and sexual satisfaction often occur as manifestations of psychiatric disorders or <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span>, but they may also be a consequence of pharmacologic treatment. Because adverse sexual reactions are presumed to be voluntarily underreported, the Arizona Sexual Experience <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">Scale</span> (ASEX), a validated measure designed to identify sexual side effects, was used prospectively in 4 MDD placebo-controlled trials. In these trials, as shown in below, patients treated with Cymbalta experienced significantly more <span class="conditions" mdrptid="36919202" mdrpt="sexual dysfunction">sexual dysfunction</span>, as measured by the total score on the ASEX, than did patients treated with placebo. Gender analysis showed that this difference occurred only in males. Males treated with Cymbalta experienced more difficulty with ability to reach orgasm (ASEX Item 4) than males treated with placebo. Females did not experience more <span class="conditions" mdrptid="36919202" mdrpt="sexual dysfunction">sexual dysfunction</span> on Cymbalta than on placebo as measured by ASEX total score. Negative numbers signify an improvement from a baseline level of dysfunction, which is commonly seen in depressed patients. Physicians should routinely inquire about possible sexual side effects.
                    <a href="#t5">Table 5</a>
                </p>
                <a name="t5"></a><table width="100%">
                    <caption><span>Table 5: Mean Change in ASEX Scores by Gender in MDD Placebo-Controlled Trials</span></caption>
                    <col align="left" width="38.568%">
                    <col align="left" width="16.343%">
                    <col align="left" width="14.703%">
                    <col align="left" width="14.703%">
                    <col align="left" width="15.683%">
                    <tfoot>
                        <tr class="First">
                            <td align="left" colspan="5" valign="top">
                                <p class="First Footnote">
                                    n=Number of patients with non-missing change score for ASEX total
                                    <span class="Sup">a</span>
                                </p>
                            </td>
                        </tr>
                        <tr>
                            <td align="left" colspan="5" valign="top">
                                <p class="First Footnote">
                                    p=0.013 versus placebo
                                    <span class="Sup">b</span>
                                </p>
                            </td>
                        </tr>
                        <tr class="Last">
                            <td align="left" colspan="5" valign="top">
                                <p class="First Footnote">
                                    p&lt;0.001 versus placebo
                                    <span class="Sup">c</span>
                                </p>
                            </td>
                        </tr>
                    </tfoot>
                    <tbody class="Headless">
                        <tr class="First">
                            <td class="Lrule Rrule Toprule" align="left" valign="top"></td>
                            <td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
                                <span class="Bold">Male Patients</span><span class="Bold"><span class="Sup">a</span></span>
                            </td>
                            <td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
                                <span class="Bold">Female Patients</span><span class="Bold"><span class="Sup">a</span></span>
                            </td>
                        </tr>
                        <tr>
                            <td class="Lrule Rrule" align="left" valign="top"></td>
                            <td class="Botrule Rrule" align="center" valign="top">
                                <span class="Bold">
                                    Cymbalta (n=175)
                                    <br>
                                </span>
                            </td>
                            <td class="Botrule Rrule" align="center" valign="top">
                                <span class="Bold">
                                    Placebo (n=83)
                                    <br>
                                </span>
                            </td>
                            <td class="Botrule Rrule" align="center" valign="top">
                                <span class="Bold">
                                    Cymbalta (n=241)
                                    <br>
                                </span>
                            </td>
                            <td class="Botrule Rrule" align="center" valign="top">
                                <span class="Bold">
                                    Placebo (n=126)
                                    <br>
                                </span>
                            </td>
                        </tr>
                        <tr>
                            <td class="Lrule Rrule" align="left" valign="top">ASEX Total (Items 1-5)</td>
                            <td class="Rrule" align="center" valign="top">
                                0.56
                                <span class="Sup">b</span>
                            </td>
                            <td class="Rrule" align="center" valign="top">-1.07</td>
                            <td class="Rrule" align="center" valign="top">-1.15</td>
                            <td class="Rrule" align="center" valign="top">-1.07</td>
                        </tr>
                        <tr>
                            <td class="Lrule Rrule" align="left" valign="top">Item 1 — Sex drive</td>
                            <td class="Rrule" align="center" valign="top">-0.07</td>
                            <td class="Rrule" align="center" valign="top">-0.12</td>
                            <td class="Rrule" align="center" valign="top">-0.32</td>
                            <td class="Rrule" align="center" valign="top">-0.24</td>
                        </tr>
                        <tr>
                            <td class="Lrule Rrule" align="left" valign="top">Item 2 — Arousal</td>
                            <td class="Rrule" align="center" valign="top">0.01</td>
                            <td class="Rrule" align="center" valign="top">-0.26</td>
                            <td class="Rrule" align="center" valign="top">-0.21</td>
                            <td class="Rrule" align="center" valign="top">-0.18</td>
                        </tr>
                        <tr>
                            <td class="Lrule Rrule" align="left" valign="top">Item 3 — Ability to achieve erection (men); Lubrication (women)</td>
                            <td class="Rrule" align="center" valign="top">0.03</td>
                            <td class="Rrule" align="center" valign="top">-0.25</td>
                            <td class="Rrule" align="center" valign="top">-0.17</td>
                            <td class="Rrule" align="center" valign="top">-0.18</td>
                        </tr>
                        <tr>
                            <td class="Lrule Rrule" align="left" valign="top">Item 4 — Ease of reaching orgasm</td>
                            <td class="Rrule" align="center" valign="top">
                                0.40
                                <span class="Sup">c</span>
                            </td>
                            <td class="Rrule" align="center" valign="top">-0.24</td>
                            <td class="Rrule" align="center" valign="top">-0.09</td>
                            <td class="Rrule" align="center" valign="top">-0.13</td>
                        </tr>
                        <tr class="Last">
                            <td class="Botrule Lrule Rrule" align="left" valign="top">Item 5 — Orgasm satisfaction</td>
                            <td class="Botrule Rrule" align="center" valign="top">0.09</td>
                            <td class="Botrule Rrule" align="center" valign="top">-0.13</td>
                            <td class="Botrule Rrule" align="center" valign="top">-0.11</td>
                            <td class="Botrule Rrule" align="center" valign="top">-0.17</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s84"></a><a name="section-6.7"></a><p></p>
                <h2>6.7 Vital Sign Changes</h2>
                <p class="First">
                    In placebo-controlled clinical trials across approved indications for change from baseline to endpoint, duloxetine treatment was associated with mean increases of 0.23 mm Hg in <span class="conditions" mdrptid="36312084" mdrpt="blood pressure systolic">systolic blood pressure</span> and 0.73 mm Hg in diastolic <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span> compared to mean decreases of 1.09 mm Hg systolic and 0.55 mm Hg diastolic in placebo-treated patients. There was no significant difference in the frequency of sustained (3 consecutive visits) elevated <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span> .
                    <span class="Italics">
                        [see Warnings and Precautions ( and )]
                        <a href="#s39">5.3</a><a href="#s46">5.11</a>
                    </span>
                </p>
                <p>Duloxetine treatment, for up to 26 weeks in placebo-controlled trials across approved indications, typically caused a small increase in <span class="conditions" mdrptid="36311980" mdrpt="heart rate">heart rate</span> for change from baseline to endpoint compared to placebo of up to 1.37 beats per minute (increase of 1.20 beats per minute in duloxetine-treated patients, decrease of 0.17 beats per minute in placebo-treated patients).</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s85"></a><a name="section-6.8"></a><p></p>
                <h2>6.8 Weight Changes</h2>
                <p class="First">In placebo-controlled clinical trials, MDD and <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span> patients treated with Cymbalta for up to 10 weeks experienced a mean <span class="conditions" mdrptid="36315380" mdrpt="weight decreased">weight loss</span> of approximately 0.5 kg, compared with a mean <span class="conditions" mdrptid="36315381" mdrpt="weight increased">weight gain</span> of approximately 0.2 kg in placebo-treated patients. In studies of DPNP, FM, OA, and CLBP, patients treated with Cymbalta for up to 26 weeks experienced a mean <span class="conditions" mdrptid="36315380" mdrpt="weight decreased">weight loss</span> of approximately 0.6 kg compared with a mean <span class="conditions" mdrptid="36315381" mdrpt="weight increased">weight gain</span> of approximately 0.2 kg in placebo-treated patients. In one long-term <span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">fibromyalgia</span> 60-week uncontrolled study, duloxetine patients had a mean <span class="conditions" mdrptid="36315381" mdrpt="weight increased">weight increase</span> of 0.7 kg. In one long-term CLBP 54-week study (13-week, placebo-controlled acute phase and 41-week, uncontrolled extension phase), duloxetine patients had a mean <span class="conditions" mdrptid="36315380" mdrpt="weight decreased">weight decrease</span> of 0.6 kg in 13 weeks of acute phase compared to study entry, then a mean <span class="conditions" mdrptid="36315381" mdrpt="weight increased">weight increase</span> of 1.4 kg in 41 weeks of extension phase compared to end of acute phase.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s86"></a><a name="section-6.9"></a><p></p>
                <h2>6.9 Laboratory Changes</h2>
                <p class="First">
                    Cymbalta treatment in placebo-controlled clinical trials across approved indications, was associated with small mean increases from baseline to endpoint in ALT, <span class="conditions" mdrptid="36313531" mdrpt="aspartate aminotransferase">AST</span>, <span class="conditions" mdrptid="36312525" mdrpt="blood creatine phosphokinase">CPK</span>, <span class="conditions" mdrptid="36312565" mdrpt="blood alkaline phosphatase">alkaline phosphatase</span>; infrequent, modest, transient, abnormal values were observed for these analytes in Cymbalta-treated patients when compared with placebo-treated patients . High <span class="conditions" mdrptid="36316336" mdrpt="blood bicarbonate">bicarbonate</span> and <span class="conditions" mdrptid="36313982" mdrpt="blood cholesterol">cholesterol</span> and abnormal (high or low) <span class="conditions" mdrptid="36316379" mdrpt="blood potassium">potassium</span> were observed more frequently in duloxetine treated patients compared to placebo.
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s38">5.2</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s87"></a><a name="section-6.10"></a><p></p>
                <h2>6.10 <span class="conditions" mdrptid="36311902" mdrpt="electrocardiogram">Electrocardiogram</span> Changes</h2>
                <p class="First">The effect of duloxetine 160 mg and 200 mg administered twice daily to steady state was evaluated in a randomized, double-blinded, two-way crossover study in 117 healthy female subjects. No <span class="conditions" mdrptid="36311920" mdrpt="electrocardiogram qt interval">QT interval</span> prolongation was detected. Duloxetine appears to be associated with concentration-dependent but not clinically meaningful QT shortening.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s88"></a><a name="section-6.11"></a><p></p>
                <h2>6.11 Other Adverse Reactions Observed During the Premarketing and Postmarketing Clinical Trial Evaluation of Duloxetine</h2>
                <p class="First">Following is a list of treatment-emergent adverse reactions reported by patients treated with duloxetine in clinical trials. In clinical trials of all indications, 34,756 patients were treated with duloxetine. Of these, 26.9% (9337) took duloxetine for at least 6 months, and 12.4% (4317) for at least one year. The following listing is not intended to include reactions (1) already listed in previous tables or elsewhere in labeling, (2) for which a drug cause was remote, (3) which were so general as to be uninformative, (4) which were not considered to have significant clinical implications, or (5) which occurred at a rate equal to or less than placebo.</p>
                <p>Reactions are categorized by body system according to the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients; infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; rare reactions are those occurring in fewer than 1/1000 patients.</p>
                <p>
                    — <span class="conditions" mdrptid="35205034" mdrpt="palpitations">palpitations</span>; <span class="conditions" mdrptid="35205189" mdrpt="myocardial infarction">myocardial infarction</span> and <span class="conditions" mdrptid="35204948" mdrpt="tachycardia">tachycardia</span>.
                    <span class="Bold">Cardiac Disorders</span><span class="Italics">Frequent:</span><span class="Italics">Infrequent:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="35406392" mdrpt="vertigo">vertigo</span>; <span class="conditions" mdrptid="35406319" mdrpt="ear pain">ear pain</span> and <span class="conditions" mdrptid="35406391" mdrpt="tinnitus">tinnitus</span>.
                    <span class="Bold">Ear and Labyrinth Disorders</span><span class="Italics">Frequent:</span><span class="Italics">Infrequent:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="35506797" mdrpt="hypothyroidism">hypothyroidism</span>.
                    <span class="Bold">Endocrine Disorders</span><span class="Italics">Infrequent:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="35607483" mdrpt="vision blurred">vision blurred</span>; <span class="conditions" mdrptid="35607470" mdrpt="diplopia">diplopia</span>, <span class="conditions" mdrptid="35606946" mdrpt="dry eye">dry eye</span>, and <span class="conditions" mdrptid="35607485" mdrpt="visual impairment">visual impairment</span>.
                    <span class="Bold">Eye Disorders</span><span class="Italics">Frequent:</span><span class="Italics">Infrequent:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="35708153" mdrpt="flatulence">flatulence</span>; <span class="conditions" mdrptid="35708171" mdrpt="dysphagia">dysphagia</span>, <span class="conditions" mdrptid="35708141" mdrpt="eructation">eructation</span>, <span class="conditions" mdrptid="35708050" mdrpt="gastritis">gastritis</span>, <span class="conditions" mdrptid="35707864" mdrpt="gastrointestinal haemorrhage">gastrointestinal hemorrhage</span>, <span class="conditions" mdrptid="35708168" mdrpt="breath odour">halitosis</span>, and <span class="conditions" mdrptid="35708642" mdrpt="stomatitis">stomatitis</span>; <span class="conditions" mdrptid="35708278" mdrpt="gastric ulcer">gastric ulcer</span>.
                    <span class="Bold">Gastrointestinal Disorders</span><span class="Italics">Frequent:</span><span class="Italics">Infrequent:</span><span class="Italics">Rare:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="35809082" mdrpt="chills">chills</span>/<span class="conditions" mdrptid="35809082" mdrpt="chills">rigors</span>; falls, <span class="conditions" mdrptid="35809083" mdrpt="feeling abnormal">feeling abnormal</span>, <span class="conditions" mdrptid="35809086" mdrpt="feeling hot">feeling hot</span> and/or cold, <span class="conditions" mdrptid="35809079" mdrpt="malaise">malaise</span>, and <span class="conditions" mdrptid="35809098" mdrpt="thirst">thirst</span>; <span class="conditions" mdrptid="35809104" mdrpt="gait disturbance">gait disturbance</span>.
                    <span class="Bold">General Disorders and Administration Site Conditions</span><span class="Italics">Frequent:</span><span class="Italics">Infrequent:</span><span class="Italics">Rare:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="35707907" mdrpt="gastroenteritis">gastroenteritis</span> and <span class="conditions" mdrptid="36110693" mdrpt="laryngitis">laryngitis</span>.
                    <span class="Bold">Infections and Infestations</span><span class="Italics">Infrequent:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="36315381" mdrpt="weight increased">weight increased</span>, <span class="conditions" mdrptid="36315380" mdrpt="weight decreased">weight decreased</span>; <span class="conditions" mdrptid="36313985" mdrpt="blood cholesterol increased">blood cholesterol increased</span>.
                    <span class="Bold">Investigations</span><span class="Italics">Frequent:</span><span class="Italics">Infrequent:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="36416606" mdrpt="dehydration">dehydration</span> and <span class="conditions" mdrptid="36416638" mdrpt="hyperlipidaemia">hyperlipidemia</span>; <span class="conditions" mdrptid="36416641" mdrpt="dyslipidaemia">dyslipidemia</span>.
                    <span class="Bold">Metabolism and Nutrition Disorders</span><span class="Italics">Infrequent:</span><span class="Italics">Rare:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">musculoskeletal pain</span>; <span class="conditions" mdrptid="36516850" mdrpt="muscle tightness">muscle tightness</span> and <span class="conditions" mdrptid="36516851" mdrpt="muscle twitching">muscle twitching</span>.
                    <span class="Bold">Musculoskeletal and Connective Tissue Disorders</span><span class="Italics">Frequent:</span><span class="Italics">Infrequent:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="35708724" mdrpt="dysgeusia">dysgeusia</span>, <span class="conditions" mdrptid="35809077" mdrpt="lethargy">lethargy</span>, and <span class="conditions" mdrptid="36718379" mdrpt="paraesthesia">parasthesia</span>/<span class="conditions" mdrptid="36718395" mdrpt="hypoaesthesia">hypoesthesia</span>; <span class="conditions" mdrptid="36718180" mdrpt="disturbance in attention">disturbance in attention</span>, <span class="conditions" mdrptid="36718199" mdrpt="dyskinesia">dyskinesia</span>, <span class="conditions" mdrptid="36718362" mdrpt="myoclonus">myoclonus</span>, and <span class="conditions" mdrptid="36718569" mdrpt="poor quality sleep">poor quality sleep</span>; <span class="conditions" mdrptid="36718418" mdrpt="dysarthria">dysarthria</span>.
                    <span class="Bold"><span class="conditions" mdrptid="36918860" mdrpt="nervousness">Nervous</span> System Disorders</span><span class="Italics">Frequent:</span><span class="Italics">Infrequent:</span><span class="Italics">Rare:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="36718543" mdrpt="abnormal dreams">abnormal dreams</span> and <span class="conditions" mdrptid="36919209" mdrpt="sleep disorder">sleep disorder</span>; <span class="conditions" mdrptid="36919054" mdrpt="apathy">apathy</span>, <span class="conditions" mdrptid="35708169" mdrpt="bruxism">bruxism</span>, <span class="conditions" mdrptid="36718354" mdrpt="disorientation">disorientation</span>/<span class="conditions" mdrptid="36718301" mdrpt="confusional state">confusional state</span>, <span class="conditions" mdrptid="35809139" mdrpt="irritability">irritability</span>, <span class="conditions" mdrptid="36919052" mdrpt="mood swings">mood swings</span>, and <span class="conditions" mdrptid="36919236" mdrpt="suicide attempt">suicide attempt</span>; <span class="conditions" mdrptid="36919230" mdrpt="completed suicide">completed suicide</span>.
                    <span class="Bold">Psychiatric Disorders</span><span class="Italics">Frequent:</span><span class="Italics">Infrequent:</span><span class="Italics">Rare:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="37019401" mdrpt="pollakiuria">urinary frequency</span>; <span class="conditions" mdrptid="37019396" mdrpt="dysuria">dysuria</span>, <span class="conditions" mdrptid="37019399" mdrpt="micturition urgency">micturition urgency</span>, <span class="conditions" mdrptid="37019449" mdrpt="nocturia">nocturia</span>, <span class="conditions" mdrptid="37019450" mdrpt="polyuria">polyuria</span>, and urine odor abnormal.
                    <span class="Bold">Renal and Urinary Disorders</span><span class="Italics">Frequent:</span><span class="Italics">Infrequent:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="36919165" mdrpt="anorgasmia">anorgasmia</span>/<span class="conditions" mdrptid="36919168" mdrpt="orgasm abnormal">orgasm abnormal</span>; <span class="conditions" mdrptid="37119537" mdrpt="menopausal symptoms">menopausal symptoms</span>, <span class="conditions" mdrptid="36919202" mdrpt="sexual dysfunction">sexual dysfunction</span>, and <span class="conditions" mdrptid="37119688" mdrpt="testicular pain">testicular pain</span>; <span class="conditions" mdrptid="37119544" mdrpt="menstrual disorder">menstrual disorder</span>.
                    <span class="Bold">Reproductive System and Breast Disorders</span><span class="Italics">Frequent:</span><span class="Italics">Infrequent:</span><span class="Italics">Rare:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="37219966" mdrpt="yawning">yawning</span>, <span class="conditions" mdrptid="35708628" mdrpt="oropharyngeal pain">oropharyngeal pain</span>; <span class="conditions" mdrptid="36919109" mdrpt="throat tightness">throat tightness</span>.
                    <span class="Bold">Respiratory, Thoracic and Mediastinal Disorders</span><span class="Italics">Frequent:</span><span class="Italics">Infrequent:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="37320197" mdrpt="pruritus">pruritus</span>; <span class="conditions" mdrptid="35809112" mdrpt="cold sweat">cold sweat</span>, <span class="conditions" mdrptid="36009735" mdrpt="dermatitis contact">dermatitis contact</span>, <span class="conditions" mdrptid="37320158" mdrpt="erythema">erythema</span>, <span class="conditions" mdrptid="35104123" mdrpt="increased tendency to bruise">increased tendency to bruise</span>, <span class="conditions" mdrptid="35809151" mdrpt="night sweats">night sweats</span>, and <span class="conditions" mdrptid="37320193" mdrpt="photosensitivity reaction">photosensitivity reaction</span>; <span class="conditions" mdrptid="35104119" mdrpt="ecchymosis">ecchymosis</span>.
                    <span class="Bold">Skin and Subcutaneous Tissue Disorders</span><span class="Italics">Frequent:</span><span class="Italics">Infrequent:</span><span class="Italics">Rare:</span>
                </p>
                <p>
                    — <span class="conditions" mdrptid="35809133" mdrpt="hot flush">hot flush</span>; <span class="conditions" mdrptid="35809130" mdrpt="flushing">flushing</span>, <span class="conditions" mdrptid="37622451" mdrpt="orthostatic hypotension">orthostatic hypotension</span>, and <span class="conditions" mdrptid="35809092" mdrpt="peripheral coldness">peripheral coldness</span>.
                    <span class="Bold">Vascular Disorders</span><span class="Italics">Frequent:</span><span class="Italics">Infrequent:</span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s89"></a><a name="section-6.12"></a><p></p>
                <h2>6.12 Postmarketing Spontaneous Reports</h2>
                <p class="First">The following adverse reactions have been identified during postapproval use of Cymbalta. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
                <p>Adverse reactions reported since market introduction that were temporally related to duloxetine therapy and not mentioned elsewhere in labeling include: <span class="conditions" mdrptid="36009756" mdrpt="anaphylactic reaction">anaphylactic reaction</span>, <span class="conditions" mdrptid="36919059" mdrpt="aggression">aggression</span> and <span class="conditions" mdrptid="36919042" mdrpt="anger">anger</span> (particularly early in treatment or after treatment discontinuation), <span class="conditions" mdrptid="36009762" mdrpt="angioedema">angioneurotic edema</span>, angle-closure <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">glaucoma</span>, <span class="conditions" mdrptid="36718201" mdrpt="extrapyramidal disorder">extrapyramidal disorder</span>, <span class="conditions" mdrptid="35506663" mdrpt="galactorrhoea">galactorrhea</span>, gynecological <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">bleeding</span>, <span class="conditions" mdrptid="36918984" mdrpt="hallucination">hallucinations</span>, <span class="conditions" mdrptid="35506628" mdrpt="hyperglycaemia">hyperglycemia</span>, <span class="conditions" mdrptid="35506649" mdrpt="hyperprolactinaemia">hyperprolactinemia</span>, <span class="conditions" mdrptid="36009711" mdrpt="hypersensitivity">hypersensitivity</span>, <span class="conditions" mdrptid="37622521" mdrpt="hypertensive crisis">hypertensive crisis</span>, <span class="conditions" mdrptid="36516848" mdrpt="muscle spasms">muscle spasm</span>, <span class="conditions" mdrptid="37320212" mdrpt="rash">rash</span>, <span class="conditions" mdrptid="36516858" mdrpt="restless legs syndrome">restless legs syndrome</span>, <span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizures</span> upon treatment discontinuation, supraventricular <span class="conditions" mdrptid="35204924" mdrpt="arrhythmia">arrhythmia</span>, <span class="conditions" mdrptid="35406391" mdrpt="tinnitus">tinnitus</span> (upon treatment discontinuation), <span class="conditions" mdrptid="36516874" mdrpt="trismus">trismus</span>, and <span class="conditions" mdrptid="36009783" mdrpt="urticaria">urticaria</span>.</p>
            </div>
        </div>
        <div class="Section" data-sectionCode="34073-7">
            <a name="s90"></a><a name="section-7"></a><p></p>
            <h1>7 DRUG INTERACTIONS</h1>
            <p class="First">Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism.</p>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s91"></a><a name="section-7.1"></a><p></p>
                <h2>7.1 Inhibitors of CYP1A2</h2>
                <p class="First">
                    When duloxetine 60 mg was co-administered with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to male subjects (n=14) duloxetine AUC was increased approximately 6-fold, the C was increased about 2.5-fold, and duloxetine t was increased approximately 3-fold. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin .
                    <span class="Sub">max</span><span class="Sub">1/2</span><span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s47">5.12</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s92"></a><a name="section-7.2"></a><p></p>
                <h2>7.2 Inhibitors of CYP2D6</h2>
                <p class="First">
                    Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s47">5.12</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s93"></a><a name="section-7.3"></a><p></p>
                <h2>7.3 Dual Inhibition of CYP1A2 and CYP2D6</h2>
                <p class="First">
                    Concomitant administration of duloxetine 40 mg twice daily with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metabolizer subjects (n=14) resulted in a 6-fold increase in duloxetine AUC and C .
                    <span class="Sub">max</span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s94"></a><a name="section-7.4"></a><p></p>
                <h2>7.4 Drugs that Interfere with <span class="conditions" mdrptid="37521165" mdrpt="haemostasis">Hemostasis</span> (e.g., NSAIDs, Aspirin, and Warfarin)</h2>
                <p class="First">
                    Serotonin release by platelets plays an important role in <span class="conditions" mdrptid="37521165" mdrpt="haemostasis">hemostasis</span>. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper <span class="conditions" mdrptid="35707864" mdrpt="gastrointestinal haemorrhage">gastrointestinal bleeding</span> have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">bleeding</span>. Altered anticoagulant effects, including increased <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">bleeding</span>, have been reported when SSRIs or SNRIs are co-administered with warfarin. Concomitant administration of warfarin (2-9 mg once daily) under steady state conditions with duloxetine 60 or 120 mg once daily for up to 14 days in healthy subjects (n=15) did not significantly change <span class="conditions" mdrptid="36313046" mdrpt="international normalised ratio">INR</span> from baseline (mean <span class="conditions" mdrptid="36313046" mdrpt="international normalised ratio">INR</span> changes ranged from 0.05 to +0.07). The total warfarin (<span class="conditions" mdrptid="36315537" mdrpt="protein total">protein</span> bound plus free drug) pharmacokinetics (AUC , C or t ) for both R- and S-warfarin were not altered by duloxetine. Because of the potential effect of duloxetine on platelets, patients receiving warfarin therapy should be carefully monitored when duloxetine is initiated or discontinued .
                    <span class="Sub">τ</span><span class="Sub">,ss</span><span class="Sub">max,ss</span><span class="Sub">max,ss</span><span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s41">5.5</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s95"></a><a name="section-7.5"></a><p></p>
                <h2>7.5 Lorazepam</h2>
                <p class="First">Under steady-state conditions for duloxetine (60 mg Q 12 hours) and lorazepam (2 mg Q 12 hours), the pharmacokinetics of duloxetine were not affected by co-administration.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s96"></a><a name="section-7.6"></a><p></p>
                <h2>7.6 Temazepam</h2>
                <p class="First">Under steady-state conditions for duloxetine (20 mg qhs) and temazepam (30 mg qhs), the pharmacokinetics of duloxetine were not affected by co-administration.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s97"></a><a name="section-7.7"></a><p></p>
                <h2>7.7 Drugs that Affect Gastric Acidity</h2>
                <p class="First">
                    Cymbalta has an enteric coating that resists dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5. In extremely acidic conditions, Cymbalta, unprotected by the enteric coating, may undergo hydrolysis to form naphthol. Caution is advised in using Cymbalta in patients with conditions that may slow gastric emptying (e.g., some diabetics). Drugs that raise the gastrointestinal pH may lead to an earlier release of duloxetine. However, co-administration of Cymbalta with <span class="conditions" mdrptid="36316211" mdrpt="blood aluminium">aluminum</span>- and magnesium-containing antacids (51 mEq) or Cymbalta with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose. It is unknown whether the concomitant administration of proton pump inhibitors affects duloxetine absorption .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s57">5.14</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s98"></a><a name="section-7.8"></a><p></p>
                <h2>7.8 Drugs Metabolized by CYP1A2</h2>
                <p class="First">
                    <span class="conditions" mdrptid="35809310" mdrpt="drug interaction">drug interaction</span> studies demonstrate that duloxetine does not induce CYP1A2 activity. Therefore, an increase in the metabolism of CYP1A2 substrates (e.g., theophylline, caffeine) resulting from <span class="conditions" mdrptid="37521955" mdrpt="induction and maintenance of anaesthesia">induction</span> is not anticipated, although clinical studies of <span class="conditions" mdrptid="37521955" mdrpt="induction and maintenance of anaesthesia">induction</span> have not been performed. Duloxetine is an inhibitor of the CYP1A2 isoform in studies, and in two clinical studies the average (90% confidence interval) increase in theophylline AUC was 7% (1%-15%) and 20% (13%-27%) when co-administered with duloxetine (60 mg twice daily).
                    <span class="Italics">In vitro</span><span class="Italics">in vitro</span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s99"></a><a name="section-7.9"></a><p></p>
                <h2>7.9 Drugs Metabolized by CYP2D6</h2>
                <p class="First">
                    Duloxetine is a moderate inhibitor of CYP2D6. When duloxetine was administered (at a dose of 60 mg twice daily) in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s47">5.12</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s100"></a><a name="section-7.10"></a><p></p>
                <h2>7.10 Drugs Metabolized by CYP2C9</h2>
                <p class="First">
                    Results of studies demonstrate that duloxetine does not inhibit activity. In a clinical study, the pharmacokinetics of S-warfarin, a CYP2C9 substrate, were not significantly affected by duloxetine .
                    <span class="Italics">in vitro</span><span class="Italics">
                        [see Drug Interactions ( )]
                        <a href="#s94">7.4</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s101"></a><a name="section-7.11"></a><p></p>
                <h2>7.11 Drugs Metabolized by CYP3A</h2>
                <p class="First">
                    Results of studies demonstrate that duloxetine does not inhibit or induce CYP3A activity. Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from <span class="conditions" mdrptid="37521955" mdrpt="induction and maintenance of anaesthesia">induction</span> or inhibition is not anticipated, although clinical studies have not been performed.
                    <span class="Italics">in vitro</span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s102"></a><a name="section-7.12"></a><p></p>
                <h2>7.12 Drugs Metabolized by CYP2C19</h2>
                <p class="First">
                    Results of studies demonstrate that duloxetine does not inhibit CYP2C19 activity at therapeutic concentrations. Inhibition of the metabolism of CYP2C19 substrates is therefore not anticipated, although clinical studies have not been performed.
                    <span class="Italics">in vitro</span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s103"></a><a name="section-7.13"></a><p></p>
                <h2>7.13 Monoamine Oxidase Inhibitors (MAOIs)</h2>
                <p class="First">
                    .
                    <span class="Italics">
                        [See Dosage and Administration ( , ), Contraindications ( ), and Warnings and Precautions ( )]
                        <a href="#s30">2.5</a><a href="#s30a">2.6</a><a href="#s33">4.1</a><a href="#s40">5.4</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s104"></a><a name="section-7.14"></a><p></p>
                <h2>7.14 Serotonergic Drugs</h2>
                <p class="First">
                    .
                    <span class="Italics">
                        [See Dosage and Administration ( , ), Contraindications ( ), and Warnings and Precautions ( )]
                        <a href="#s30">2.5</a><a href="#s30a">2.6</a><a href="#s33">4.1</a><a href="#s40">5.4</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s106"></a><a name="section-7.15"></a><p></p>
                <h2>7.15 Alcohol</h2>
                <p class="First">When Cymbalta and ethanol were administered several hours apart so that peak concentrations of each would coincide, Cymbalta did not increase the impairment of mental and motor skills caused by alcohol.</p>
                <p>
                    In the Cymbalta clinical trials database, three Cymbalta-treated patients had <span class="conditions" mdrptid="35909503" mdrpt="liver injury">liver injury</span> as manifested by ALT and total <span class="conditions" mdrptid="36313547" mdrpt="blood bilirubin">bilirubin</span> elevations, with evidence of <span class="conditions" mdrptid="35809153" mdrpt="obstruction">obstruction</span>. Substantial intercurrent ethanol use was present in each of these cases, and this may have contributed to the abnormalities seen .
                    <span class="Italics">
                        [see Warnings and Precautions ( and )]
                        <a href="#s38">5.2</a><a href="#s47">5.12</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s107"></a><a name="section-7.16"></a><p></p>
                <h2>7.16 CNS Drugs</h2>
                <p class="First">
                    .
                    <span class="Italics">
                        [See Warnings and Precautions ( )]
                        <a href="#s47">5.12</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s108"></a><a name="section-7.17"></a><p></p>
                <h2>7.17 Drugs Highly Bound to <span class="conditions" mdrptid="36315537" mdrpt="protein total">Plasma Protein</span></h2>
                <p class="First">
                    Because duloxetine is highly bound to <span class="conditions" mdrptid="36315537" mdrpt="protein total">plasma protein</span>, administration of Cymbalta to a patient taking another drug that is highly <span class="conditions" mdrptid="36315537" mdrpt="protein total">protein</span> bound may cause increased free concentrations of the other drug, potentially resulting in adverse reactions. However, co-administration of duloxetine (60 or 120 mg) with warfarin (2-9 mg), a highly <span class="conditions" mdrptid="36315537" mdrpt="protein total">protein</span>-bound drug, did not result in significant changes in <span class="conditions" mdrptid="36313046" mdrpt="international normalised ratio">INR</span> and in the pharmacokinetics of either total S-or total R-warfarin (<span class="conditions" mdrptid="36315537" mdrpt="protein total">protein</span> bound plus free drug) .
                    <span class="Italics">
                        [see Drug Interactions ( )]
                        <a href="#s94">7.4</a>
                    </span>
                </p>
            </div>
        </div>
        <div class="Section" data-sectionCode="43684-0">
            <a name="s109"></a><a name="section-8"></a><p></p>
            <h1>8 USE IN SPECIFIC POPULATIONS</h1>
            <div class="Section" data-sectionCode="42228-7">
                <a name="s110"></a><a name="section-8.1"></a><p></p>
                <h2>8.1 <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span></h2>
                <div class="Section" data-sectionCode="34077-8">
                    <a name="s111"></a><a name="section-8.1.1"></a><p></p>
                    <p class="First">
                        — In animal reproduction studies, duloxetine has been shown to have adverse effects on embryo/fetal and postnatal development.
                        <span class="Underline">Teratogenic Effects, <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span> Category C</span>
                    </p>
                    <p>
                        When duloxetine was administered orally to <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> rats and rabbits during the period of organogenesis, there was no evidence of <span class="conditions" mdrptid="35305516" mdrpt="teratogenicity">teratogenicity</span> at doses up to 45 mg/kg/day (7 times the maximum recommended human dose [MRHD, 60 mg/day] and 4 times the human dose of 120 mg/day on a mg/m basis, in rat; 15 times the MRHD and 7 times the human dose of 120 mg/day on a mg/m basis in rabbit). However, fetal weights were decreased at this dose, with a no-effect dose of 10 mg/kg/day (2 times the MRHD and ≈1 times the human dose of 120 mg/day on a mg/m basis in rats; 3 times the MRHD and 2 times the human dose of 120 mg/day on a mg/m basis in rabbits).
                        <span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span>
                    </p>
                    <p>
                        When duloxetine was administered orally to <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> rats throughout gestation and lactation, the survival of pups to 1 day postpartum and pup body weights at birth and during the lactation period were decreased at a dose of 30 mg/kg/day (5 times the MRHD and 2 times the human dose of 120 mg/day on a mg/m basis); the no-effect dose was 10 mg/kg/day. Furthermore, behaviors consistent with increased reactivity, such as increased startle response to noise and decreased <span class="conditions" mdrptid="35809331" mdrpt="drug tolerance">habituation</span> of locomotor activity, were observed in pups following maternal exposure to 30 mg/kg/day. Post-weaning growth and reproductive performance of the progeny were not affected adversely by maternal duloxetine treatment.
                        <span class="Sup">2</span>
                    </p>
                    <p>There are no adequate and well-controlled studies in <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> women; therefore, duloxetine should be used during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> only if the potential benefit justifies the potential risk to the fetus.</p>
                </div>
                <div class="Section" data-sectionCode="34078-6">
                    <a name="s112"></a><a name="section-8.1.2"></a><p></p>
                    <p class="First">
                        — Neonates exposed to SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon <span class="conditions" mdrptid="36818826" mdrpt="delivery">delivery</span>. Reported clinical findings have included <span class="conditions" mdrptid="37219897" mdrpt="respiratory distress">respiratory distress</span>, <span class="conditions" mdrptid="35205023" mdrpt="cyanosis">cyanosis</span>, <span class="conditions" mdrptid="37219885" mdrpt="apnoea">apnea</span>, <span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizures</span>, temperature instability, feeding difficulty, <span class="conditions" mdrptid="35708208" mdrpt="vomiting">vomiting</span>, <span class="conditions" mdrptid="35506636" mdrpt="hypoglycaemia">hypoglycemia</span>, <span class="conditions" mdrptid="36516865" mdrpt="hypotonia">hypotonia</span>, <span class="conditions" mdrptid="36516863" mdrpt="hypertonia">hypertonia</span>, <span class="conditions" mdrptid="36718272" mdrpt="hyperreflexia">hyperreflexia</span>, <span class="conditions" mdrptid="36718265" mdrpt="tremor">tremor</span>, <span class="conditions" mdrptid="35809087" mdrpt="feeling jittery">jitteriness</span>, <span class="conditions" mdrptid="35809139" mdrpt="irritability">irritability</span>, and constant <span class="conditions" mdrptid="36718353" mdrpt="crying">crying</span>. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span> .
                        <span class="Underline">Nonteratogenic Effects</span><span class="Italics">
                            [see Warnings and Precautions ( )]
                            <a href="#s40">5.4</a>
                        </span>
                    </p>
                    <p>
                        When treating <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> women with Cymbalta during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. The physician may consider tapering Cymbalta in the third trimester .
                        <span class="Italics">
                            [see Dosage and Administration ( )]
                            <a href="#s22">2.3</a>
                        </span>
                    </p>
                    <p>Lilly maintains a <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> registry to monitor the <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> outcomes of women exposed to Cymbalta while <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span>. Healthcare providers are encouraged to register any patient who is exposed to Cymbalta during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> by calling the Cymbalta <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span> Registry at 1-866-814-6975 or by visiting www.cymbaltapregnancyregistry.com</p>
                </div>
            </div>
            <div class="Section" data-sectionCode="34079-4">
                <a name="s113"></a><a name="section-8.2"></a><p></p>
                <h2>8.2 Labor and <span class="conditions" mdrptid="36818826" mdrpt="delivery">Delivery</span></h2>
                <p class="First">The effect of duloxetine on labor and <span class="conditions" mdrptid="36818826" mdrpt="delivery">delivery</span> in humans is unknown. Duloxetine should be used during labor and <span class="conditions" mdrptid="36818826" mdrpt="delivery">delivery</span> only if the potential benefit justifies the potential risk to the fetus.</p>
            </div>
            <div class="Section" data-sectionCode="34080-2">
                <a name="s114"></a><a name="section-8.3"></a><p></p>
                <h2>8.3 Nursing Mothers</h2>
                <p class="First">Duloxetine is excreted into the milk of lactating women. The estimated daily <span class="conditions" mdrptid="37420351" mdrpt="infant">infant</span> dose on a mg/kg basis is approximately 0.14% of the maternal dose. Because the safety of duloxetine in infants is not known, nursing while on Cymbalta is not recommended. However, if the physician determines that the benefit of duloxetine therapy for the mother outweighs any potential risk to the <span class="conditions" mdrptid="37420351" mdrpt="infant">infant</span>, no dosage adjustment is required as lactation did not influence duloxetine pharmacokinetics.</p>
                <p>
                    The disposition of duloxetine was studied in 6 lactating women who were at least 12 weeks postpartum. Duloxetine 40 mg twice daily was given for 3.5 days. Like many other drugs, duloxetine is detected in breast milk, and steady state concentrations in breast milk are about one-fourth those in plasma. The amount of duloxetine in breast milk is approximately 7 μg/day while on 40 mg BID dosing. The excretion of duloxetine metabolites into breast milk was not examined. Because the safety of duloxetine in infants is not known, nursing while on Cymbalta is not recommended .
                    <span class="Italics">
                        [see Dosage and Administration ( )]
                        <a href="#s22">2.3</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="34081-0">
                <a name="s115"></a><a name="section-8.4"></a><p></p>
                <h2>8.4 Pediatric Use</h2>
                <p class="First">
                    Efficacy was not demonstrated in two 10-week, placebo-controlled trials with 800 pediatric patients with MDD, age 7-17. Neither Cymbalta nor the active control (indicated for treatment of pediatric <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span>) statistically separated from placebo. Duloxetine steady state plasma concentration was comparable in children (7 - 12 years), adolescents (13 - 17 years) and adults. Cymbalta has not been studied in patients under the age of 7. Thus, safety and effectiveness in the pediatric population has not been established .
                    <span class="Italics">
                        [see and Warnings and Precautions ( )]
                        <a href="#s2">Boxed Warning</a><a href="#s36">5.1</a>
                    </span>
                </p>
                <p><span class="conditions" mdrptid="36416514" mdrpt="decreased appetite">Decreased appetite</span> and <span class="conditions" mdrptid="36315380" mdrpt="weight decreased">weight loss</span> have been observed in association with the use of SSRIs and SNRIs. Pediatric patients treated with Cymbalta in MDD clinical trials experienced a 0.2 kg mean decrease in weight at 10-weeks, compared with a mean <span class="conditions" mdrptid="36315381" mdrpt="weight increased">weight gain</span> of approximately 0.6 kg in placebo-treated patients. The proportion of patients who experienced a clinically significant decrease in weight (≥3.5%) was greater in the Cymbalta group than in the placebo group (11% and 6%, respectively). Subsequently, over the six-month uncontrolled extension period, most Cymbalta-treated patients trended toward recovery to their expected baseline weight percentile based on population data from age- and gender-matched peers. Perform regular monitoring of weight and growth in children and adolescents treated with an SNRI such as Cymbalta.</p>
                <p>In the 2 pediatric MDD studies, the safety findings were consistent with the known safety and tolerability profile for Cymbalta.</p>
                <p>Duloxetine administration to young rats from post-natal day 21 (weaning) through post-natal day 90 (adult) resulted in decreased body weights that persisted into adulthood, but recovered when drug treatment was discontinued; slightly delayed (~1.5 days) sexual maturation in females, without any effect on fertility; and a delay in learning a complex task in adulthood, which was not observed after drug treatment was discontinued. These effects were observed at the high dose of 45 mg/kg/day; the no-effect-level was 20 mg/kg/day.</p>
            </div>
            <div class="Section" data-sectionCode="34082-8">
                <a name="s116"></a><a name="section-8.5"></a><p></p>
                <h2>8.5 Geriatric Use</h2>
                <p class="First">
                    Of the 2,418 patients in premarketing clinical studies of Cymbalta for MDD, 5.9% (143) were 65 years of age or over. Of the 1041 patients in CLBP premarketing studies, 21.2% (221) were 65 years of age or over. Of the 487 patients in OA premarketing studies, 40.5% (197) were 65 years of age or over. Of the 1,074 patients in the DPNP premarketing studies, 33% (357) were 65 years of age or over. Of the 1,761 patients in FM premarketing studies, 7.9% (140) were 65 years of age or over. Premarketing clinical studies of <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span> did not include sufficient numbers of subjects age 65 or over to determine whether they respond differently from younger subjects. In the MDD, DPNP, FM, OA, and CLBP studies, no overall differences in safety or effectiveness were generally observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the <span class="conditions" mdrptid="37420350" mdrpt="elderly">elderly</span> and younger patients, but greater sensitivity of some older individuals cannot be ruled out. SSRIs and SNRIs, including Cymbalta have been associated with cases of clinically significant <span class="conditions" mdrptid="36416600" mdrpt="hyponatraemia">hyponatremia</span> in <span class="conditions" mdrptid="37420350" mdrpt="elderly">elderly</span> patients, who may be at greater risk for this <span class="conditions" mdrptid="35809320" mdrpt="adverse event">adverse event</span> . In a subgroup analysis of patients 65 years of age and older (N=3278) from all placebo-controlled trials, 1.1% of patients treated with duloxetine reported one or more falls, compared with 0.4% of patients treated with placebo. While many patients with falls had underlying potential risk factors for falls (e.g., medications; medical comorbidities; gait disturbances), the impact of these factors on falls is unclear. Fall with serious consequences including bone fractures and hospitalizations have been reported .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s56">5.13</a>
                    </span><span class="Italics">
                        [see Other Adverse Reactions Observed During the Premarketing and Postmarketing Clinical Trial Evaluation of Duloxetine ( )]
                        <a href="#s88">6.11</a>
                    </span>
                </p>
                <p>
                    The pharmacokinetics of duloxetine after a single dose of 40 mg were compared in healthy <span class="conditions" mdrptid="37420350" mdrpt="elderly">elderly</span> females (65 to 77 years) and healthy middle-age females (32 to 50 years). There was no difference in the C , but the AUC of duloxetine was somewhat (about 25%) higher and the half-life about 4 hours longer in the <span class="conditions" mdrptid="37420350" mdrpt="elderly">elderly</span> females. Population pharmacokinetic analyses suggest that the typical values for clearance decrease by approximately 1% for each year of age between 25 to 75 years of age; but age as a predictive factor only accounts for a small percentage of between-patient variability. Dosage adjustment based on the age of the patient is not necessary .
                    <span class="Sub">max</span><span class="Italics">
                        [see Dosage and Administration ( )]
                        <a href="#s22">2.3</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s117"></a><a name="section-8.6"></a><p></p>
                <h2>8.6 Gender</h2>
                <p class="First">Duloxetine's half-life is similar in men and women. Dosage adjustment based on gender is not necessary.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s118"></a><a name="section-8.7"></a><p></p>
                <h2>8.7 Smoking Status</h2>
                <p class="First">Duloxetine bioavailability (AUC) appears to be reduced by about one-third in smokers. Dosage modifications are not recommended for smokers.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s119"></a><a name="section-8.8"></a><p></p>
                <h2>8.8 Race</h2>
                <p class="First">No specific <span class="conditions" mdrptid="36316180" mdrpt="drug level">pharmacokinetic study</span> was conducted to investigate the effects of race.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s120"></a><a name="section-8.9"></a><p></p>
                <h2>8.9 <span class="conditions" mdrptid="35909518" mdrpt="hepatic failure">Hepatic Insufficiency</span></h2>
                <p class="First">
                    Patients with clinically evident <span class="conditions" mdrptid="35909518" mdrpt="hepatic failure">hepatic insufficiency</span> have decreased duloxetine metabolism and elimination. After a single 20 mg dose of Cymbalta, 6 cirrhotic patients with moderate liver impairment (Child-Pugh Class B) had a mean plasma duloxetine clearance about 15% that of age- and gender-matched healthy subjects, with a 5-fold increase in mean exposure (AUC). Although C was similar to normals in the cirrhotic patients, the half-life was about 3 times longer .
                    <span class="Sub">max</span><span class="Italics">
                        [see Dosage and Administration ( ) and Warnings and Precautions ( )]
                        <a href="#s22">2.3</a><a href="#s57">5.14</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s121"></a><a name="section-8.10"></a><p></p>
                <h2>8.10 Severe <span class="conditions" mdrptid="37019321" mdrpt="renal impairment">Renal Impairment</span></h2>
                <p class="First">
                    Limited data are available on the effects of duloxetine in patients with end-stage <span class="conditions" mdrptid="37019308" mdrpt="renal disorder">renal disease</span> (ESRD). After a single 60 mg dose of duloxetine, C and AUC values were approximately 100% greater in patients with end-stage <span class="conditions" mdrptid="37019308" mdrpt="renal disorder">renal disease</span> receiving chronic intermittent <span class="conditions" mdrptid="37521163" mdrpt="haemodialysis">hemodialysis</span> than in subjects with normal renal function. The elimination half-life, however, was similar in both groups. The AUCs of the major circulating metabolites, 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate, largely excreted in urine, were approximately 7- to 9-fold higher and would be expected to increase further with multiple dosing. Population PK analyses suggest that mild to moderate degrees of renal dysfunction (estimated CrCl 30-80 mL/min) have no significant effect on duloxetine apparent clearance .
                    <span class="Sub">max</span><span class="Italics">
                        [see Dosage and Administration ( ) and Warnings and Precautions ( )]
                        <a href="#s22">2.3</a><a href="#s57">5.14</a>
                    </span>
                </p>
            </div>
        </div>
        <div class="Section" data-sectionCode="42227-9">
            <a name="s122"></a><a name="section-9"></a><p></p>
            <h1>9 <span class="conditions" mdrptid="36919127" mdrpt="drug abuse">DRUG ABUSE</span> AND <span class="conditions" mdrptid="36919126" mdrpt="dependence">DEPENDENCE</span></h1>
            <div class="Section" data-sectionCode="34086-9">
                <a name="s123"></a><a name="section-9.1"></a><p></p>
                <h2>9.2 <span class="conditions" mdrptid="36919132" mdrpt="substance abuse">Abuse</span></h2>
                <p class="First">In animal studies, duloxetine did not demonstrate barbiturate-like (depressant) <span class="conditions" mdrptid="36919132" mdrpt="substance abuse">abuse</span> potential.</p>
                <p>While Cymbalta has not been systematically studied in humans for its potential for <span class="conditions" mdrptid="36919132" mdrpt="substance abuse">abuse</span>, there was no indication of drug-seeking behavior in the clinical trials. However, it is not possible to predict on the basis of premarketing experience the extent to which a CNS active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate patients for a history of <span class="conditions" mdrptid="36919127" mdrpt="drug abuse">drug abuse</span> and follow such patients closely, observing them for signs of misuse or <span class="conditions" mdrptid="36919132" mdrpt="substance abuse">abuse</span> of Cymbalta (e.g., development of <span class="conditions" mdrptid="35809331" mdrpt="drug tolerance">tolerance</span>, incrementation of dose, drug-seeking behavior).</p>
            </div>
            <div class="Section" data-sectionCode="34087-7">
                <a name="s124"></a><a name="section-9.2"></a><p></p>
                <h2>9.3 <span class="conditions" mdrptid="36919126" mdrpt="dependence">Dependence</span></h2>
                <p class="First">In <span class="conditions" mdrptid="36919128" mdrpt="drug dependence">drug dependence</span> studies, duloxetine did not demonstrate <span class="conditions" mdrptid="36919126" mdrpt="dependence">dependence</span>-producing potential in rats.</p>
            </div>
        </div>
        <div class="Section" data-sectionCode="34088-5">
            <a name="s125"></a><a name="section-10"></a><p></p>
            <h1>10 OVERDOSAGE</h1>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s126"></a><a name="section-10.1"></a><p></p>
                <h2>10.1 Signs and Symptoms</h2>
                <p class="First">In postmarketing experience, fatal outcomes have been reported for acute overdoses, primarily with mixed overdoses, but also with duloxetine only, at doses as low as 1000 mg. Signs and symptoms of <span class="conditions" mdrptid="36211496" mdrpt="overdose">overdose</span> (duloxetine alone or with mixed drugs) included <span class="conditions" mdrptid="36718321" mdrpt="somnolence">somnolence</span>, <span class="conditions" mdrptid="36718288" mdrpt="coma">coma</span>, <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span>, <span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizures</span>, <span class="conditions" mdrptid="35205037" mdrpt="syncope">syncope</span>, <span class="conditions" mdrptid="35204948" mdrpt="tachycardia">tachycardia</span>, <span class="conditions" mdrptid="37622449" mdrpt="hypotension">hypotension</span>, <span class="conditions" mdrptid="37622529" mdrpt="hypertension">hypertension</span>, and <span class="conditions" mdrptid="35708208" mdrpt="vomiting">vomiting</span>.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s127"></a><a name="section-10.2"></a><p></p>
                <h2>10.2 Management of <span class="conditions" mdrptid="36211496" mdrpt="overdose">Overdose</span></h2>
                <p class="First">There is no specific antidote to Cymbalta, but if <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span> ensues, specific treatment (such as with cyproheptadine and/or temperature control) may be considered. In case of <span class="conditions" mdrptid="36211496" mdrpt="overdose">acute overdose</span>, treatment should consist of those general measures employed in the management of <span class="conditions" mdrptid="36211496" mdrpt="overdose">overdose</span> with any drug.</p>
                <p>An adequate airway, oxygenation, and ventilation should be assured, and cardiac rhythm and vital signs should be monitored. <span class="conditions" mdrptid="37521955" mdrpt="induction and maintenance of anaesthesia">Induction</span> of <span class="conditions" mdrptid="35708208" mdrpt="vomiting">emesis</span> is not recommended. <span class="conditions" mdrptid="37521002" mdrpt="gastric lavage">Gastric lavage</span> with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients.</p>
                <p>
                    Activated charcoal may be useful in limiting absorption of duloxetine from the gastrointestinal tract. Administration of activated charcoal has been shown to decrease AUC and C by an average of one-third, although some subjects had a limited effect of activated charcoal. Due to the large volume of distribution of this drug, forced <span class="conditions" mdrptid="37019450" mdrpt="polyuria">diuresis</span>, <span class="conditions" mdrptid="37521159" mdrpt="dialysis">dialysis</span>, hemoperfusion, and exchange <span class="conditions" mdrptid="37521144" mdrpt="transfusion">transfusion</span> are unlikely to be beneficial.
                    <span class="Sub">max</span>
                </p>
                <p>
                    In managing <span class="conditions" mdrptid="36211496" mdrpt="overdose">overdose</span>, the possibility of multiple drug involvement should be considered. A specific caution involves patients who are taking or have recently taken Cymbalta and might ingest excessive quantities of a TCA. In such a case, decreased clearance of the parent tricyclic and/or its active metabolite may increase the possibility of clinically significant sequelae and extend the time needed for close <span class="conditions" mdrptid="36315318" mdrpt="medical observation">medical observation</span> . The physician should consider contacting a poison control center for additional information on the treatment of any <span class="conditions" mdrptid="36211496" mdrpt="overdose">overdose</span>. Telephone numbers for certified poison control centers are listed in the (PDR).
                    <span class="Italics">
                        [see Warnings and Precautions ( ) and Drug Interactions ( )]
                        <a href="#s40">5.4</a><a href="#s90">7</a>
                    </span><span class="Italics">Physicians' Desk Reference</span>
                </p>
            </div>
        </div>
        <div class="Section" data-sectionCode="34089-3">
            <a name="s128"></a><a name="section-11"></a><p></p>
            <h1>11 DESCRIPTION</h1>
            <p class="First">
                Cymbalta (Duloxetine Delayed-Release Capsules) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Its chemical designation is (+)-( )- -methyl-γ-(1-naphthyloxy)-2-thiophenepropylamine hydrochloride. The empirical formula is C H NOS•HCl, which corresponds to a molecular weight of 333.88. The structural formula is:
                <span class="Sup">®</span><span class="Italics">S</span><span class="Italics">N</span><span class="Sub">18</span><span class="Sub">19</span>
            </p>
            <div class="Figure">
                <a name="f01"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=00acd9e9-b26a-4626-949e-112ecd2f27e6&amp;name=cymbalta-01.jpg">
            </div>
            <p>Duloxetine hydrochloride is a white to slightly brownish white solid, which is slightly soluble in water.</p>
            <p>Each capsule contains enteric-coated pellets of 22.4, 33.7, or 67.3 mg of duloxetine hydrochloride equivalent to 20, 30, or 60 mg of duloxetine, respectively. These enteric-coated pellets are designed to prevent degradation of the drug in the acidic environment of the stomach. Inactive ingredients include FD&amp;C Blue No. 2, gelatin, hypromellose, hydroxypropyl methylcellulose acetate succinate, <span class="conditions" mdrptid="36316389" mdrpt="blood sodium">sodium</span> lauryl sulfate, sucrose, sugar spheres, talc, titanium dioxide, and triethyl citrate. The 20 and 60 mg capsules also contain iron oxide yellow.</p>
        </div>
        <div class="Section" data-sectionCode="34090-1">
            <a name="s129"></a><a name="section-12"></a><p></p>
            <h1>12 CLINICAL PHARMACOLOGY</h1>
            <div class="Section" data-sectionCode="43679-0">
                <a name="s130"></a><a name="section-12.1"></a><p></p>
                <h2>12.1 Mechanism of Action</h2>
                <p class="First">Although the exact mechanisms of the antidepressant, central <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.</p>
            </div>
            <div class="Section" data-sectionCode="43681-6">
                <a name="s131"></a><a name="section-12.2"></a><p></p>
                <h2>12.2 Pharmacodynamics</h2>
                <p class="First">
                    Preclinical studies have shown that duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors . Duloxetine does not inhibit monoamine oxidase (MAO).
                    <span class="Italics">in vitro</span>
                </p>
                <p>Cymbalta is in a class of drugs known to affect urethral resistance. If symptoms of <span class="conditions" mdrptid="37019409" mdrpt="urinary hesitation">urinary hesitation</span> develop during treatment with Cymbalta, consideration should be given to the possibility that they might be drug-related.</p>
            </div>
            <div class="Section" data-sectionCode="43682-4">
                <a name="s132"></a><a name="section-12.3"></a><p></p>
                <h2>12.3 Pharmacokinetics</h2>
                <p class="First">Duloxetine has an elimination half-life of about 12 hours (range 8 to 17 hours) and its pharmacokinetics are dose proportional over the therapeutic range. Steady-state plasma concentrations are typically achieved after 3 days of dosing. Elimination of duloxetine is mainly through hepatic metabolism involving two P450 isozymes, CYP1A2 and CYP2D6.</p>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s133"></a><a name="section-12.3.1"></a><p></p>
                    <p class="First">
                        — Orally administered duloxetine hydrochloride is well absorbed. There is a median 2 hour lag until absorption begins (T ), with maximal plasma concentrations (C ) of duloxetine occurring 6 hours post dose. Food does not affect the C of duloxetine, but delays the time to reach peak concentration from 6 to 10 hours and it marginally decreases the extent of absorption (AUC) by about 10%. There is a 3 hour delay in absorption and a one-third increase in apparent clearance of duloxetine after an evening dose as compared to a morning dose.
                        <span class="Underline">Absorption and Distribution</span><span class="Sub">lag</span><span class="Sub">max</span><span class="Sub">max</span>
                    </p>
                    <p>
                        The apparent volume of distribution averages about 1640 L. Duloxetine is highly bound (&gt;90%) to proteins in human plasma, binding primarily to albumin and α -acid glycoprotein. The <span class="conditions" mdrptid="35809310" mdrpt="drug interaction">interaction</span> between duloxetine and other highly <span class="conditions" mdrptid="36315537" mdrpt="protein total">protein</span> bound drugs has not been fully evaluated. <span class="conditions" mdrptid="36315537" mdrpt="protein total">Plasma protein</span> binding of duloxetine is not affected by renal or <span class="conditions" mdrptid="35909501" mdrpt="liver disorder">hepatic impairment</span>.
                        <span class="Sub">1</span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s134"></a><a name="section-12.3.2"></a><p></p>
                    <p class="First">
                        — Biotransformation and disposition of duloxetine in humans have been determined following oral administration of C-labeled duloxetine. Duloxetine comprises about 3% of the total radiolabeled material in the plasma, indicating that it undergoes extensive metabolism to numerous metabolites. The major biotransformation pathways for duloxetine involve oxidation of the naphthyl ring followed by conjugation and further oxidation. Both CYP1A2 and CYP2D6 catalyze the oxidation of the naphthyl ring . Metabolites found in plasma include 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate. Many additional metabolites have been identified in urine, some representing only minor pathways of elimination. Only trace (&lt;1% of the dose) amounts of unchanged duloxetine are present in the urine. Most (about 70%) of the duloxetine dose appears in the urine as metabolites of duloxetine; about 20% is excreted in the feces. Duloxetine undergoes extensive metabolism, but the major circulating metabolites have not been shown to contribute significantly to the pharmacologic activity of duloxetine.
                        <span class="Underline">Metabolism and Elimination</span><span class="Sup">14</span><span class="Italics">in vitro</span>
                    </p>
                </div>
            </div>
        </div>
        <div class="Section" data-sectionCode="43680-8">
            <a name="s135"></a><a name="section-13"></a><p></p>
            <h1>13 NONCLINICAL TOXICOLOGY</h1>
            <div class="Section" data-sectionCode="34083-6">
                <a name="s136"></a><a name="section-13.1"></a><p></p>
                <h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s137"></a><a name="section-13.1.1"></a><p></p>
                    <p class="First">
                        — Duloxetine was administered in the diet to mice and rats for 2 years.
                        <span class="Underline">Carcinogenesis</span>
                    </p>
                    <p>
                        In female mice receiving duloxetine at 140 mg/kg/day (11 times the maximum recommended human dose [MRHD, 60 mg/day] and 6 times the human dose of 120 mg/day on a mg/m basis), there was an increased incidence of hepatocellular adenomas and carcinomas. The no-effect dose was 50 mg/kg/day (4 times the MRHD and 2 times the human dose of 120 mg/day on a mg/m basis). Tumor incidence was not increased in male mice receiving duloxetine at doses up to 100 mg/kg/day (8 times the MRHD and 4 times the human dose of 120 mg/day on a mg/m basis).
                        <span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span>
                    </p>
                    <p>
                        In rats, dietary doses of duloxetine up to 27 mg/kg/day in females (4 times the MRHD and 2 times the human dose of 120 mg/day on a mg/m basis) and up to 36 mg/kg/day in males (6 times the MRHD and 3 times the human dose of 120 mg/day on a mg/m basis) did not increase the incidence of tumors.
                        <span class="Sup">2</span><span class="Sup">2</span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s138"></a><a name="section-13.1.2"></a><p></p>
                    <p class="First">
                        — Duloxetine was not mutagenic in the bacterial reverse mutation assay (Ames test) and was not clastogenic in an chromosomal aberration test in mouse bone marrow cells. Additionally, duloxetine was not genotoxic in an mammalian forward <span class="conditions" mdrptid="35305472" mdrpt="gene mutation">gene mutation</span> assay in mouse <span class="conditions" mdrptid="35104461" mdrpt="lymphoma">lymphoma</span> cells or in an unscheduled DNA synthesis (UDS) assay in primary rat hepatocytes, and did not induce sister chromatid exchange in Chinese hamster bone marrow .
                        <span class="Underline">Mutagenesis</span><span class="Italics">in vitro</span><span class="Italics">in vivo</span><span class="Italics">in vitro</span><span class="Italics">in vitro</span><span class="Italics">in vivo</span>
                    </p>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s139"></a><a name="section-13.1.3"></a><p></p>
                    <p class="First">
                        — Duloxetine administered orally to either male or female rats prior to and throughout mating at doses up to 45 mg/kg/day (7 times the maximum recommended human dose of 60 mg/day and 4 times the human dose of 120 mg/day on a mg/m basis) did not alter mating or fertility.
                        <span class="Underline">Impairment of Fertility</span><span class="Sup">2</span>
                    </p>
                </div>
            </div>
        </div>
        <div class="Section" data-sectionCode="34092-7">
            <a name="s140"></a><a name="section-14"></a><p></p>
            <h1>14 CLINICAL STUDIES</h1>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s141"></a><a name="section-14.1"></a><p></p>
                <h2>14.1 Major <span class="conditions" mdrptid="36918942" mdrpt="depression">Depressive Disorder</span></h2>
                <p class="First">The efficacy of Cymbalta as a treatment for depression was established in 4 randomized, double-blind, placebo-controlled, fixed-dose studies in adult outpatients (18 to 83 years) meeting DSM-IV criteria for <span class="conditions" mdrptid="36918945" mdrpt="major depression">major depression</span>. In 2 studies, patients were randomized to Cymbalta 60 mg once daily (N=123 and N=128, respectively) or placebo (N=122 and N=139, respectively) for 9 weeks; in the third study, patients were randomized to Cymbalta 20 or 40 mg twice daily (N=86 and N=91, respectively) or placebo (N=89) for 8 weeks; in the fourth study, patients were randomized to Cymbalta 40 or 60 mg twice daily (N=95 and N=93, respectively) or placebo (N=93) for 8 weeks. There is no evidence that doses greater than 60 mg/day confer additional benefits.</p>
                <p>In all 4 studies, Cymbalta demonstrated superiority over placebo as measured by improvement in the 17-item Hamilton <span class="conditions" mdrptid="36918942" mdrpt="depression">Depression</span> Rating <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">Scale</span> (HAMD-17) total score.</p>
                <p>In all of these clinical studies, analyses of the relationship between treatment outcome and age, gender, and race did not suggest any differential responsiveness on the basis of these patient characteristics.</p>
                <p>In another study, 533 patients meeting DSM-IV criteria for MDD received Cymbalta 60 mg once daily during an initial 12-week open-label treatment phase. Two hundred and seventy-eight patients who responded to open label treatment (defined as meeting the following criteria at weeks 10 and 12: a HAMD-17 total score ≤9, Clinical Global Impressions of Severity (CGI-S) ≤2, and not meeting the DSM-IV criteria for MDD) were randomly assigned to continuation of Cymbalta at the same dose (N=136) or to placebo (N=142) for 6 months. Patients on Cymbalta experienced a statistically significantly longer time to relapse of <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span> than did patients on placebo. Relapse was defined as an increase in the CGI-S score of ≥2 points compared with that obtained at week 12, as well as meeting the DSM-IV criteria for MDD at 2 consecutive visits at least 2 weeks apart, where the 2-week temporal criterion had to be satisfied at only the second visit. The effectiveness of Cymbalta in hospitalized patients with major <span class="conditions" mdrptid="36918942" mdrpt="depression">depressive disorder</span> has not been studied.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s142"></a><a name="section-14.2"></a><p></p>
                <h2>14.2 <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">Generalized Anxiety Disorder</span></h2>
                <p class="First">The efficacy of Cymbalta in the treatment of <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">generalized anxiety disorder</span> (<span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span>) was established in 1 fixed-dose randomized, double-blind, placebo-controlled trial and 2 flexible-dose randomized, double-blind, placebo-controlled trials in adult outpatients between 18 and 83 years of age meeting the DSM-IV criteria for <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span>.</p>
                <p>In 1 flexible-dose study and in the fixed-dose study, the starting dose was 60 mg once daily where down titration to 30 mg once daily was allowed for tolerability reasons before increasing it to 60 mg once daily. Fifteen percent of patients were down titrated. One flexible-dose study had a starting dose of 30 mg once daily for 1 week before increasing it to 60 mg once daily.</p>
                <p>The 2 flexible-dose studies involved dose titration with Cymbalta doses ranging from 60 mg once daily to 120 mg once daily (N=168 and N=162) compared to placebo (N=159 and N=161) over a 10-week treatment period. The mean dose for completers at endpoint in the flexible-dose studies was 104.75 mg/day. The fixed-dose study evaluated Cymbalta doses of 60 mg once daily (N=168) and 120 mg once daily (N=170) compared to placebo (N=175) over a 9-week treatment period. While a 120 mg/day dose was shown to be effective, there is no evidence that doses greater than 60 mg/day confer additional benefit.</p>
                <p>In all 3 studies, Cymbalta demonstrated superiority over placebo as measured by greater improvement in the Hamilton <span class="conditions" mdrptid="36918858" mdrpt="anxiety">Anxiety</span> <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">Scale</span> (<span class="conditions" mdrptid="36111003" mdrpt="tropical spastic paresis">HAM</span>-A) total score and by the Sheehan <span class="conditions" mdrptid="37420519" mdrpt="disability">Disability</span> <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">Scale</span> (SDS) global functional impairment score. The SDS is a widely used and well-validated <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">scale</span> that measures the extent emotional symptoms disrupt patient functioning in 3 life domains: work/school, social life/leisure activities, and family life/home responsibilities.</p>
                <p>In another study, 887 patients meeting DSM-IV-TR criteria for <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span> received Cymbalta 60 mg to 120 mg once daily during an initial 26-week open-label treatment phase. Four hundred and twenty-nine patients who responded to open-label treatment (defined as meeting the following criteria at weeks 24 and 26: a decrease from baseline <span class="conditions" mdrptid="36111003" mdrpt="tropical spastic paresis">HAM</span>-A total score by at least 50% to a score no higher than 11, and a Clinical Global Impressions of Improvement [CGI-Improvement] score of 1 or 2) were randomly assigned to continuation of Cymbalta at the same dose (N=216) or to placebo (N=213) and were observed for relapse. Of the patients randomized, 73% had been in a responder status for at least 10 weeks. Relapse was defined as an increase in CGI-Severity score at least 2 points to a score ≥4 and a MINI (Mini-International Neuropsychiatric Interview) diagnosis of <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span> (excluding duration), or discontinuation due to lack of efficacy. Patients taking Cymbalta experienced a statistically significantly longer time to relapse of <span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span> than did patients taking placebo.</p>
                <p>Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of age or gender.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s143"></a><a name="section-14.3"></a><p></p>
                <h2>14.3 <span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span></h2>
                <p class="First">The efficacy of Cymbalta for the management of <span class="conditions" mdrptid="36718401" mdrpt="neuralgia">neuropathic pain</span> associated with <span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">diabetic peripheral neuropathy</span> was established in 2 randomized, 12-week, double-blind, placebo-controlled, fixed-dose studies in adult patients having <span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">diabetic peripheral neuropathic pain</span> for at least 6 months. Study DPNP-1 and Study DPNP-2 enrolled a total of 791 patients of whom 592 (75%) completed the studies. Patients enrolled had Type I or II <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes mellitus</span> with a diagnosis of painful distal symmetrical sensorimotor <span class="conditions" mdrptid="36718463" mdrpt="polyneuropathy">polyneuropathy</span> for at least 6 months. The patients had a baseline <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> score of ≥4 on an 11-point <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">scale</span> ranging from 0 (no <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span>) to 10 (worst possible <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span>). Patients were permitted up to 4 g of acetaminophen per day as needed for <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span>, in addition to Cymbalta. Patients recorded their <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> daily in a diary.</p>
                <p>
                    Both studies compared Cymbalta 60 mg once daily or 60 mg twice daily with placebo. DPNP-1 additionally compared Cymbalta 20 mg with placebo. A total of 457 patients (342 Cymbalta, 115 placebo) were enrolled in DPNP-1 and a total of 334 patients (226 Cymbalta, 108 placebo) were enrolled in DPNP-2. Treatment with Cymbalta 60 mg one or two times a day statistically significantly improved the endpoint mean <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> scores from baseline and increased the proportion of patients with at least a 50% reduction in <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> scores from baseline. For various degrees of improvement in <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> from baseline to study endpoint, and show the fraction of patients achieving that degree of improvement. The figures are cumulative, so that patients whose change from baseline is, for example, 50%, are also included at every level of improvement below 50%. Patients who did not complete the study were assigned 0% improvement. Some patients experienced a decrease in <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> as early as week 1, which persisted throughout the study.
                    <a href="#f02">Figures 1</a><a href="#f03">2</a>
                </p>
                <div class="Figure">
                    <a name="f02"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=00acd9e9-b26a-4626-949e-112ecd2f27e6&amp;name=cymbalta-02.jpg"><p class="MultiMediaCaption">Figure 1: Percentage of Patients Achieving Various Levels of <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> Relief as Measured by 24-Hour Average <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> Severity - DPNP-1</p>
                </div>
                <div class="Figure">
                    <a name="f03"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=00acd9e9-b26a-4626-949e-112ecd2f27e6&amp;name=cymbalta-03.jpg"><p class="MultiMediaCaption">Figure 2: Percentage of Patients Achieving Various Levels of <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> Relief as Measured by 24-Hour Average <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> Severity - DPNP-2</p>
                </div>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s144"></a><a name="section-14.4"></a><p></p>
                <h2>14.4 <span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">Fibromyalgia</span></h2>
                <p class="First">The efficacy of Cymbalta for the management of <span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">fibromyalgia</span> was established in two randomized, double-blind, placebo-controlled, fixed-dose studies in adult patients meeting the American College of Rheumatology criteria for <span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">fibromyalgia</span> (a history of widespread <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> for 3 months, and <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> present at 11 or more of the 18 specific tender point sites). Study FM-1 was three months in duration and enrolled female patients only. Study FM-2 was six months in duration and enrolled male and female patients. Approximately 25% of participants had a comorbid diagnosis of major <span class="conditions" mdrptid="36918942" mdrpt="depression">depressive disorder</span> (MDD). FM-1 and FM-2 enrolled a total of 874 patients of whom 541 (62%) completed the studies. The patients had a baseline <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> score of 6.5 on an 11-point <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">scale</span> ranging from 0 (no <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span>) to 10 (worse possible <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span>).</p>
                <p>
                    Both studies compared Cymbalta 60 mg once daily or 120 mg daily (given in divided doses in FM-1 and as a single daily dose in FM-2) with placebo. FM-2 additionally compared Cymbalta 20 mg with placebo during the initial three months of a six-month study. A total of 354 patients (234 Cymbalta, 120 placebo) were enrolled in FM-1 and a total of 520 patients (376 Cymbalta, 144 placebo) were enrolled in FM-2 (5% male, 95% female). Treatment with Cymbalta 60 mg or 120 mg daily statistically significantly improved the endpoint mean <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> scores from baseline and increased the proportion of patients with at least a 50% reduction in <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> score from baseline. <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> reduction was observed in patients both with and without comorbid MDD. However, the degree of <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> reduction may be greater in patients with comorbid MDD. For various degrees of improvement in <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> from baseline to study endpoint, and show the fraction of patients achieving that degree of improvement. The figures are cumulative so that patients whose change from baseline is, for example, 50%, are also included at every level of improvement below 50%. Patients who did not complete the study were assigned 0% improvement. Some patients experienced a decrease in <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> as early as week 1, which persisted throughout the study. Improvement was also demonstrated on measures of function (<span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">Fibromyalgia</span> Impact Questionnaires) and patient global impression of change (PGI). Neither study demonstrated a benefit of 120 mg compared to 60 mg, and a higher dose was associated with more adverse reactions and premature discontinuations of treatment.
                    <a href="#f04">Figures 3</a><a href="#f05">4</a>
                </p>
                <div class="Figure">
                    <a name="f04"></a><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=00acd9e9-b26a-4626-949e-112ecd2f27e6&amp;name=cymbalta-13.jpg"><p class="MultiMediaCaption">Figure 3: Percentage of Patients Achieving Various Levels of <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> Relief as Measured by 24-Hour Average <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> Severity - FM-1</p>
                </div>
                <div class="Figure">
                    <a name="f05"></a><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=00acd9e9-b26a-4626-949e-112ecd2f27e6&amp;name=cymbalta-14.jpg"><p class="MultiMediaCaption">Figure 4: Percentage of Patients Achieving Various Levels of <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> Relief as Measured by 24-Hour Average <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> Severity - FM-2</p>
                </div>
                <p>Additionally, the benefit of up-titration in non-responders to Cymbalta at 60 mg/day was evaluated in a separate study. Patients were initially treated with Cymbalta 60 mg once daily for eight weeks in open-label fashion. Subsequently, completers of this phase were randomized to double-blind treatment with Cymbalta at either 60 mg once daily or 120 mg once daily. Those patients who were considered non-responders, where response was defined as at least a 30% reduction in <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> score from baseline at the end of the 8-week treatment, were no more likely to meet response criteria at the end of 60 weeks of treatment if blindly titrated to Cymbalta 120 mg as compared to those who were blindly continued on Cymbalta 60 mg.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s145"></a><a name="section-14.5"></a><p></p>
                <h2>14.5 Chronic <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">Musculoskeletal Pain</span></h2>
                <p class="First">Cymbalta is indicated for the management of chronic <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">musculoskeletal pain</span>. This has been established in studies in patients with chronic <span class="conditions" mdrptid="36516951" mdrpt="back pain">low back pain</span> and <span class="conditions" mdrptid="35809243" mdrpt="pain">chronic pain</span> due to <span class="conditions" mdrptid="36516824" mdrpt="osteoarthritis">osteoarthritis</span>.</p>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s146"></a><a name="section-14.5.1"></a><p></p>
                    <p class="First">
                        —
                        <span class="Underline">Studies in Chronic <span class="conditions" mdrptid="36516951" mdrpt="back pain">Low Back Pain</span></span>
                    </p>
                    <p>The efficacy of Cymbalta in chronic <span class="conditions" mdrptid="36516951" mdrpt="back pain">low back pain</span> (CLBP) was assessed in two double-blind, placebo-controlled, randomized clinical trials of 13-weeks duration (Study CLBP-1 and Study CLBP-2), and one of 12-weeks duration (CLBP-3). CLBP-1 and CLBP-3 demonstrated efficacy of Cymbalta in the treatment of chronic <span class="conditions" mdrptid="36516951" mdrpt="back pain">low back pain</span>. Patients in all studies had no signs of <span class="conditions" mdrptid="36718595" mdrpt="radiculopathy">radiculopathy</span> or spinal stenosis.</p>
                    <p>
                        : Two hundred thirty-six adult patients (N=115 on Cymbalta, N=121 on placebo) enrolled and 182 (77%) completed 13-week treatment phase. After 7 weeks of treatment, Cymbalta patients with less than 30% reduction in average daily <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> and who were able to tolerate duloxetine 60 mg once daily had their dose of Cymbalta, in a double-blinded fashion, increased to 120 mg once daily for the remainder of the study. Patients had a mean baseline <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> rating of 6 on a numerical rating <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">scale</span> ranging from 0 (no <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span>) to 10 (worst possible <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span>). After 13 weeks of treatment, patients taking Cymbalta 60-120 mg daily had a significantly greater <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> reduction compared to placebo. Randomization was stratified by the patients' baseline NSAIDs-use status. Subgroup analyses did not indicate that there were differences in treatment outcomes as a function of NSAIDs use.
                        <span class="Italics">Study CLBP-1</span>
                    </p>
                    <p>
                        : Four hundred and four patients were randomized to receive fixed doses of Cymbalta daily or a matching placebo (N=59 on Cymbalta 20 mg, N=116 on Cymbalta 60 mg, N=112 on Cymbalta 120 mg, N=117 on placebo) and 267 (66%) completed the entire 13-week study. After 13 weeks of treatment, none of the three Cymbalta doses showed a statistically significant difference in <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> reduction compared to placebo.
                        <span class="Italics">Study CLBP-2</span>
                    </p>
                    <p>
                        : Four hundred and one patients were randomized to receive fixed doses of Cymbalta 60 mg daily or placebo (N=198 on Cymbalta, N=203 on placebo), and 303 (76%) completed the study. Patients had a mean baseline <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> rating of 6 on a numerical rating <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">scale</span> ranging from 0 (no <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span>) to 10 (worst possible <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span>). After 12 weeks of treatment, patients taking Cymbalta 60 mg daily had significantly greater <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> reduction compared to placebo.
                        <span class="Italics">Study CLBP-3</span>
                    </p>
                    <p>
                        For various degrees of improvement in <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> from baseline to study endpoint, and show the fraction of patients in CLBP-1 and CLBP-3 achieving that degree of improvement. The figures are cumulative, so that patients whose change from baseline is, for example, 50%, are also included at every level of improvement below 50%. Patients who did not complete the study were assigned the value of 0% improvement.
                        <a href="#f06">Figures 5</a><a href="#f07">6</a>
                    </p>
                    <div class="Figure">
                        <a name="f06"></a><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=00acd9e9-b26a-4626-949e-112ecd2f27e6&amp;name=cymbalta-15.jpg"><p class="MultiMediaCaption">Figure 5: Percentage of Patients Achieving Various Levels of <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> Relief as Measured by 24-Hour Average <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> Severity – CLBP-1</p>
                    </div>
                    <div class="Figure">
                        <a name="f07"></a><img alt="Figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=00acd9e9-b26a-4626-949e-112ecd2f27e6&amp;name=cymbalta-16.jpg"><p class="MultiMediaCaption">Figure 6: Percentage of Patients Achieving Various Levels of <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> Relief as Measured by 24-Hour Average <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> Severity – CLBP-3</p>
                    </div>
                </div>
                <div class="Section" data-sectionCode="42229-5">
                    <a name="s147"></a><a name="section-14.5.2"></a><p></p>
                    <p class="First">
                        —
                        <span class="Underline">Studies in <span class="conditions" mdrptid="35809243" mdrpt="pain">Chronic Pain</span> Due to <span class="conditions" mdrptid="36516824" mdrpt="osteoarthritis">Osteoarthritis</span></span>
                    </p>
                    <p>The efficacy of Cymbalta in <span class="conditions" mdrptid="35809243" mdrpt="pain">chronic pain</span> due to <span class="conditions" mdrptid="36516824" mdrpt="osteoarthritis">osteoarthritis</span> was assessed in 2 double-blind, placebo-controlled, randomized clinical trials of 13-weeks duration (Study OA-1 and Study OA-2). All patients in both studies fulfilled the ACR clinical and radiographic criteria for classification of idiopathic <span class="conditions" mdrptid="36516824" mdrpt="osteoarthritis">osteoarthritis</span> of the knee. Randomization was stratified by the patients' baseline NSAIDs-use status. Patients assigned to Cymbalta started treatment in both studies at a dose of 30 mg once daily for one week. After the first week, the dose of Cymbalta was increased to 60 mg once daily. After 7 weeks of treatment with Cymbalta 60 mg once daily, in OA-1 patients with sub-optimal response to treatment (&lt;30% <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> reduction) and tolerated duloxetine 60 mg once daily had their dose increased to 120 mg. However, in OA-2, all patients, regardless of their response to treatment after 7 weeks, were re-randomized to either continue receiving Cymbalta 60 mg once daily or have their dose increased to 120 mg once daily for the remainder of the study. Patients in the placebo treatment groups in both studies received a matching placebo for the entire duration of studies. For both studies, efficacy analyses were conducted using 13-week data from the combined Cymbalta 60 mg and 120 mg once daily treatment groups compared to the placebo group.</p>
                    <div class="Section" data-sectionCode="42229-5">
                        <a name="s148"></a><a name="section-14.5.2.1"></a><p></p>
                        <p class="First">
                            : Two hundred fifty-six patients (N=128 on Cymbalta, N=128 on placebo) enrolled and 204 (80%) completed the study. Patients had a mean baseline <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> rating of 6 on a numerical rating <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">scale</span> ranging from 0 (no <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span>) to 10 (worst possible <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span>). After 13 weeks of treatment, patients taking Cymbalta had significantly greater <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> reduction. Subgroup analyses did not indicate that there were differences in treatment outcomes as a function of NSAIDs use.
                            <span class="Italics">Study OA-1</span>
                        </p>
                    </div>
                    <div class="Section" data-sectionCode="42229-5">
                        <a name="s149"></a><a name="section-14.5.2.2"></a><p></p>
                        <p class="First">
                            : Two hundred thirty-one patients (N=111 on Cymbalta, N=120 on placebo) enrolled and 173 (75%) completed the study. Patients had a mean baseline <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> of 6 on a numerical rating <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">scale</span> ranging from 0 (no <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span>) to 10 (worst possible <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span>). After 13 weeks of treatment, patients taking Cymbalta did not show a significantly greater <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> reduction.
                            <span class="Italics">Study OA-2</span>
                        </p>
                        <p>
                            In Study OA-1, for various degrees of improvement in <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span> from baseline to study endpoint, shows the fraction of patients achieving that degree of improvement. The figure is cumulative, so that patients whose change from baseline is, for example, 50%, are also included at every level of improvement below 50%. Patients who did not complete the study were assigned the value of 0% improvement.
                            <a href="#f08">Figure 7</a>
                        </p>
                        <div class="Figure">
                            <a name="f08"></a><img alt="Figure 7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=00acd9e9-b26a-4626-949e-112ecd2f27e6&amp;name=cymbalta-17.jpg"><p class="MultiMediaCaption">Figure 7: Percentage of Patients Achieving Various Levels of <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> Relief as Measured by 24-Hour Average <span class="conditions" mdrptid="35809243" mdrpt="pain">Pain</span> Severity – OA-1</p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
        <div class="Section" data-sectionCode="34069-5">
            <a name="s150"></a><a name="section-15"></a><p></p>
            <h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
            <p class="First">NDC:68151-4734-6 in a PACKAGE of 1 CAPSULE, DELAYED RELEASES</p>
            <div class="Section" data-sectionCode="34069-5">
                <a name="s151"></a><a name="section-15.1"></a><p></p>
                <h2>16.1 How Supplied</h2>
                <p class="First">Cymbalta is available as delayed release capsules in the following strengths, colors, imprints, and presentations:</p>
                <table width="100%">
                    <col align="left" width="27.934%">
                    <col align="left" width="22.875%">
                    <col align="left" width="23.695%">
                    <col align="left" width="7.359%">
                    <col align="left" width="18.136%">
                    <tfoot>
                        <tr class="First">
                            <td align="left" colspan="5" valign="top">
                                <p class="First Footnote">
                                    equivalent to duloxetine base
                                    <span class="Sup">a</span>
                                </p>
                            </td>
                        </tr>
                        <tr class="Last">
                            <td align="left" colspan="5" valign="top">
                                <p class="First Footnote">
                                    Identi-Dose® (unit dose medication, Lilly)
                                    <span class="Sup">†</span>
                                </p>
                            </td>
                        </tr>
                    </tfoot>
                    <tbody class="Headless">
                        <tr class="First">
                            <td class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Features</span></td>
                            <td class="Botrule Rrule Toprule" align="center" colspan="4" valign="top"><span class="Bold">Strengths</span></td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top"></td>
                            <td class="Botrule Rrule" align="center" valign="top">
                                <span class="Bold">20 mg</span><span class="Bold"><span class="Sup">a</span></span>
                            </td>
                            <td class="Botrule Rrule" align="center" valign="top">
                                <span class="Bold">30 mg</span><span class="Bold"><span class="Sup">a</span></span>
                            </td>
                            <td class="Botrule Rrule" align="center" colspan="2" valign="top">
                                <span class="Bold">60 mg</span><span class="Bold"><span class="Sup">a</span></span>
                            </td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">Body color</td>
                            <td class="Botrule Rrule" align="center" valign="top">Opaque green</td>
                            <td class="Botrule Rrule" align="center" valign="top">Opaque white</td>
                            <td class="Botrule Rrule" align="center" colspan="2" valign="top">Opaque green</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">Cap color</td>
                            <td class="Botrule Rrule" align="center" valign="top">Opaque green</td>
                            <td class="Botrule Rrule" align="center" valign="top">Opaque blue</td>
                            <td class="Botrule Rrule" align="center" colspan="2" valign="top">Opaque blue</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">Cap imprint</td>
                            <td class="Botrule Rrule" align="center" valign="top">Lilly 3235</td>
                            <td class="Botrule Rrule" align="center" valign="top">Lilly 3240</td>
                            <td class="Botrule Rrule" align="center" colspan="2" valign="top">Lilly 3270</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">Body imprint</td>
                            <td class="Botrule Rrule" align="center" valign="top">20mg</td>
                            <td class="Botrule Rrule" align="center" valign="top">30mg</td>
                            <td class="Botrule Rrule" align="center" colspan="2" valign="top">60mg</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">Capsule number</td>
                            <td class="Botrule Rrule" align="center" valign="top">PU3235</td>
                            <td class="Botrule Rrule" align="center" valign="top">PU3240</td>
                            <td class="Botrule Rrule" align="center" colspan="2" valign="top">PU3270</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule" align="left" valign="top">Presentations and NDC Codes</td>
                            <td class="Botrule" align="center" valign="top"></td>
                            <td class="Botrule" align="center" valign="top"></td>
                            <td class="Botrule" align="center" valign="top"></td>
                            <td class="Botrule Rrule" align="center" valign="top"></td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">Bottles of 30</td>
                            <td class="Botrule Rrule" align="center" valign="top">NA</td>
                            <td class="Botrule Rrule" align="center" valign="top">0002-3240-30</td>
                            <td class="Botrule Rrule" align="center" colspan="2" valign="top">0002-3270-30</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">Bottles of 60</td>
                            <td class="Botrule Rrule" align="center" valign="top">0002-3235-60</td>
                            <td class="Botrule Rrule" align="center" valign="top">NA</td>
                            <td class="Botrule Rrule" align="center" colspan="2" valign="top">NA</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">Bottles of 90</td>
                            <td class="Botrule Rrule" align="center" valign="top">NA</td>
                            <td class="Botrule Rrule" align="center" valign="top">0002-3240-90</td>
                            <td class="Botrule Rrule" align="center" colspan="2" valign="top">NA</td>
                        </tr>
                        <tr>
                            <td class="Botrule Lrule Rrule" align="left" valign="top">Bottles of 1000</td>
                            <td class="Botrule Rrule" align="center" valign="top">NA</td>
                            <td class="Botrule Rrule" align="center" valign="top">NA</td>
                            <td class="Botrule Rrule" align="center" colspan="2" valign="top">0002-3270-04</td>
                        </tr>
                        <tr class="Last">
                            <td class="Botrule Lrule Rrule" align="left" valign="top"><span class="conditions" mdrptid="36211383" mdrpt="blister">Blisters</span> ID†100</td>
                            <td class="Botrule Rrule" align="center" valign="top">NA</td>
                            <td class="Botrule Rrule" align="center" valign="top">0002-3240-33</td>
                            <td class="Botrule Rrule" align="center" colspan="2" valign="top">0002-3270-33</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="Section" data-sectionCode="44425-7">
                <a name="s152"></a><a name="section-15.2"></a><p></p>
                <h2>16.2 Storage and Handling</h2>
                <p class="First">
                    Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [ USP Controlled Room Temperature].
                    <span class="Italics">see</span>
                </p>
            </div>
        </div>
        <div class="Section" data-sectionCode="34076-0">
            <a name="s153"></a><a name="section-16"></a><p></p>
            <h1>17 PATIENT COUNSELING INFORMATION</h1>
            <p class="First">
                See FDA-approved patient labeling ( ).
                <a href="#s174">Medication Guide</a>
            </p>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s154"></a><a name="section-16.1"></a><p></p>
                <h2>17.1 Information on Medication Guide</h2>
                <p class="First">Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with Cymbalta and should counsel them in its appropriate use. A patient Medication Guide is available for Cymbalta. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide before starting Cymbalta and each time their prescription is renewed, and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.</p>
                <p>Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking Cymbalta.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s155"></a><a name="section-16.2"></a><p></p>
                <h2>17.2 Suicidal Thoughts and Behaviors</h2>
                <p class="First">
                    Patients, their families, and their caregivers should be encouraged to be alert to the emergence of <span class="conditions" mdrptid="36918858" mdrpt="anxiety">anxiety</span>, <span class="conditions" mdrptid="36718347" mdrpt="agitation">agitation</span>, <span class="conditions" mdrptid="36918904" mdrpt="panic attack">panic attacks</span>, <span class="conditions" mdrptid="36718555" mdrpt="insomnia">insomnia</span>, <span class="conditions" mdrptid="35809139" mdrpt="irritability">irritability</span>, <span class="conditions" mdrptid="36919069" mdrpt="hostility">hostility</span>, <span class="conditions" mdrptid="36919059" mdrpt="aggression">aggressiveness</span>, impulsivity, <span class="conditions" mdrptid="36718193" mdrpt="akathisia">akathisia</span> (<span class="conditions" mdrptid="36718368" mdrpt="restlessness">psychomotor restlessness</span>), <span class="conditions" mdrptid="36919035" mdrpt="hypomania">hypomania</span>, <span class="conditions" mdrptid="36919036" mdrpt="mania">mania</span>, other unusual changes in behavior, worsening of <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span>, and <span class="conditions" mdrptid="36919235" mdrpt="suicidal ideation">suicidal ideation</span>, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to observe for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication .
                    <span class="Italics">
                        [see , and Warnings and Precautions ( )]
                        <a href="#s2">Boxed Warning</a><a href="#s36">5.1</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s156"></a><a name="section-16.3"></a><p></p>
                <h2>17.3 Medication Administration</h2>
                <p class="First">Cymbalta should be swallowed whole and should not be chewed or crushed, nor should the capsule be opened and its contents be sprinkled on food or mixed with liquids. All of these might affect the enteric coating.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s157"></a><a name="section-16.4"></a><p></p>
                <h2>17.4 Continuing the Therapy Prescribed</h2>
                <p class="First">While patients may notice improvement with Cymbalta therapy in 1 to 4 weeks, they should be advised to continue therapy as directed.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s158"></a><a name="section-16.5"></a><p></p>
                <h2>17.5 <span class="conditions" mdrptid="35909625" mdrpt="hepatotoxicity">Hepatotoxicity</span></h2>
                <p class="First">
                    Patients should be informed that severe liver problems, sometimes fatal, have been reported in patients treated with Cymbalta. Patients should be instructed to talk to their healthcare provider if they develop <span class="conditions" mdrptid="37320197" mdrpt="pruritus">itching</span>, right upper belly <span class="conditions" mdrptid="35809243" mdrpt="pain">pain</span>, dark urine, or <span class="conditions" mdrptid="35809173" mdrpt="yellow skin">yellow skin</span>/eyes while taking Cymbalta, which may be signs of liver problems. Patients should talk to their healthcare provider about their alcohol consumption. Use of Cymbalta with heavy alcohol intake may be associated with severe <span class="conditions" mdrptid="35909503" mdrpt="liver injury">liver injury</span> .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s38">5.2</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s159"></a><a name="section-16.6"></a><p></p>
                <h2>17.6 Alcohol</h2>
                <p class="First">
                    Although Cymbalta does not increase the impairment of mental and motor skills caused by alcohol, use of Cymbalta concomitantly with heavy alcohol intake may be associated with severe <span class="conditions" mdrptid="35909503" mdrpt="liver injury">liver injury</span>. For this reason, Cymbalta should not be prescribed for patients with substantial <span class="conditions" mdrptid="37420495" mdrpt="alcohol use">alcohol use</span> .
                    <span class="Italics">
                        [see Warnings and Precautions ( ) and Drug Interactions ( )]
                        <a href="#s38">5.2</a><a href="#s106">7.15</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s160"></a><a name="section-16.7"></a><p></p>
                <h2>17.7 <span class="conditions" mdrptid="37622451" mdrpt="orthostatic hypotension">Orthostatic Hypotension</span> and <span class="conditions" mdrptid="35205037" mdrpt="syncope">Syncope</span></h2>
                <p class="First">
                    Patients should be advised of the risk of <span class="conditions" mdrptid="37622451" mdrpt="orthostatic hypotension">orthostatic hypotension</span> and <span class="conditions" mdrptid="35205037" mdrpt="syncope">syncope</span>, especially during the period of initial use and subsequent dose escalation, and in association with the use of concomitant drugs that might potentiate the orthostatic effect of duloxetine .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s39">5.3</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s161"></a><a name="section-16.8"></a><p></p>
                <h2>17.8 <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">Serotonin Syndrome</span></h2>
                <p class="First">
                    Patients should be cautioned about the risk of <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span> with the concomitant use of Cymbalta and other serotonergic agents including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan and St. John's Wort .
                    <span class="Italics">
                        [see Contraindications ( ), Warnings and Precautions ( ), and Drug Interactions ( )]
                        <a href="#s33">4.1</a><a href="#s40">5.4</a><a href="#s104">7.14</a>
                    </span>
                </p>
                <p>Patients should be advised of the signs and symptoms associated with <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">serotonin syndrome</span> that may include <span class="conditions" mdrptid="36919118" mdrpt="mental status changes">mental status changes</span> (e.g., <span class="conditions" mdrptid="36718347" mdrpt="agitation">agitation</span>, <span class="conditions" mdrptid="36918984" mdrpt="hallucination">hallucinations</span>, <span class="conditions" mdrptid="36918937" mdrpt="delirium">delirium</span>, and <span class="conditions" mdrptid="36718288" mdrpt="coma">coma</span>), <span class="conditions" mdrptid="35809073" mdrpt="autonomic nervous system imbalance">autonomic instability</span> (e.g., <span class="conditions" mdrptid="35204948" mdrpt="tachycardia">tachycardia</span>, <span class="conditions" mdrptid="37622440" mdrpt="labile blood pressure">labile blood pressure</span>, <span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span>, <span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">diaphoresis</span>, <span class="conditions" mdrptid="35809130" mdrpt="flushing">flushing</span>, <span class="conditions" mdrptid="35809039" mdrpt="hyperthermia">hyperthermia</span>), neuromuscular changes (e.g., <span class="conditions" mdrptid="36718265" mdrpt="tremor">tremor</span>, <span class="conditions" mdrptid="36516867" mdrpt="muscle rigidity">rigidity</span>, <span class="conditions" mdrptid="36718362" mdrpt="myoclonus">myoclonus</span>, <span class="conditions" mdrptid="36718272" mdrpt="hyperreflexia">hyperreflexia</span>, <span class="conditions" mdrptid="36718285" mdrpt="coordination abnormal">incoordination</span>), <span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizures</span>, and/or gastrointestinal symptoms (e.g., <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span>, <span class="conditions" mdrptid="35708208" mdrpt="vomiting">vomiting</span>, <span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">diarrhea</span>). Patients should be cautioned to seek medical care immediately if they experience these symptoms.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s162"></a><a name="section-16.9"></a><p></p>
                <h2>17.9 Abnormal <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">Bleeding</span></h2>
                <p class="First">
                    Patients should be cautioned about the concomitant use of duloxetine and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation since combined use of psychotropic drugs that interfere with serotonin reuptake and these agents has been associated with an increased risk of <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">bleeding</span>
                    <span class="Italics">
                        [see Warnings and Precautions ( )].
                        <a href="#s41">5.5</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s163"></a><a name="section-16.10"></a><p></p>
                <h2>17.10 Severe Skin Reactions</h2>
                <p class="First">
                    Patients should be cautioned that Cymbalta may cause serious skin reactions. This may need to be treated in a hospital and may be life-threatening. Patients should be counseled to call their doctor right away or get emergency help if they have skin <span class="conditions" mdrptid="36211383" mdrpt="blister">blisters</span>, <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">peeling</span> <span class="conditions" mdrptid="37320212" mdrpt="rash">rash</span>, sores in their mouth, <span class="conditions" mdrptid="36009783" mdrpt="urticaria">hives</span>, or any other allergic reactions .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s42">5.6</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s164"></a><a name="section-16.11"></a><p></p>
                <h2>17.11 Discontinuation of Treatment</h2>
                <p class="First">
                    Patients should be instructed that discontinuation of Cymbalta may be associated with symptoms such as <span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span>, <span class="conditions" mdrptid="36718132" mdrpt="headache">headache</span>, <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span>, <span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">diarrhea</span>, <span class="conditions" mdrptid="36718379" mdrpt="paraesthesia">paresthesia</span>, <span class="conditions" mdrptid="35809139" mdrpt="irritability">irritability</span>, <span class="conditions" mdrptid="35708208" mdrpt="vomiting">vomiting</span>, <span class="conditions" mdrptid="36718555" mdrpt="insomnia">insomnia</span>, <span class="conditions" mdrptid="36918858" mdrpt="anxiety">anxiety</span>, <span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">hyperhidrosis</span>, and <span class="conditions" mdrptid="35809076" mdrpt="fatigue">fatigue</span>, and should be advised not to alter their dosing regimen, or stop taking Cymbalta without consulting their physician .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s43">5.7</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s165"></a><a name="section-16.12"></a><p></p>
                <h2>17.12 Activation of <span class="conditions" mdrptid="36919036" mdrpt="mania">Mania</span> or <span class="conditions" mdrptid="36919035" mdrpt="hypomania">Hypomania</span></h2>
                <p class="First">
                    Patients with depressive symptoms should be adequately screened for risk of <span class="conditions" mdrptid="36919033" mdrpt="bipolar disorder">bipolar disorder</span> (e.g. <span class="conditions" mdrptid="37420426" mdrpt="familial risk factor">family history of suicide</span>, <span class="conditions" mdrptid="36919033" mdrpt="bipolar disorder">bipolar disorder</span>, and <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span>) prior to initiating treatment with Cymbalta. Patients should be advised to report any signs or symptoms of a <span class="conditions" mdrptid="36919036" mdrpt="mania">manic reaction</span> such as greatly increased energy, severe trouble sleeping, <span class="conditions" mdrptid="36718183" mdrpt="tachyphrenia">racing thoughts</span>, reckless behavior, talking more or faster than usual, unusually grand ideas, and excessive happiness or <span class="conditions" mdrptid="35809139" mdrpt="irritability">irritability</span> .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s44">5.8</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="e166"></a><a name="section-16.13"></a><p></p>
                <h2>17.13 Angle-Closure <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">Glaucoma</span></h2>
                <p class="First">
                    Patients should be advised that taking Cymbalta can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle-closure <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">glaucoma</span>. Pre-existing <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">glaucoma</span> is almost always <span class="conditions" mdrptid="35606991" mdrpt="open angle glaucoma">open-angle glaucoma</span> because angle-closure <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">glaucoma</span>, when diagnosed, can be treated definitively with <span class="conditions" mdrptid="37520878" mdrpt="iridectomy">iridectomy</span>. <span class="conditions" mdrptid="35606991" mdrpt="open angle glaucoma">Open-angle glaucoma</span> is not a risk factor for angle-closure <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">glaucoma</span>. Patients may wish to be examined to determine whether they are susceptible to angle-closure, and have a <span class="conditions" mdrptid="37522077" mdrpt="prophylaxis">prophylactic</span> procedure (e.g., <span class="conditions" mdrptid="37520878" mdrpt="iridectomy">iridectomy</span>), if they are susceptible.
                    <span class="Italics">
                        [See Warnings and Precautions ( )]
                        <a href="#e44">5.9</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s166"></a><a name="section-16.14"></a><p></p>
                <h2>17.14 <span class="conditions" mdrptid="36718526" mdrpt="convulsion">Seizures</span></h2>
                <p class="First">
                    Patients should be advised to inform their physician if they have a history of <span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizure</span> disorder .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s45">5.10</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s167"></a><a name="section-16.15"></a><p></p>
                <h2>17.15 Effects on <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">Blood Pressure</span></h2>
                <p class="First">
                    Patients should be cautioned that Cymbalta may cause an increase in <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span> .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s46">5.11</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s168"></a><a name="section-16.16"></a><p></p>
                <h2>17.16 Concomitant Medications</h2>
                <p class="First">
                    Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter medications, since there is a potential for interactions .
                    <span class="Italics">
                        [see Dosage and Administration ( ), Contraindications ( ), Warnings and Precautions ( and ), and Drug Interactions ( )]
                        <a href="#s30">2.5</a><a href="#s33">4.1</a><a href="#s40">5.4</a><a href="#s47">5.12</a><a href="#s90">7</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s169"></a><a name="section-16.17"></a><p></p>
                <h2>17.17 <span class="conditions" mdrptid="36416600" mdrpt="hyponatraemia">Hyponatremia</span></h2>
                <p class="First">
                    Patients should be advised that <span class="conditions" mdrptid="36416600" mdrpt="hyponatraemia">hyponatremia</span> has been reported as a result of treatment with SNRIs and SSRIs, including Cymbalta. Patients should be advised of the signs and symptoms of <span class="conditions" mdrptid="36416600" mdrpt="hyponatraemia">hyponatremia</span>
                    <span class="Italics">
                        [see Warnings and Precautions ( )].
                        <a href="#s56">5.13</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s170"></a><a name="section-16.18"></a><p></p>
                <h2>17.18 Concomitant Illnesses</h2>
                <p class="First">
                    Patients should be advised to inform their physicians about all of their medical conditions
                    <span class="Italics">
                        [see Warnings and Precautions ( )].
                        <a href="#s57">5.14</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s171"></a><a name="section-16.19"></a><p></p>
                <h2>17.19 <span class="conditions" mdrptid="37019409" mdrpt="urinary hesitation">Urinary Hesitancy</span> and Retention</h2>
                <p class="First">
                    Cymbalta is in a class of medicines that may affect urination. Patients should be instructed to consult with their healthcare provider if they develop any problems with urine flow .
                    <span class="Italics">
                        [see Warnings and Precautions ( )]
                        <a href="#s62">5.15</a>
                    </span>
                </p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s172"></a><a name="section-16.20"></a><p></p>
                <h2>17.20 <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span> and <span class="conditions" mdrptid="37420447" mdrpt="breast feeding">Breast Feeding</span></h2>
                <p class="First">Patients should be advised to notify their physician if they</p>
                <ul class="Disc">
                    <li>become <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> during therapy</li>
                    <li>intend to become <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> during therapy</li>
                    <li>
                        are <span class="conditions" mdrptid="37420447" mdrpt="breast feeding">breast feeding</span> .
                        <span class="Italics">
                            [see Dosage and Administration ( ) and Use in Specific Populations ( , , and )]
                            <a href="#s22">2.3</a><a href="#s110">8.1</a><a href="#s113">8.2</a><a href="#s114">8.3</a>
                        </span>
                    </li>
                </ul>
                <p>Lilly maintains a <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> registry to monitor the <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> outcomes of women exposed to Cymbalta while <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span>. Healthcare providers are encouraged to register any patient who is exposed to Cymbalta during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> by calling the Cymbalta <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span> Registry at 1-866-814-6975 or by visiting www.cymbaltapregnancyregistry.com.</p>
            </div>
            <div class="Section" data-sectionCode="42229-5">
                <a name="s173"></a><a name="section-16.21"></a><p></p>
                <h2>17.21 Interference with Psychomotor Performance</h2>
                <p class="First">Any psychoactive drug may impair judgment, thinking, or motor skills. Although in controlled studies Cymbalta has not been shown to impair psychomotor performance, cognitive function, or memory, it may be associated with <span class="conditions" mdrptid="36718320" mdrpt="sedation">sedation</span> and <span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span>. Therefore, patients should be cautioned about operating hazardous machinery including automobiles, until they are reasonably certain that Cymbalta therapy does not affect their ability to engage in such activities.</p>
            </div>
        </div>
        <div class="Section" data-sectionCode="42229-5">
            <a name="x999"></a><a name="section-17"></a><p></p>
            <p class="First">Literature revised July 17, 2014</p>
            <p><span class="Bold">Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA</span></p>
            <p>Copyright © 2004, 2014, Eli Lilly and Company. All rights reserved.</p>
            <p>CYM-0002-USPI-20140717</p>
        </div>
        <div class="Section" data-sectionCode="42231-1">
            <a name="s174"></a><a name="section-18"></a><p></p>
            <p class="First"><span class="Bold">Medication Guide</span></p>
            <p>
                <span class="Bold">
                    Cymbalta [sim-BALL-tah] (Duloxetine Delayed-Release Capsules)
                    <span class="Sup">®</span><br>
                </span>
            </p>
            <p>
                Read the Medication Guide that comes with Cymbalta before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk with your healthcare provider if there is something you do not understand or want to learn more about.
                <span class="Sup">®</span>
            </p>
            <p><a name="p01"></a><span class="Bold">What is the most important information I should know about Cymbalta?</span></p>
            <p>Cymbalta and other antidepressant medicines may cause serious side effects, including:</p>
            <p><span class="Bold">1.  Suicidal thoughts or actions:</span></p>
            <ul class="Disc">
                <li>
                    in some children, teenagers, or young adults within the
                    <span class="Bold">Cymbalta and other antidepressant medicines may increase suicidal thoughts or actions</span><span class="Bold">first few months of treatment or when the dose is changed.</span>
                </li>
                <li><span class="conditions" mdrptid="36918942" mdrpt="depression">Depression</span> or other serious mental illnesses are the most important causes of suicidal thoughts or actions.</li>
                <li>
                    Watch for these changes and call your healthcare provider right away if you notice:
                    <ul class="Disc">
                        <li>New or sudden changes in mood, behavior, actions, thoughts, or feelings, especially if severe.</li>
                        <li>Pay particular attention to such changes when Cymbalta is started or when the dose is changed.</li>
                        <li>Keep all follow-up visits with your healthcare provider and call between visits if you are worried about symptoms.</li>
                    </ul>
                </li>
            </ul>
            <p><span class="Bold">Call your healthcare provider right away if you have any of the following symptoms, or call 911 if an emergency, especially if they are new, worse, or <span class="conditions" mdrptid="36918858" mdrpt="anxiety">worry</span> you:</span></p>
            <ul class="Disc">
                <li>attempts to commit <span class="conditions" mdrptid="36919230" mdrpt="completed suicide">suicide</span></li>
                <li>acting on dangerous impulses</li>
                <li>acting aggressive or <span class="conditions" mdrptid="36919059" mdrpt="aggression">violent</span></li>
                <li>thoughts about <span class="conditions" mdrptid="36919230" mdrpt="completed suicide">suicide</span> or dying</li>
                <li>new or worse <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span></li>
                <li>new or worse <span class="conditions" mdrptid="36918858" mdrpt="anxiety">anxiety</span> or <span class="conditions" mdrptid="36918904" mdrpt="panic attack">panic attacks</span></li>
                <li>feeling <span class="conditions" mdrptid="36718347" mdrpt="agitation">agitated</span>, <span class="conditions" mdrptid="36718368" mdrpt="restlessness">restless</span>, angry or <span class="conditions" mdrptid="35809139" mdrpt="irritability">irritable</span></li>
                <li>trouble sleeping</li>
                <li>an increase in activity or talking more than what is normal for you</li>
                <li>other unusual changes in behavior or mood</li>
            </ul>
            <p><span class="Bold">Call your healthcare provider right away if you have any of the following symptoms, or call 911 if an emergency. Cymbalta may be associated with these serious side effects:</span></p>
            <p><span class="Bold">2.  <span class="conditions" mdrptid="35909503" mdrpt="liver injury">Liver damage</span>- symptoms may include:</span></p>
            <ul class="Disc">
                <li><span class="conditions" mdrptid="37320197" mdrpt="pruritus">itching</span></li>
                <li>right <span class="conditions" mdrptid="35708156" mdrpt="abdominal pain upper">upper abdominal pain</span></li>
                <li>dark urine</li>
                <li><span class="conditions" mdrptid="35909613" mdrpt="hepatitis">hepatitis</span> with <span class="conditions" mdrptid="35809173" mdrpt="yellow skin">yellow skin</span> or eyes</li>
                <li>enlarged liver</li>
                <li>increased liver enzymes</li>
            </ul>
            <p><span class="Bold">3.  <span class="conditions" mdrptid="36718458" mdrpt="serotonin syndrome">Serotonin Syndrome</span> - This condition can be life-threatening and may include:</span></p>
            <ul class="Disc">
                <li><span class="conditions" mdrptid="36718347" mdrpt="agitation">agitation</span>, <span class="conditions" mdrptid="36918984" mdrpt="hallucination">hallucinations</span>, <span class="conditions" mdrptid="36718288" mdrpt="coma">coma</span> or other changes in mental status</li>
                <li>coordination problems or <span class="conditions" mdrptid="36516851" mdrpt="muscle twitching">muscle twitching</span> (<span class="conditions" mdrptid="36718214" mdrpt="psychomotor hyperactivity">overactive</span> reflexes)</li>
                <li>racing heartbeat, high or <span class="conditions" mdrptid="37622449" mdrpt="hypotension">low blood pressure</span></li>
                <li><span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">sweating</span> or <span class="conditions" mdrptid="35809054" mdrpt="pyrexia">fever</span></li>
                <li><span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span>, <span class="conditions" mdrptid="35708208" mdrpt="vomiting">vomiting</span>, or <span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">diarrhea</span></li>
                <li><span class="conditions" mdrptid="36516867" mdrpt="muscle rigidity">muscle rigidity</span></li>
                <li><span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span></li>
                <li><span class="conditions" mdrptid="35809130" mdrpt="flushing">flushing</span></li>
                <li><span class="conditions" mdrptid="36718265" mdrpt="tremor">tremor</span></li>
                <li><span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizures</span></li>
            </ul>
            <p>
                Cymbalta and other antidepressant medicines may increase your risk of <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">bleeding</span> or <span class="conditions" mdrptid="36211385" mdrpt="contusion">bruising</span>, especially if you take the blood thinner warfarin (Coumadin*, Jantoven*), a non-steroidal anti-inflammatory drug (NSAIDs, like ibuprofen or naproxen), or aspirin.
                <span class="Bold">4.  Abnormal <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">bleeding</span>:</span>
            </p>
            <p>
                Cymbalta may cause serious skin reactions that may require stopping its use. This may need to be treated in a hospital and may be life-threatening. Call your doctor right away or get emergency help if you have skin <span class="conditions" mdrptid="36211383" mdrpt="blister">blisters</span>, <span class="conditions" mdrptid="37320170" mdrpt="skin exfoliation">peeling</span> <span class="conditions" mdrptid="37320212" mdrpt="rash">rash</span>, sores in the mouth, <span class="conditions" mdrptid="36009783" mdrpt="urticaria">hives</span> or any other allergic reactions.
                <span class="Bold">5.  Severe skin reactions:</span>
            </p>
            <p><span class="Bold">6.  <span class="conditions" mdrptid="36919036" mdrpt="mania">Manic</span> episodes:</span></p>
            <ul class="Disc">
                <li>greatly increased energy</li>
                <li>severe trouble sleeping</li>
                <li><span class="conditions" mdrptid="36718183" mdrpt="tachyphrenia">racing thoughts</span></li>
                <li>reckless behavior</li>
                <li>unusually grand ideas</li>
                <li>excessive happiness or <span class="conditions" mdrptid="35809139" mdrpt="irritability">irritability</span></li>
                <li>talking more or faster than usual</li>
            </ul>
            <p><span class="Bold">7.  Visual Problems</span></p>
            <ul class="Disc">
                <li><span class="conditions" mdrptid="35606964" mdrpt="eye pain">eye pain</span></li>
                <li>changes in vision</li>
                <li><span class="conditions" mdrptid="35809166" mdrpt="swelling">swelling</span> or <span class="conditions" mdrptid="37320158" mdrpt="erythema">redness</span> in or around the eye</li>
            </ul>
            <p>Only some people are at risk for these problems. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are.</p>
            <p><span class="Bold">8.  <span class="conditions" mdrptid="36718526" mdrpt="convulsion">Seizures</span> or <span class="conditions" mdrptid="36718526" mdrpt="convulsion">convulsions</span></span></p>
            <p>
                Monitor your <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span> before starting and throughout treatment. Cymbalta may:
                <span class="Bold">9.  Changes in <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span>.</span>
            </p>
            <ul class="Disc">
                <li>increase your <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span>.</li>
                <li>decrease your <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span> when standing and cause <span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span> or <span class="conditions" mdrptid="35205037" mdrpt="syncope">fainting</span>, mostly when first starting Cymbalta or when increasing the dose.</li>
            </ul>
            <p>
                <span class="conditions" mdrptid="37420350" mdrpt="elderly">Elderly</span> people may be at greater risk for this. Symptoms may include:
                <span class="Bold">10.  Low salt (<span class="conditions" mdrptid="36316389" mdrpt="blood sodium">sodium</span>) levels in the blood.</span>
            </p>
            <ul class="Disc">
                <li><span class="conditions" mdrptid="36718132" mdrpt="headache">headache</span></li>
                <li><span class="conditions" mdrptid="35809072" mdrpt="asthenia">weakness</span> or feeling unsteady</li>
                <li><span class="conditions" mdrptid="36718301" mdrpt="confusional state">confusion</span>, problems concentrating or thinking or memory problems</li>
            </ul>
            <p><span class="Bold">11.  Problems with urination include:</span></p>
            <ul class="Disc">
                <li>decreased urine flow</li>
                <li>unable to pass any urine</li>
            </ul>
            <p>
                Children and adolescents should have height and weight monitored during treatment.
                <span class="Bold">12.  Changes in appetite or weight.</span>
            </p>
            <p>
                Stopping Cymbalta too quickly or changing from another antidepressant too quickly may result in serious symptoms including:
                <span class="Bold">Do not stop Cymbalta without first talking to your healthcare provider.</span>
            </p>
            <ul class="Disc">
                <li><span class="conditions" mdrptid="36918858" mdrpt="anxiety">anxiety</span>, <span class="conditions" mdrptid="35809139" mdrpt="irritability">irritability</span></li>
                <li>feeling tired or problems sleeping</li>
                <li><span class="conditions" mdrptid="36718132" mdrpt="headache">headache</span>, <span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">sweating</span>, <span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span></li>
                <li><span class="conditions" mdrptid="36211294" mdrpt="electric shock">electric shock</span>-like sensations</li>
                <li><span class="conditions" mdrptid="35708208" mdrpt="vomiting">vomiting</span>, <span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span>, <span class="conditions" mdrptid="35708093" mdrpt="diarrhoea">diarrhea</span></li>
            </ul>
            <p><span class="Bold">What is Cymbalta?</span></p>
            <p>Cymbalta is a prescription medicine used to treat <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span>. It is important to talk with your healthcare provider about the risks of treating <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span> and also the risks of not treating it. You should discuss all treatment choices with your healthcare provider.</p>
            <p>Cymbalta is also used to treat or manage:</p>
            <ul class="Disc">
                <li>Major <span class="conditions" mdrptid="36918942" mdrpt="depression">Depressive Disorder</span> (MDD)</li>
                <li><span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">Generalized Anxiety Disorder</span> (<span class="conditions" mdrptid="36918855" mdrpt="generalised anxiety disorder">GAD</span>)</li>
                <li><span class="conditions" mdrptid="35506521" mdrpt="diabetic neuropathy">Diabetic Peripheral Neuropathic Pain</span> (DPNP)</li>
                <li><span class="conditions" mdrptid="36516836" mdrpt="fibromyalgia">Fibromyalgia</span> (FM)</li>
                <li>Chronic <span class="conditions" mdrptid="36516957" mdrpt="musculoskeletal pain">Musculoskeletal Pain</span></li>
            </ul>
            <p>Talk to your healthcare provider if you do not think that your condition is getting better with Cymbalta treatment.</p>
            <p><span class="Bold">Who should not take Cymbalta?</span></p>
            <p>Do NOT take Cymbalta if you:</p>
            <ul class="Disc">
                <li>take a Monoamine Oxidase Inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid.</li>
                <li>Do not take an MAOI within 5 days of stopping Cymbalta unless directed to do so by your physician.</li>
                <li>Do not start Cymbalta if you stopped taking an MAOI in the last 2 weeks unless directed to do so by your physician.</li>
            </ul>
            <p><span class="Bold">People who take Cymbalta close in time to an MAOI may have serious or even life-threatening side effects. Get medical help right away if you have any of these symptoms:</span></p>
            <ul class="Disc">
                <li>high <span class="conditions" mdrptid="35809054" mdrpt="pyrexia">fever</span></li>
                <li>uncontrolled <span class="conditions" mdrptid="36516848" mdrpt="muscle spasms">muscle spasms</span></li>
                <li>stiff muscles</li>
                <li>rapid changes in <span class="conditions" mdrptid="36311980" mdrpt="heart rate">heart rate</span> or <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span></li>
                <li><span class="conditions" mdrptid="36718301" mdrpt="confusional state">confusion</span></li>
                <li><span class="conditions" mdrptid="36718317" mdrpt="loss of consciousness">loss of consciousness</span> (pass out)</li>
                <li><span class="Bold">take Mellaril* (thioridazine) because this can cause serious heart rhythm problems or <span class="conditions" mdrptid="35204976" mdrpt="sudden death">sudden death</span></span></li>
            </ul>
            <p><span class="Bold">What should I tell my healthcare provider before taking Cymbalta? Ask if you are not sure.</span></p>
            <p>Before starting Cymbalta, tell your healthcare provider if you:</p>
            <ul class="Disc">
                <li>
                    Are taking certain drugs such as:
                    <ul class="Disc">
                        <li>Triptans used to treat <span class="conditions" mdrptid="36718141" mdrpt="migraine">migraine headache</span></li>
                        <li>Medicines used to treat mood, <span class="conditions" mdrptid="36918858" mdrpt="anxiety">anxiety</span>, <span class="conditions" mdrptid="36919149" mdrpt="psychotic disorder">psychotic</span> or thought disorders, including tricyclics, lithium, buspirone, SSRIs, SNRIs or MAOIs</li>
                        <li>Tramadol and fentanyl</li>
                        <li>Cimetidine</li>
                        <li>The antibiotics ciprofloxacin, enoxacin</li>
                        <li>Medicine to control <span class="conditions" mdrptid="36311980" mdrpt="heart rate">heart rate</span> such as propafenone, flecainide, quinidine</li>
                        <li>Theophylline</li>
                        <li>The blood thinner warfarin (Coumadin*, Jantoven*)</li>
                        <li>Non-steroidal anti-inflammatory drug (NSAID), like ibuprofen, naproxen or aspirin.</li>
                        <li>Over-the-counter supplements such as tryptophan or St. John's Wort</li>
                    </ul>
                </li>
                <li>have heart problems or high <span class="conditions" mdrptid="36312063" mdrpt="blood pressure">blood pressure</span></li>
                <li>have <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span> (Cymbalta treatment worsens the control of blood sugar in some patients with <span class="conditions" mdrptid="35506609" mdrpt="diabetes mellitus">diabetes</span>)</li>
                <li>have liver problems</li>
                <li>have kidney problems</li>
                <li>have angle-closure <span class="conditions" mdrptid="35606985" mdrpt="glaucoma">glaucoma</span></li>
                <li>have or had <span class="conditions" mdrptid="36718526" mdrpt="convulsion">seizures</span> or <span class="conditions" mdrptid="36718526" mdrpt="convulsion">convulsions</span></li>
                <li>have <span class="conditions" mdrptid="36919033" mdrpt="bipolar disorder">bipolar disorder</span> or <span class="conditions" mdrptid="36919036" mdrpt="mania">mania</span></li>
                <li>have low <span class="conditions" mdrptid="36316389" mdrpt="blood sodium">sodium</span> levels in your blood</li>
                <li>have delayed stomach emptying</li>
                <li>have or had <span class="conditions" mdrptid="37622518" mdrpt="haemorrhage">bleeding</span> problems</li>
                <li>are <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> or plan to become <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span>. It is not known if Cymbalta will harm your unborn baby. Talk to your healthcare provider about the benefits and risks of treating <span class="conditions" mdrptid="36918942" mdrpt="depression">depression</span> or other conditions with Cymbalta during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span>. Lilly, the company that markets Cymbalta, maintains a <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span> registry. The Cymbalta <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">Pregnancy</span> Registry collects information from voluntary participants who are <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnant</span> and who have been exposed to Cymbalta at any time during <span class="conditions" mdrptid="36818833" mdrpt="pregnancy">pregnancy</span>. Women who are interested in enrolling may contact the Registry directly by calling 1-866-814-6975 or by visiting www.cymbaltapregnancyregistry.com</li>
                <li>are breast-feeding or plan to breast-feed. Some Cymbalta may pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking Cymbalta.</li>
            </ul>
            <p>
                including prescription and non-prescription medicines, vitamins, and herbal supplements. Cymbalta and some medicines may interact with each other, may not work as well, or may cause serious side effects.
                <span class="Bold">Tell your healthcare provider about all the medicines that you take,</span>
            </p>
            <p>Your healthcare provider or pharmacist can tell you if it is safe to take Cymbalta with your other medicines. Do not start or stop any medicine while taking Cymbalta without talking to your healthcare provider first.</p>
            <table width="100%">
                <col align="left" width="100.000%">
                <tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="left" valign="top">If you take Cymbalta, you should not take any other medicines that contain duloxetine.</td></tr></tbody>
            </table>
            <p><span class="Bold">How should I take Cymbalta?</span></p>
            <ul class="Disc">
                <li>Take Cymbalta exactly as prescribed. Your healthcare provider may need to change the dose of Cymbalta until it is the right dose for you.</li>
                <li>Do not open, break or chew the capsule; it must be swallowed whole.</li>
                <li>Cymbalta may be taken with or without food.</li>
                <li>If you miss a dose of Cymbalta, take the missed dose as soon as you remember. If it is almost time for the next dose, skip the missed dose and take your next dose at the regular time. Do not take two doses of Cymbalta at the same time.</li>
                <li>If you take too much Cymbalta, call your healthcare provider or poison control center right away, or get emergency treatment.</li>
                <li>When switching from another antidepressant to Cymbalta your doctor may want to lower the dose of the initial antidepressant first to potentially avoid side effects.</li>
            </ul>
            <p><span class="Bold">What should I avoid while taking Cymbalta?</span></p>
            <ul class="Disc">
                <li>Cymbalta can cause <span class="conditions" mdrptid="36718321" mdrpt="somnolence">sleepiness</span> or may affect your ability to make decisions, think clearly, or react quickly. You should not drive, operate heavy machinery, or do other dangerous activities until you know how Cymbalta affects you.</li>
                <li>Use of Cymbalta concomitantly with heavy alcohol intake may be associated with severe <span class="conditions" mdrptid="35909503" mdrpt="liver injury">liver injury</span>. Avoid heavy <span class="conditions" mdrptid="37420495" mdrpt="alcohol use">alcohol use</span> while taking Cymbalta.</li>
            </ul>
            <p><span class="Bold">What are the possible side effects of Cymbalta?</span></p>
            <p>
                Cymbalta may cause serious side effects, including all of those described in the section entitled “ ”
                <a href="#p01">What is the most important information I should know about Cymbalta?</a>
            </p>
            <p>Common possible side effects in people who take Cymbalta include:</p>
            <ul class="Disc">
                <li><span class="conditions" mdrptid="35708202" mdrpt="nausea">nausea</span></li>
                <li><span class="conditions" mdrptid="35708690" mdrpt="dry mouth">dry mouth</span></li>
                <li><span class="conditions" mdrptid="36718321" mdrpt="somnolence">sleepiness</span></li>
                <li><span class="conditions" mdrptid="35809076" mdrpt="fatigue">fatigue</span></li>
                <li>loss of appetite</li>
                <li>increased <span class="conditions" mdrptid="35809134" mdrpt="hyperhidrosis">sweating</span></li>
                <li><span class="conditions" mdrptid="35205025" mdrpt="dizziness">dizziness</span></li>
            </ul>
            <p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Cymbalta. For more information, ask your healthcare provider or pharmacist.</p>
            <p><span class="Bold">CALL YOUR DOCTOR FOR MEDICAL ADVICE ABOUT SIDE EFFECTS. YOU MAY REPORT SIDE EFFECTS TO THE FDA AT 1-800-FDA-1088.</span></p>
            <p><span class="Bold">How should I store Cymbalta?</span></p>
            <p>Store Cymbalta at room temperature between 59°F and 86°F (15°C to 30°C).</p>
            <p><span class="Bold">Keep Cymbalta and all medicines out of the reach of children.</span></p>
            <p><span class="Bold">General information about Cymbalta</span></p>
            <p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Cymbalta for a condition for which it was not prescribed. Do not give Cymbalta to other people, even if they have the same condition. It may harm them.</p>
            <p>This Medication Guide summarizes the most important information about Cymbalta. If you would like more information, talk with your healthcare provider. You may ask your healthcare provider or pharmacist for information about Cymbalta that is written for healthcare professionals.</p>
            <p>For more information about Cymbalta call 1-800-Lilly Rx (1-800-545-5979).</p>
            <p><span class="Bold">What are the ingredients in Cymbalta?</span></p>
            <p>Active ingredient: duloxetine hydrochloride</p>
            <p>Inactive ingredients:</p>
            <ul class="Disc">
                <li>
                    FD&amp;C Blue No. 2, gelatin, hypromellose, hydroxypropyl methylcellulose acetate succinate, <span class="conditions" mdrptid="36316389" mdrpt="blood sodium">sodium</span> lauryl sulfate, sucrose, sugar spheres, talc, titanium dioxide, and triethyl citrate. The 20 and 60 mg capsules also contain iron oxide yellow.
                    <span class="Bold">Delayed Release Capsules:</span>
                </li>
            </ul>
            <p><span class="Italics">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
            <p>*The brands listed are trademarks of their respective owners and not trademarks of Eli Lilly and Company.</p>
            <p>Medication Guide revised: July 17, 2014</p>
            <p>
                <span class="Bold">
                    Marketed by: Lilly USA, LLC Indianapolis, IN 46285, USA
                    <br>
                </span>
            </p>
            <p><span class="Bold">Cymbalta is a registered trademark of Eli Lilly and Company.</span></p>
            <p>Copyright © 2009, 2014, Eli Lilly and Company. All rights reserved.</p>
            <p>CYM-0001-MG-20140717</p>
        </div>
        <div class="Section" data-sectionCode="51945-4">
            <a name="s175"></a><a name="section-19"></a><p></p>
            <h1>Duloxetine HCL</h1>
            <div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=00acd9e9-b26a-4626-949e-112ecd2f27e6&amp;name=68151-4734.jpg"></div>
        </div>
    </div>
    <div class="DataElementsTables">
        <table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%">
            <tbody>
                <tr>
                    <td class="contentTableTitle">
                        <strong>
                            CYMBALTA 
                        </strong><br><span class="contentTableReg">duloxetine hydrochloride capsule, delayed release</span>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Product Type</td>
                                <td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
                                <td class="formLabel">Item Code (Source)</td>
                                <td class="formItem">NDC:68151-4734(NDC:0002-3235)</td>
                            </tr>
                            <tr class="formTableRow">
                                <td width="30%" class="formLabel">Route of Administration</td>
                                <td class="formItem">ORAL</td>
                                <td width="30%" class="formLabel">DEA Schedule</td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
                            <tr>
                                <th class="formTitle" scope="col">Ingredient Name</th>
                                <th class="formTitle" scope="col">Basis of Strength</th>
                                <th class="formTitle" scope="col">Strength</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem">
                                    <strong>Duloxetine hydrochloride</strong> (Duloxetine)
                                </td>
                                <td class="formItem">Duloxetine</td>
                                <td class="formItem">20 mg</td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
                            <tr>
                                <th class="formTitle" scope="col">Ingredient Name</th>
                                <th class="formTitle" scope="col">Strength</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>GELATIN</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>HYPROMELLOSES</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>HYPROMELLOSE ACETATE SUCCINATE 16070722 (3 MM2/S)</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong><span class="conditions" mdrptid="36316389" mdrpt="blood sodium">SODIUM</span> LAURYL SULFATE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>SUCROSE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>TALC</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
                                <td class="formItem"> </td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Color</td>
                                <td class="formItem">green (opaque green) </td>
                                <td class="formLabel">Score</td>
                                <td class="formItem">no score</td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formLabel">Shape</td>
                                <td class="formItem">CAPSULE</td>
                                <td class="formLabel">Size</td>
                                <td class="formItem">15mm</td>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formLabel">Flavor</td>
                                <td class="formItem"></td>
                                <td class="formLabel">Imprint Code</td>
                                <td class="formItem">LILLY;3235;20;mg</td>
                            </tr>
                            <tr class="formTableRow">
                                <td class="formLabel">Contains</td>
                                <td class="formItem">    </td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr>
                    <td>
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
                            <tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
                            <tr>
                                <th scope="col" width="1" class="formTitle">#</th>
                                <th scope="col" class="formTitle">Item Code</th>
                                <th scope="col" class="formTitle">Package Description</th>
                                <th scope="col" class="formTitle">Marketing Start Date</th>
                                <th scope="col" class="formTitle">Marketing End Date</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <th scope="row" class="formItem">1</th>
                                <td class="formItem">NDC:68151-4734-6</td>
                                <td class="formItem">1  in 1 PACKAGE</td>
                                <td class="formItem"></td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
                <tr><td></td></tr>
                <tr>
                    <td class="normalizer">
                        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
                            <tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
                            <tr>
                                <th scope="col" class="formTitle">Marketing Category</th>
                                <th scope="col" class="formTitle">Application Number or Monograph Citation</th>
                                <th scope="col" class="formTitle">Marketing Start Date</th>
                                <th scope="col" class="formTitle">Marketing End Date</th>
                            </tr>
                            <tr class="formTableRowAlt">
                                <td class="formItem">NDA</td>
                                <td class="formItem">NDA021427</td>
                                <td class="formItem">08/24/2004</td>
                                <td class="formItem"></td>
                            </tr>
                        </table>
                    </td>
                </tr>
            </tbody>
        </table>
        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
            <tr>
                <td colspan="4" class="formHeadingReg">
                    <span class="formHeadingTitle">Labeler - </span>Carilion Materials Management
                    (079239644)
                </td>
            </tr>
        </table>
        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
            <tr>
                <td colspan="4" class="formHeadingReg">
                    <span class="formHeadingTitle">Registrant - </span>Carilion Materials Management (079239644)
                </td>
            </tr>
        </table>
        <table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
            <tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
            <tr>
                <th scope="col" class="formTitle">Name</th>
                <th scope="col" class="formTitle">Address</th>
                <th scope="col" class="formTitle">ID/FEI</th>
                <th scope="col" class="formTitle">Business Operations</th>
            </tr>
            <tr class="formTableRowAlt">
                <td class="formItem">Carilion Materials Management</td>
                <td class="formItem"></td>
                <td class="formItem">079239644</td>
                <td class="formItem">REPACK(68151-4734)</td>
            </tr>
        </table>
    </div>
    <p>
        <div class="EffectiveDate">
            Revised: 7/2014<div class="DocumentMetadata">
                <div>
                    <a href="javascript:toggleMixin();">Document Id: </a>ea281201-a47d-48b5-8448-a086cafc2523
                </div>
                <div>Set id: 00acd9e9-b26a-4626-949e-112ecd2f27e6</div>
                <div>Version: 2</div>
                <div>Effective Time: 20140717</div>
            </div>
        </div> <div class="DistributorName">Carilion Materials Management</div>
    </p>
</body>
</html>
